0001642545-23-000031.txt : 20230508 0001642545-23-000031.hdr.sgml : 20230508 20230508163128 ACCESSION NUMBER: 0001642545-23-000031 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 64 CONFORMED PERIOD OF REPORT: 20230331 FILED AS OF DATE: 20230508 DATE AS OF CHANGE: 20230508 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Shockwave Medical, Inc. CENTRAL INDEX KEY: 0001642545 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 270494101 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38829 FILM NUMBER: 23898246 BUSINESS ADDRESS: STREET 1: 5403 BETSY ROSS DRIVE CITY: SANTA CLARA STATE: CA ZIP: 95054 BUSINESS PHONE: (510) 279-4262 MAIL ADDRESS: STREET 1: 5403 BETSY ROSS DRIVE CITY: SANTA CLARA STATE: CA ZIP: 95054 FORMER COMPANY: FORMER CONFORMED NAME: ShockWave Medical, Inc. DATE OF NAME CHANGE: 20150515 10-Q 1 swav-20230331.htm 10-Q swav-20230331
0001642545December 312023Q1falsehttp://fasb.org/us-gaap/2022#ProductMemberhttp://fasb.org/us-gaap/2022#ProductMemberhttp://fasb.org/us-gaap/2022#ProductMemberhttp://fasb.org/us-gaap/2022#ProductMemberhttp://fasb.org/us-gaap/2022#ProductMemberhttp://fasb.org/us-gaap/2022#ProductMemberhttp://fasb.org/us-gaap/2022#ProductMemberhttp://fasb.org/us-gaap/2022#ProductMemberP2YP3Y00016425452023-01-012023-03-3100016425452023-05-02xbrli:shares00016425452023-03-31iso4217:USD00016425452022-12-3100016425452022-01-012022-03-31iso4217:USDxbrli:shares0001642545us-gaap:CommonStockMember2022-12-310001642545us-gaap:AdditionalPaidInCapitalMember2022-12-310001642545us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001642545us-gaap:RetainedEarningsMember2022-12-310001642545us-gaap:CommonStockMember2023-01-012023-03-310001642545us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001642545us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001642545us-gaap:RetainedEarningsMember2023-01-012023-03-310001642545us-gaap:CommonStockMember2023-03-310001642545us-gaap:AdditionalPaidInCapitalMember2023-03-310001642545us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001642545us-gaap:RetainedEarningsMember2023-03-310001642545us-gaap:CommonStockMember2021-12-310001642545us-gaap:AdditionalPaidInCapitalMember2021-12-310001642545us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001642545us-gaap:RetainedEarningsMember2021-12-3100016425452021-12-310001642545us-gaap:CommonStockMember2022-01-012022-03-310001642545us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001642545us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001642545us-gaap:RetainedEarningsMember2022-01-012022-03-310001642545us-gaap:CommonStockMember2022-03-310001642545us-gaap:AdditionalPaidInCapitalMember2022-03-310001642545us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310001642545us-gaap:RetainedEarningsMember2022-03-3100016425452022-03-31swav:subsidiary0001642545us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001642545us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001642545us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001642545us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001642545us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001642545us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001642545us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001642545us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001642545us-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001642545us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001642545us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001642545us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001642545us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001642545us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001642545us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001642545us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001642545us-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-03-310001642545us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-03-310001642545us-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001642545us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001642545us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001642545us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001642545us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001642545us-gaap:FairValueMeasurementsRecurringMember2023-03-310001642545us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001642545us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001642545us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001642545us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001642545us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001642545us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001642545us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001642545us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001642545us-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001642545us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001642545us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001642545us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001642545us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001642545us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001642545us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001642545us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001642545us-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-12-310001642545us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-12-310001642545us-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001642545us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001642545us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001642545us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001642545us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001642545us-gaap:FairValueMeasurementsRecurringMember2022-12-310001642545us-gaap:USTreasurySecuritiesMember2023-03-310001642545us-gaap:MoneyMarketFundsMember2023-03-310001642545us-gaap:CommercialPaperMember2023-03-310001642545us-gaap:CorporateBondSecuritiesMember2023-03-310001642545us-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-03-310001642545us-gaap:USTreasurySecuritiesMember2022-12-310001642545us-gaap:MoneyMarketFundsMember2022-12-310001642545us-gaap:CommercialPaperMember2022-12-310001642545us-gaap:CorporateBondSecuritiesMember2022-12-310001642545us-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-12-310001642545us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2022-10-190001642545us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2022-10-192022-10-190001642545us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2023-03-162023-03-160001642545us-gaap:SubsequentEventMemberswav:LoanAndSecurityAgreementMember2023-04-262023-04-260001642545us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMembersrt:MinimumMemberus-gaap:BaseRateMember2022-10-192022-10-19xbrli:pure0001642545us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:BaseRateMembersrt:MaximumMember2022-10-192022-10-190001642545us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMembersrt:MinimumMember2022-10-192022-10-190001642545us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMembersrt:MinimumMemberswav:SecuredOvernightFinancingRateSOFRMember2022-10-192022-10-190001642545us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMembersrt:MaximumMemberswav:SecuredOvernightFinancingRateSOFRMember2022-10-192022-10-190001642545us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMembersrt:MaximumMember2022-10-192022-10-190001642545us-gaap:FederalFundsEffectiveSwapRateMemberus-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2022-10-192022-10-190001642545us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMemberswav:SecuredOvernightFinancingRateSOFRMember2022-10-192022-10-190001642545us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2023-03-310001642545us-gaap:CostOfSalesMember2023-01-012023-03-310001642545us-gaap:CostOfSalesMember2022-01-012022-03-310001642545us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-03-310001642545us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-03-310001642545us-gaap:SellingAndMarketingExpenseMember2023-01-012023-03-310001642545us-gaap:SellingAndMarketingExpenseMember2022-01-012022-03-310001642545us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-03-310001642545us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-03-3100016425452019-02-2800016425452019-02-012019-02-2800016425452022-01-012022-12-310001642545us-gaap:PerformanceSharesMembersrt:MinimumMember2023-01-012023-03-310001642545us-gaap:PerformanceSharesMembersrt:MaximumMember2023-01-012023-03-310001642545us-gaap:PerformanceSharesMember2023-01-012023-03-310001642545us-gaap:RestrictedStockUnitsRSUMember2022-12-310001642545us-gaap:PerformanceSharesMember2022-12-310001642545us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-03-310001642545us-gaap:RestrictedStockUnitsRSUMember2023-03-310001642545us-gaap:PerformanceSharesMember2023-03-310001642545us-gaap:EmployeeStockMember2019-03-060001642545us-gaap:EmployeeStockMember2023-01-012023-03-310001642545us-gaap:EmployeeStockMember2022-01-012022-03-310001642545us-gaap:EmployeeStockMember2023-03-310001642545us-gaap:EmployeeStockOptionMember2023-01-012023-03-310001642545us-gaap:EmployeeStockOptionMember2022-01-012022-03-310001642545us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-03-310001642545swav:CoronaryMember2023-01-012023-03-310001642545swav:CoronaryMember2022-01-012022-03-310001642545swav:PeripheralMember2023-01-012023-03-310001642545swav:PeripheralMember2022-01-012022-03-310001642545us-gaap:ProductAndServiceOtherMember2023-01-012023-03-310001642545us-gaap:ProductAndServiceOtherMember2022-01-012022-03-310001642545country:US2023-01-012023-03-310001642545country:US2022-01-012022-03-310001642545srt:EuropeMember2023-01-012023-03-310001642545srt:EuropeMember2022-01-012022-03-310001642545swav:AllOtherCountriesMember2023-01-012023-03-310001642545swav:AllOtherCountriesMember2022-01-012022-03-310001642545swav:JVAgreementWithGenesisMedTechMemberswav:ShareSubscriptionAgreementMember2021-03-192021-03-190001642545swav:JVAgreementWithGenesisMedTechMemberswav:ShareSubscriptionAgreementMember2021-03-190001642545swav:JVAgreementWithGenesisMedTechMemberswav:LicenseAgreementMember2021-03-192021-03-190001642545swav:JVAgreementWithGenesisMedTechMemberswav:LicenseAgreementMember2021-03-190001642545swav:JVAgreementWithGenesisMedTechMember2023-03-310001642545us-gaap:CoVenturerMember2021-03-190001642545us-gaap:CoVenturerMember2021-03-192021-03-190001642545us-gaap:SubsequentEventMemberswav:NeovascIncMember2023-04-110001642545swav:BusinessCombinationContingentConsiderationArrangementsMaximumValuePerShareMemberus-gaap:SubsequentEventMemberswav:NeovascIncMember2023-04-112023-04-110001642545us-gaap:SubsequentEventMemberswav:NeovascIncMember2023-04-112023-05-03

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
___________________________________________________
FORM 10-Q
___________________________________________________
(Mark One)
xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2023
OR
oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ___________to ___________
Commission File Number: 001-38829
___________________________________________________
Shockwave Medical, Inc.
(Exact Name of Registrant as Specified in its Charter)
___________________________________________________
Delaware27-0494101
(State or other jurisdiction of
incorporation or organization)		(I.R.S. Employer
Identification No.)
5403 Betsy Ross Drive
Santa Clara, California
95054
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (510) 279-4262
___________________________________________________
Securities registered pursuant to Section 12(b) of the Act:
Title of each class of securitiesTrading symbol(s)Name of each national exchange and principal
U.S. market for the securities
Shockwave Medical, Inc., common stock, par value $0.001 per share
SWAV
The Nasdaq Stock Market LLC
(Nasdaq Global Select Market)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filerxAccelerated filero
Non-accelerated fileroSmaller reporting companyo
Emerging growth companyo
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x
As of May 2, 2023, the registrant had 36,626,211 shares of common stock, $0.001 par value per share, outstanding.


Table of Contents
Page


SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q contains statements relating to our expectations, projections, beliefs, and prospects, which are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as “believe,” “will,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “might,” “plan,” “expect,” “predict,” “could,” “potentially” or the negative of these terms or similar expressions. You should read these statements carefully because they may relate to future expectations around growth, strategy, and anticipated trends in our business, contain projections of future results of operations or financial condition, or state other “forward-looking” information. These statements are only predictions based on our current expectations, estimates, assumptions, and projections about future events and are applicable only as of the dates of such statements. Forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to, statements about:
•our ability to design, develop, manufacture and market innovative products to treat patients with challenging medical conditions, particularly in peripheral artery disease, coronary artery disease and aortic stenosis;
•our ability to successfully execute our commercialization strategy for our approved or cleared products;
•our expected future growth, including growth in international sales;
• the size and growth potential of the markets for our products, and our ability to serve those markets;
•the rate and degree of market acceptance of our products;
•coverage and reimbursement for procedures performed using our products;
•the performance of third parties in connection with the development of our products, including third-party suppliers;
•the impact of government laws and regulatory developments in the United States and foreign countries;
•our ability to obtain and maintain regulatory approval or clearance of our products on expected timelines;
•our ability to scale our organizational culture of cooperative product development and commercial execution;
•the expected benefits of our recent acquisition of Neovasc Inc., a corporation existing under the Canada Business Corporations Act;
•the development, regulatory approval, efficacy and commercialization of competing products;
•our ability to develop and maintain our corporate infrastructure, including our internal controls;
•our estimates regarding expenses, future financial performance and capital requirements;
•our expectations regarding our ability to obtain and maintain intellectual property protection for our products, as well as our ability to operate our business without infringing the intellectual property rights of others; and
•the impact of macroeconomic conditions, including inflation, rising interest rates, instability in the global banking system and volatile market conditions, and global events, including the COVID-19 pandemic, on our operations, financial results, liquidity and capital resources, sales, expenses, supply chain, manufacturing, research and development activities, clinical trials and employees.
We caution you that the foregoing list may not contain all of the forward-looking statements made in this Quarterly Report on Form 10-Q. We have based these forward-looking statements on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions and other factors that could cause our actual results, level of activity, performance, or achievements to differ materially from the results, level of activity, performance or achievements
1

expressed or implied by the forward-looking statements, including those described in the section titled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022, together with any updates in the section titled “Risk Factors” in this Quarterly Report on Form 10-Q, and the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in this Quarterly Report on Form 10-Q. There may also be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business. Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance or achievements. Except to the extent required by law, we undertake no obligation to update any of these forward-looking statements after the date of this Quarterly Report on Form 10-Q to conform our prior statements to actual results or revised expectations.
2

PART I—FINANCIAL INFORMATION
Item 1. Financial Statements.
SHOCKWAVE MEDICAL, INC.
Condensed Consolidated Balance Sheets
(Unaudited)
(in thousands)
March 31,
2023		December 31,
20221
ASSETS
CURRENT ASSETS:
Cash and cash equivalents$280,932 $156,586 
Short-term investments 135,929 147,907 
Accounts receivable, net 84,309 71,366 
Inventory83,256 75,112 
Prepaid expenses and other current assets6,399 8,292 
Total current assets590,825 459,263 
Operating lease right-of-use assets31,623 32,365 
Property and equipment, net54,057 48,152 
Equity method investment2,689 3,512 
Deferred tax assets97,941 97,568 
Other assets6,112 5,229 
TOTAL ASSETS$783,247 $646,089 
LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES:
Accounts payable$11,050 $6,721 
Debt, current portion80,000— 
Accrued liabilities49,640 55,375 
Lease liability, current portion1,308 1,278 
Total current liabilities141,998 63,374 
Lease liability, noncurrent portion34,058 34,928 
Debt, noncurrent portion24,231 24,198 
Related party contract liability, noncurrent portion12,273 12,273 
TOTAL LIABILITIES212,560 134,773 
STOCKHOLDERS’ EQUITY:
Preferred stock— — 
Common stock37 36 
Additional paid-in capital568,705 548,960 
Accumulated other comprehensive loss(367)(867)
Retained earnings (accumulated deficit)2,312 (36,813)
TOTAL STOCKHOLDERS’ EQUITY570,687 511,316 
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY$783,247 $646,089 
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

1 The condensed consolidated balance sheet as of December 31, 2022 is derived from the audited consolidated financial statements as of that date.
3

SHOCKWAVE MEDICAL, INC.
Condensed Consolidated Statements of Operations and Comprehensive Income
(Unaudited)
(in thousands, except share and per share data)
Three Months Ended
March 31,
20232022
Revenue:
Product revenue $161,066 $93,631 
Cost of revenue:
Cost of product revenue21,066 12,890 
Gross profit140,000 80,741 
Operating expenses:
Research and development26,971 17,019 
Sales and marketing54,011 35,961 
General and administrative19,204 12,389 
Total operating expenses100,186 65,369 
Income from operations39,814 15,372 
Loss from equity method investment (823)(47)
Interest expense(636)(297)
Other income (expense), net2,382 (310)
Net income before taxes40,737 14,718 
Income tax provision1,612 197 
Net income $39,125 $14,521 
Unrealized gain (loss) on available-for-sale securities505 (815)
Adjustment for net gain realized and included in other income(5)— 
Total comprehensive income $39,625 $13,706 
Net income per share
Basic$1.07 $0.41 
Diluted$1.03 $0.39 
Shares used in computing net income per share
Basic36,427,263 35,587,337 
Diluted37,979,448 37,623,477 
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

4

SHOCKWAVE MEDICAL, INC.
Condensed Consolidated Statements of Stockholders’ Equity
(Unaudited)
(in thousands, except share data)
Common Stock
Additional
Paid-In
Capital
Accumulated
Other
Comprehensive Loss
  Retained Earnings (Accumulated
Deficit)
Total
Stockholders’
Equity
Shares Amount 
Balance — December 31, 202236,235,546 $36 $548,960 $(867)$(36,813)$511,316 
Exercise of stock options77,230 1 319 — — 320 
Unrealized gain on available-for-sale securities, net of tax— — — 505 — 505 
Net gain reclassified from accumulated other comprehensive income— — — (5)— (5)
Issuance of common stock under employee stock purchase plan19,124 — 3,092 — — 3,092 
Issuance of common stock in connection with vesting of restricted stock units257,624 — — — — — 
Taxes withheld on net settled vesting of restricted stock units(19)— (3)— — (3)
Stock-based compensation— — 16,337 — — 16,337 
Net income— — — — 39,125 39,125 
Balance — March 31, 202336,589,505 $37 $568,705 $(367)$2,312 $570,687 

Common StockAdditional
Paid-In
Capital
Accumulated
Other
Comprehensive
Loss
Accumulated
Deficit		Total
Stockholders’
Equity
Shares Amount
Balance — December 31, 202135,444,472 $35 $494,806 $(202)$(252,809)$241,830 
Exercise of stock options54,913 1 390 — — 391 
Unrealized loss on available-for-sale securities— — — (815)— (815)
Issuance of common stock under employee stock purchase plan14,172 — 2,135 — — 2,135 
Issuance of common stock in connection with vesting of restricted stock units210,835 — — — — — 
Taxes withheld on net settled vesting of restricted stock units(31)— (6)— — (6)
Stock-based compensation— — 9,767 — — 9,767 
Net income— — — — 14,521 14,521 
Balance — March 31, 202235,724,361 $36 $507,092 $(1,017)$(238,288)$267,823 
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
5

SHOCKWAVE MEDICAL, INC.
Condensed Consolidated Statements of Cash Flows
(Unaudited)
(in thousands)
Three Months Ended
March 31,
20232022
CASH FLOWS FROM OPERATING ACTIVITIES:  
Net income $39,125 $14,521 
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization1,708 953 
Loss from equity method investment823 47 
Stock-based compensation15,967 9,510 
Non-cash lease expense748 767 
Amortization of premium and discount on available-for-sale securities(718)210 
Loss on write down of fixed assets11 — 
Deferred income taxes(547)— 
Amortization of debt issuance costs33 153 
Foreign currency remeasurement(689)— 
Changes in operating assets and liabilities:
Accounts receivable(13,004)(10,407)
Inventory(7,757)(10,090)
Prepaid expenses and other current assets1,896 600 
Other assets(861)(119)
Accounts payable4,734 4,911 
Accrued and other current liabilities(6,661)(9,051)
Lease liabilities(846)(68)
Net cash provided by operating activities33,962 1,937 
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of available-for-sale securities(21,130)(42,128)
Proceeds from maturities of available-for-sale securities34,500 18,000 
Purchase of property and equipment(7,188)(3,286)
Net cash provided by (used in) investing activities6,182 (27,414)
CASH FLOWS FROM FINANCING ACTIVITIES:
Payments of taxes withheld on net settled vesting of restricted stock units(3)(6)
Proceeds from stock option exercises320 391 
Proceeds from issuance of common stock under employee stock purchase plan3,092 2,135 
Proceeds from debt financing, net of issuance costs80,000 — 
Net cash provided by financing activities83,409 2,520 
Effect of exchange rate changes on cash and cash equivalents792 — 
Net increase (decrease) in cash, cash equivalents and restricted cash124,345 (22,957)
Cash, cash equivalents and restricted cash at beginning of period158,302 90,874 
Cash, cash equivalents and restricted cash equivalents at end of period$282,647 $67,917 
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Interest paid$424 $144 
Income tax paid$322 $78 
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Property and equipment purchases included in accounts payable and accrued liabilities$6,162 $3,159 
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
6

SHOCKWAVE MEDICAL, INC.
Notes to Condensed Consolidated Financial Statements
1. Organization and Basis of Presentation
Shockwave Medical, Inc. (the “Company”) was incorporated on June 17, 2009. The Company is primarily engaged in the development of Intravascular Lithotripsy (“IVL”) technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular and heart valve disease. Built on a balloon catheter platform, the IVL technology uses lithotripsy to disrupt both superficial and deep vascular calcium, while minimizing soft tissue injury, and an integrated angioplasty balloon to dilate blockages at low pressures, restoring blood flow.
In 2016, the Company began commercial and manufacturing operations, and began selling catheters based on the IVL technology. The Company’s headquarters are in Santa Clara, California. The Company is located and operates primarily in the United States and has eleven wholly-owned foreign subsidiaries as of March 31, 2023. The unaudited condensed financial statements include the accounts of Shockwave Medical, Inc. and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated upon consolidation.
As of March 31, 2023, the Company had cash, cash equivalents and short-term investments of $416.9 million, which are available to fund future working capital requirements, investments, acquisitions, or repayments of credit facilities. The Company believes that its cash, cash equivalents, and short-term investments as of March 31, 2023, will be sufficient for the Company to continue as a going concern for at least 12 months from the date the unaudited condensed consolidated financial statements are filed with the Securities and Exchange Commission (“SEC”). The Company’s future capital requirements will depend on many factors, including its growth rate, the timing and extent of its spending to support research and development activities, and the timing and cost of establishing additional sales and marketing capabilities and the scope.
Risk and Uncertainties
The Company is subject to continuing risks and uncertainties in connection with the current macroeconomic environment, including inflation, rising interest rates, and instability in the global banking system, geopolitical factors, including the ongoing conflict between Russia and Ukraine and the responses thereto, supply chain disruptions and the remaining effects of the COVID-19 pandemic. The Company is closely monitoring the impact of these factors on all aspects of its business, including the impacts on its customers, patients, employees, suppliers, vendors, business partners and distribution channels.
In particular, while the Company has not experienced material disruptions in its supply chain to date, the Company has been and continues to be impacted by disruptions in the operations of certain of its third-party suppliers, resulting in increased lead-times, higher component costs and lower allocations for the purchase of some components. In certain cases, the Company has incurred higher logistical expenses. The Company is continuing to work closely with its manufacturing partners and suppliers to source key components and maintain appropriate inventory levels to meet customer demand.
The Company’s future results of operations and liquidity could be adversely impacted by a variety of factors, including those discussed in the section titled “Risk Factors” of the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on February 27, 2023 (the “2022 Annual Report”), together with any updates in the section titled “Risk Factors” in this Quarterly Report on Form 10-Q. As of the date of issuance of these condensed consolidated financial statements, the extent to which the current macroeconomic environment and the COVID-19 pandemic may materially impact the Company’s financial condition, liquidity, or results of operations remains uncertain.
2. Summary of Significant Accounting Policies
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) and applicable rules and regulations of the SEC regarding interim financial reporting.
The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s consolidated financial position, results of operations and
7

SHOCKWAVE MEDICAL, INC.
Notes to Condensed Consolidated Financial Statements
cash flows. The results of operations for the three months ended March 31, 2023 are not necessarily indicative of the results to be expected for the year ending December 31, 2023 or for any other future annual or interim period. The condensed consolidated balance sheet as of December 31, 2022 included herein was derived from the audited financial statements as of that date. The unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and related notes included in the 2022 Annual Report.
Cash, Cash Equivalents, and Restricted Cash
The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts.
The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated statements of cash flows:
March 31,
2023		March 31,
2022
(in thousands)
Cash and cash equivalents$280,932 $66,252 
Restricted cash1,715 1,665 
Total cash, cash equivalents, and restricted cash$282,647 $67,917 
Restricted cash as of March 31, 2023 and December 31, 2022 relates to letters of credit established for real property leases relating to the Company’s office buildings, and is recorded as other assets on the condensed consolidated balance sheets.
See Note 12 for a discussion of the Company’s subsequent payments related to the acquisition of Neovasc, Inc. and the repayment of the credit drawn on March 16, 2023 under the Credit Agreement.
Equity Method Investments
Entities which the Company has significant influence over activities of the entity, but does not control, are accounted for under the equity method of accounting in accordance with Topic 323, Investments - Equity Method and Joint Ventures. The Company’s carrying value in the equity method investment is reported as equity method investment on the Company’s consolidated balance sheets. The Company records its proportionate share of the underlying income or loss which is recognized in earnings or loss from the equity method investment. The Company eliminates a portion of intra-entity profit to the extent the goods sold by the Company have not yet been sold through by the equity method investee to an end customer at the end of the reporting period. The profit earned by the Company from the equity method investee for items not yet sold through is eliminated through equity method earnings or loss which is recognized in income (loss) from equity method investment.
The Company assesses its equity method investment for impairment when events or circumstances suggest that the carrying amount of the investment may be impaired. The Company considers all available evidence in assessing whether a decline in fair value is other than temporary. If the decline in fair value is determined to be other than temporary, the difference between the carrying amount of the investment and estimated fair value is recognized as an impairment charge.
Revenue
To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, Revenue from Contracts with Customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.
8

SHOCKWAVE MEDICAL, INC.
Notes to Condensed Consolidated Financial Statements
Product Revenue
The Company records product revenue primarily from the sale of its IVL catheters. The Company sells its products to hospitals, primarily through direct sales representatives, as well as through distributors in selected international markets. Additionally, a portion of the Company’s revenue is generated through a consignment model under which inventory is maintained at hospitals.
Product revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.
For products sold through direct sales representatives, control is transferred upon delivery to customers. For products sold to distributors internationally and products sold to customers that utilize stocking orders, control is transferred upon shipment or delivery to the customer’s named location, based on the contractual shipping terms. For consignment inventory, control is transferred at the time the IVL catheters are consumed in a procedure. The Company has elected to account for shipping and handling activities that occur after the customer has obtained control as a fulfillment activity, and not a separate performance obligation.
The Company may provide for the use of an IVL generator and connector cable under an agreement to customers at no charge to facilitate use of the IVL catheters. These agreements generally do not contain contractually enforceable minimum commitments and are generally cancellable by either party with 30 days notice.
License Revenue
For arrangements that contain a license of the Company’s functional intellectual property with a customer, the Company considers whether the license grant is distinct from other performance obligations in the arrangement. A license grant of functional intellectual property is generally considered to be capable of being distinct if a customer can benefit from the license on its own or together with other readily available resources. License revenue for licenses of functional intellectual property is recognized at a point in time when the Company satisfies its performance obligation of transferring the license to the customer.
Consideration received in advance of the satisfaction of a performance obligation is recognized as a contract liability. No license revenues were recognized for the three months ended March 31, 2023 and 2022.
Stock-Based Compensation
The Company accounts for share-based payments at fair value. The fair value of stock options is measured using the Black-Scholes option-pricing model. For share-based awards that vest subject to the satisfaction of a service requirement, the fair value measurement date for stock-based compensation awards is the date of grant and the expense is recognized on a straight-line basis, over the vesting period. For share-based awards that vest upon the satisfaction of a performance target, the related compensation cost is recognized over the requisite service period based on the expected achievement of the performance target. The Company accounts for forfeitures as they occur.

9

SHOCKWAVE MEDICAL, INC.
Notes to Condensed Consolidated Financial Statements
3. Financial Instruments and Fair Value Measurements
The following tables summarize the Company’s financial assets measured at fair value on a recurring basis by level within the fair value hierarchy:
March 31, 2023
Level 1Level 2Level 3Total
(in thousands)
Assets:
U.S. Treasury securities$95,282 $— $— $95,282 
Money market funds10,070 — — 10,070 
Commercial paper— 8,139 — 8,139 
Corporate bonds— 20,688 — 20,688 
U.S. agency securities— 11,820 — 11,820 
Total assets$105,352 $40,647 $— $145,999 
December 31, 2022
Level 1Level 2Level 3Total
(in thousands)
Assets:
U.S. Treasury securities$111,631 $— $— $111,631 
Money market funds12,076 — — 12,076 
Commercial paper— 8,039 — 8,039 
Corporate bonds— 18,808 — 18,808 
U.S. agency securities— 9,429 — 9,429 
Total assets$123,707 $36,276 $— $159,983 
4. Cash Equivalents and Short-Term Investments
The following is a summary of the Company’s cash equivalents and short-term investments:
March 31, 2023
Amortized
Cost Basis		Unrealized
Gains		Unrealized
Losses		Fair Value
(in thousands)
U.S. Treasury securities$95,784 $18 $(520)$95,282 
Money market funds10,070 — — 10,070 
Commercial paper8,140 1 (2)8,139 
Corporate bonds20,685 22 (19)20,688 
U.S. agency securities11,804 16 — 11,820 
Total$146,483 $57 $(541)$145,999 
Reported as:
Cash equivalents$10,070 
Short-term investments135,929 
Total$145,999 
10

SHOCKWAVE MEDICAL, INC.
Notes to Condensed Consolidated Financial Statements
December 31, 2022
Amortized
Cost Basis		Unrealized
Gains		Unrealized
Losses		Fair Value
(in thousands)
U.S. Treasury securities$112,719 $3 $(1,091)$111,631 
Money market funds12,076 — — 12,076 
Commercial paper8,039 — — 8,039 
Corporate bonds18,876 8 (76)18,808 
U.S. agency securities9,432 4 (7)9,429 
Total$161,142 $15 $(1,174)$159,983 
Reported as:
Cash equivalents$12,076 
Short-term investments147,907 
Total$159,983 
There were $76.4 million and $123.8 million of investments in unrealized loss positions of $0.5 million and $1.2 million as of March 31, 2023 and December 31, 2022, respectively. During the three months ended March 31, 2023 and 2022, the Company did not record any other-than-temporary impairment charges on its available-for-sale securities. Based on the Company’s procedures under the expected credit loss model, including an assessment of unrealized losses on the portfolio, the Company concluded that the unrealized losses for its marketable securities were not attributable to credit and therefore an allowance for credit losses for these securities has not been recorded as of March 31, 2023 and December 31, 2022. Also, based on the scheduled maturities of the investments, the Company was more likely than not to hold these investments for a period of time sufficient for a recovery of the Company’s cost basis.
For the three months ended March 31, 2023 and 2022, the Company recognized $5,000 and nil in realized gains on cash equivalents and short-term investments.
The remaining contractual maturities of the Company’s cash equivalents and short-term investments were as follows:
March 31,
2023
Fair Value
(in thousands)
Money market funds
$10,070 
One year or less 112,680 
Greater than one year and less than two years 23,249 
Total$145,999 
11

SHOCKWAVE MEDICAL, INC.
Notes to Condensed Consolidated Financial Statements
5. Balance Sheet Components
Inventory
Inventory consists of the following:
March 31,
2023		 December 31,
2022
(in thousands)
Raw material$21,504 $18,456 
Work in progress10,722 7,666 
Finished goods50,737 48,735 
Consigned inventory293 255 
Total inventory$83,256 $75,112 
Accrued Liabilities
Accrued liabilities consist of the following:
March 31,
2023		December 31,
2022
(in thousands)
Employee compensation$22,070 $32,885 
Asset purchases6,882 4,600 
Research and development costs4,118 4,007 
Professional services3,862 4,044 
Excise, sales, income and other taxes5,123 4,036 
Other7,585 5,803 
Total accrued liabilities$49,640 $55,375 
6. Debt
On October 19, 2022, the Company entered into a Credit Agreement (the “Credit Agreement”) with Wells Fargo Bank, National Association, as administrative agent, Wells Fargo Bank, National Association, as swingline lender and an issuing lender, Wells Fargo Securities, LLC and Silicon Valley Bank, as joint lead arrangers and joint bookrunners, Silicon Valley Bank, as syndication agent, and the several lenders party thereto. The Credit Agreement provides for a revolving credit facility in an aggregate principal amount of $175 million with the right to request increases to the revolving commitments (subject to certain conditions) of up to the greater of (x) $100 million or (y) the Company’s consolidated EBITDA for the four fiscal quarter period most recently ended prior to the date of such increase.
Concurrent with entering into the Credit Agreement, the Company drew down $25.0 million. On March 16, 2023, the Company drew down an additional $80.0 million under the Credit Agreement. See Note 12 for a discussion of the Company’s subsequent payment of the additional $80.0 million drawn under the Credit Agreement.
The revolving credit facility accrues for interest, at the election of the Company, at (A) the Base Rate (as defined below) plus a margin ranging from 0% to 1% depending on the Company's Consolidated Total Net Leverage Ratio (as defined in the Credit Agreement) (which rate is currently 0%) or (B) the applicable secured overnight financing rate (“SOFR”) plus a margin from 1% to 2%, depending on the Company's Consolidated Total Net Leverage Ratio (which rate is currently 1%). Base Rate means, at any time, the highest of (a) the Wells Fargo Bank, National Association's announced prime rate, (b) the federal funds rate plus 0.5% and (c) Term SOFR for a one-month tenor in effect on such day plus 1%. The Credit Agreement matures on October 19, 2027. The interest rate was 5.6% as of March 31, 2023.
12

SHOCKWAVE MEDICAL, INC.
Notes to Condensed Consolidated Financial Statements
The Company recorded interest expense of $0.6 million and $0.3 million for the three months ended March 31, 2023 and 2022, respectively.
Debt and debt issuance costs are as follows:
March 31,
2023		December 31,
2022
(in thousands)
Principal amount of debt$105,000 $25,000 
Debt issuance costs(769)(802)
Debt104,231 24,198 
Less: debt, current portion(80,000)— 
Debt, noncurrent portion$24,231 $24,198 
7. Stock-Based Compensation
Total stock-based compensation was as follows:
Three Months Ended
March 31,
20232022
(in thousands)
Cost of product revenue$954 $653 
Research and development3,795 2,238 
Sales and marketing6,466 3,932 
General and administrative4,752 2,687 
Total stock-based compensation$15,967 $9,510 
Stock-based compensation of $0.4 million and $0.3 million was capitalized into inventory for the three months ended March 31, 2023 and 2022, respectively. Stock-based compensation capitalized into inventory is recognized as cost of product revenue when the related product is sold.
2009 Equity Incentive Plan and 2019 Equity Incentive Plan
On June 17, 2009, the Company adopted the 2009 Equity Incentive Plan (the “2009 Plan”) under which the Company's Board of Directors (the “Board”) had the authority to issue stock options to employees, directors and consultants.
In February 2019, the Company adopted the 2019 Equity Incentive Plan (the “2019 Plan”), which became effective in connection with the Company's initial public offering (the “IPO”). As a result, effective as of March 6, 2019, the Company may not grant any additional awards under the 2009 Plan. The 2009 Plan will continue to govern outstanding equity awards granted thereunder. The Company initially reserved 2,000,430 shares of common stock for the issuance of a variety of awards under the 2019 Plan, including stock options, stock appreciation rights, awards of restricted stock and awards of restricted stock units (“RSUs”). In addition, the number of shares of common stock reserved for issuance under the 2019 Plan will automatically increase on the first day of January for a period of up to ten years, which commenced on January 1, 2020, in an amount equal to 3% of the total number of shares of the Company’s capital stock outstanding on the last day of the preceding year, or a lesser number of shares determined by the Board. As of March 31, 2023, there were 3,765,125 shares available for issuance under the 2019 Plan.
13

SHOCKWAVE MEDICAL, INC.
Notes to Condensed Consolidated Financial Statements
Stock Options
Option activity under the 2009 Plan and 2019 Plan is set forth below:
Number
of Shares		Weighted-
Average
Exercise
Price Per
Share		Weighted-
Average
Remaining
Term		Aggregate
Intrinsic
Value
(in years)(in thousands)
Balance, December 31, 20221,122,009 $5.87 4.60$224,115 
Awards authorized— 
Options exercised(77,230)4.12 
Options cancelled(6,133)2.41 
Balance, March 31, 20231,038,646 $6.02 4.41$218,961 
Vested and exercisable,
March 31, 2023		1,038,503 $6.01 4.41$218,935 
Vested and expected to vest, 
March 31, 2023		1,038,646 $6.02 4.41$218,961 
Restricted Stock Units
RSUs are share awards that entitle the holder to receive freely tradable shares of the Company’s common stock upon vesting. RSUs cannot be transferred and the awards are subject to forfeiture if the holder’s employment terminates prior to the release of the vesting restrictions. RSUs generally vest over a four-year period with straight-line quarterly vesting with a one year cliff or straight-line annual vesting, provided the employee remains continuously employed with the Company. The fair value of RSUs is equal to the closing price of the Company’s common stock on the grant date.
In February 2022 and 2023, the Company granted performance-based restricted stock units (“PRSUs”) to certain key executives. The vesting of these PRSUs is dependent on the achievement of certain performance targets related to the Company’s compound annual growth rate of revenue over a two or three year performance period, provided the executives remain employed with the Company at the time of vesting. The number of PRSUs that vest will vary from 0% to 200% of the target which will be determined based on the level of performance attained for each performance period. The fair value of these PRSUs is equal to the closing price of the Company’s common stock on the grant date. Compensation cost for PRSUs is recognized over the requisite service period based on the expected achievement of performance targets.
RSU and PRSU activity under the 2019 Plan is set forth below. Grant activity for all PRSUs is disclosed at target (100%):
Restricted Stock UnitsPerformance-Based Restricted Stock Units
Number
of Shares		Weighted-
Average
Grant Date
Fair Value
Per Share		Number
of Shares		Weighted-
Average
Grant Date
Fair Value
Per Share
Balance, December 31, 20221,125,991 $127.39 38,797 $165.74 
RSUs granted293,007 191.06 29,473 191.36
RSUs forfeited(19,803)145.72 (175)278.52 
RSUs vested(257,624)97.37 — — 
Balance, March 31, 20231,141,571 150.18 68,095 176.54 
14

SHOCKWAVE MEDICAL, INC.
Notes to Condensed Consolidated Financial Statements
Employee Stock Purchase Plan
In February 2019, the Company adopted the 2019 Employee Stock Purchase Plan (“ESPP”), which became effective in connection with the IPO on March 6, 2019. The Company initially reserved 300,650 shares of common stock for purchase under the ESPP. Each offering under the ESPP to Company employees to purchase stock under the ESPP begins on each September 1 and March 1 and ends on the following February 28 or 29 and August 31, respectively. On each purchase date, which falls on the last date of each offering period, ESPP participants will purchase shares of common stock at a price per share equal to 85% of the lesser of (1) the fair market value per share of the common stock on the offering date or (2) the fair market value of the common stock on the purchase date. The occurrence and duration of offering periods under the ESPP are subject to the determinations of the Company’s Compensation Committee of the Board, in its sole discretion.
The fair value of the ESPP shares is estimated using the Black-Scholes option pricing model. The Company recorded $1.3 million and $0.4 million of stock-based compensation expense related to the ESPP for the three months ended March 31, 2023 and 2022, respectively. At March 31, 2023, a total of 1,540,527 shares were available for issuance under the ESPP.
8. Net Income Per Share
The components of basic and diluted net income per share were as follows (in thousands, except share and per share amounts):
Three Months Ended
March 31,
20232022
Numerator:
Net income $39,125 $14,521 
Denominator:
Basic:
Weighted average number of common shares outstanding - basic36,427,263 35,587,337 
Diluted:
Weighted average number of common shares outstanding - basic36,427,263 35,587,337 
Dilutive effect of outstanding common stock options1,039,985 1,437,748 
Dilutive effect of restricted stock units510,340 597,817 
Dilutive effect of common stock pursuant to employee stock purchase plan1,860 575 
Weighted average number of common shares outstanding - diluted37,979,448 37,623,477 
Net income per share:
Basic$1.07 $0.41 
Diluted$1.03 $0.39 
15

SHOCKWAVE MEDICAL, INC.
Notes to Condensed Consolidated Financial Statements
9. Revenue
The following table represents the Company’s product revenue based on product line:
Three Months Ended
March 31,
20232022
(in thousands)
Coronary$113,875 $70,337 
Peripheral46,130 22,852 
Other 1,061 442 
Product revenue$161,066 $93,631 
Coronary product revenue encompasses sales of the Company’s C2 catheter and C2+ catheter. Peripheral product revenue encompasses sales of the Company’s M5 catheter, M5+ catheter, S4 IVL catheter, and L6 IVL catheter. Other product revenue encompasses sales of the Company’s generators and related accessories.
The following table represents the Company’s product revenue based on the location to which the product is shipped:
Three Months Ended
March 31,
20232022
(in thousands)
United States$131,623 $78,519 
Europe16,234 12,067 
All other countries13,209 3,045 
Product revenue$161,066 $93,631 
10. Equity Method Investments
Genesis Shockwave Private Limited
On March 19, 2021, the Company entered into the Joint Venture Deed (or “JV Agreement”) with Genesis MedTech International Private Limited (“Genesis”) to establish a long-term strategic partnership to develop, manufacture and commercialize certain of the Company’s interventional products in the People’s Republic of China, excluding the Special Administrative Regions of Hong Kong and Macau (the “PRC”). Under the JV Agreement, Genesis Shockwave Private Ltd. (the “JV”) was formed under the laws of Singapore to serve as a joint venture of Genesis and the Company for the purpose of establishing and managing the strategic partnership.
On the same date, Genesis and the Company entered into a Share Subscription Agreement pursuant to which, among other things, the JV issued (i) 54,900 ordinary shares which represents 55% of the total equity of the JV, to Genesis in exchange for a cash contribution of $15.0 million, of which 50% was due upon signing and the remaining 50% was due within one year of signing, and (ii) 45,000 ordinary shares, which represents 45% of the total equity of the JV, to the Company as consideration for the Shockwave License Agreement (the “License Agreement”). Under the License Agreement, the Company has agreed to contribute to the JV an exclusive license under certain of the Company’s intellectual property rights to develop, manufacture, distribute and commercialize certain products in the PRC and is entitled to receive royalties on the sales of the licensed products in the PRC. Further, the Company entered into a Distribution Agreement, pursuant to which the Company has agreed to sell certain Company-manufactured products to the JV or a PRC subsidiary of the JV for commercialization and distribution in the PRC. In May 2022, the JV obtained regulatory approval from the China National Medical Products Administration to sell the Company-manufactured Shockwave IVL System with the Shockwave C2 catheter, M5 catheter and S4 catheter in the PRC.
16

SHOCKWAVE MEDICAL, INC.
Notes to Condensed Consolidated Financial Statements
The Company has accounted for its investment in the JV under the equity method of accounting. As of March 31, 2023, the carrying value of the Company’s investment in the JV was $2.7 million and the Company owned a 45% interest in the entity. During the three months ended March 31, 2023, the Company continued to recognize product revenue on sales to the JV and eliminate a portion of intra-entity profit to the extent the goods have not yet either been consumed by the JV for use in clinical trials, or sold by the JV to an end customer at the end of the reporting period. The profit earned by the Company from the JV for items not yet sold through to an end customer is eliminated through equity method earnings or loss which is recognized in income (loss) from equity method investment.
The Company’s product revenue for products sold to the JV during the three months ended March 31, 2023 and related accounts receivable from the JV as of March 31, 2023 were immaterial. Intra-entity profit, which was recorded as a reduction to equity method investment as of and for the three months ended March 31, 2023, was also immaterial.
For the three months ended March 31, 2023 and 2022, the Company’s loss from the equity method was $0.8 million and $47,000, respectively.
Upon execution of the License Agreement, on March 19, 2021, the Company received a 45% equity stake in the JV. The Company determined that the JV met the definition of a customer under Topic 606, and that the promised goods and services of the contribution of the license of intellectual property and associated manufacturing technology transfer to the JV were considered to be a single performance obligation. The transaction price of $12.3 million was estimated by reference to the cash value of the shares that were issued at the formation of the JV.
As of March 31, 2023, the associated manufacturing technology transfer to the JV has not yet been completed. The Company maintains a related party contract liability, noncurrent, of $12.3 million for the outstanding performance obligation. The Company will satisfy the outstanding performance obligation upon the completion of training provided by the Company to the JV, and successful regulatory approval for the JV manufactured product from the China National Medical Products Administration.
11. Income Taxes
On a quarterly basis, the Company provides for income taxes based upon an estimated annual effective income tax rate, adjusted for discrete items. The Company recognized income tax expense of $1.6 million and $0.2 million for the three months ended March 31, 2023 and 2022, respectively, representing an effective tax rate of 3.96% and 1.34%, respectively. The year-over-year increase in tax expense for the three-month period ended March 31, 2023 was primarily due to the valuation allowance on the U.S. federal and other-than-California state deferred tax assets as of March 31, 2022, which was released in the fourth quarter of fiscal year 2022. For the three months ended March 31, 2023, the effective tax rate differed from the U.S. federal statutory rate primarily due to stock-based compensation for tax purposes and research credits. For the three months ended March 31, 2022, the effective tax rate differed from the U.S. federal statutory rate primarily due to the valuation allowance on the U.S. deferred tax assets.
The Company’s effective tax rate may be subject to fluctuation due to several factors, including the Company’s ability to accurately predict the pre-tax earnings in the various jurisdictions, valuation allowances against deferred tax assets, the recognition or de-recognition of tax benefits related to uncertain tax positions and the effects of tax law changes.
During the fourth quarter of 2022, the Company determined that the positive evidence overcame any negative evidence, primarily due to the Company’s transition from a cumulative loss in recent years to cumulative income in 2022 and concluded that it was more likely than not that the U.S. federal and other-than-California state deferred tax assets were realizable. As a result, the Company released the valuation allowance against all of the U.S. federal deferred tax assets and other-than-California state deferred tax assets during the fourth quarter of fiscal year 2022.
12. Subsequent Events
Acquisition of Neovasc, Inc.
On April 11, 2023, the Company completed the previously announced acquisition of Neovasc Inc. (“Neovasc”), a corporation existing under the Canada Business Corporations Act, in accordance with the Arrangement Agreement (the “Arrangement Agreement”). Pursuant to the Arrangement Agreement, the Company acquired all of the issued and outstanding common shares of Neovasc and Neovasc became a wholly owned subsidiary of the Company by means of a
17

SHOCKWAVE MEDICAL, INC.
Notes to Condensed Consolidated Financial Statements
plan of arrangement under the Canada Business Corporations Act. Each common share of Neovasc that was issued and outstanding immediately prior to April 11, 2023 was transferred to the Company in exchange for $27.25 per share in cash and one contingent value right entitling the holder to receive up to $12.00 per share in cash, with such receipt and amount contingent on whether the U.S. Food and Drug Administration grants marketing approval for the device known as the Neovasc Reducer for the treatment of angina within specified timeframes set forth in the Arrangement Agreement
Since the completion of the acquisition, the Company has paid a total of $107.2 million to Neovasc shareholders.
Pay-off of Credit Agreement Draw
On April 26, 2023, the Company repaid the $80.0 million drawn under the Credit Agreement in March 2023.

18

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
You should read the following discussion and analysis of our financial condition and results of operations together with our condensed financial statements and related notes included in this Quarterly Report on Form 10-Q and our audited consolidated financial statements and related notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on February 27, 2023 (the “2022 Annual Report”). Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10-Q, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. As a result of many important factors, including those set forth under “Special Note Regarding Forward-Looking Statements,” in the “Risk Factors” section of this Quarterly Report on Form 10-Q and in the “Risk Factors” section of our 2022 Annual Report, our actual results could differ materially from the results described in, or implied, by those forward-looking statements.
Overview
We are a medical device company focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. We aim to establish a new standard of care for medical device treatment of atherosclerotic cardiovascular disease through our differentiated and proprietary local delivery of sonic pressure waves for the treatment of calcified plaque, which we refer to as intravascular lithotripsy (“IVL”). Our IVL system (our “IVL System”), which leverages our IVL technology (our “IVL Technology”), is a minimally invasive, easy-to-use, and safe way to significantly improve outcomes for patients with calcified cardiovascular disease. We are currently selling the following products in a number of countries around the world where we have applicable regulatory approvals:
Products for the Treatment of Peripheral Artery Disease (“PAD”):
•Our Shockwave M5 IVL catheter (“M5 catheter”) and Shockwave M5+ IVL catheter (“M5+ catheter”) are five-emitter catheters for use in our IVL System in medium-diameter vessels for the treatment of PAD. The M5 catheter was CE-Marked in April 2018 and cleared by the U.S. Food and Drug Administration (“FDA”) in July 2018. The M5+ catheter was CE-Marked in November 2020 and cleared by the FDA in April 2021. In May 2022, we obtained regulatory approval, through our joint venture with Genesis MedTech International Private Limited (“Genesis”), from the China National Medical Products Administration (“NMPA”) to sell our M5 catheter in the People’s Republic of China, excluding the Special Administrative Regions of Hong Kong and Macau (the “PRC”).
•Our Shockwave S4 IVL catheter (“S4 catheter”) is a four-emitter catheter for use in our IVL System in small-diameter vessels for the treatment of PAD. The S4 catheter was CE-Marked in April 2018. The second version of our S4 catheter was cleared by the FDA in August 2019 and accepted by our EU notified body in May 2020 for use in our IVL System. In May 2022, we obtained regulatory approval, through our joint venture with Genesis, from the NMPA to sell our S4 catheter in the PRC.
•Our Shockwave L6 IVL catheter (“L6 catheter”) is a six-emitter catheter for use in our IVL System in large diameter vessels for the treatment of PAD. Our L6 catheter was cleared by the FDA in August 2022 for use in our IVL System. We commenced a U.S. limited market release for our L6 catheter in the fourth quarter of 2022 followed by a full market release in March 2023.
Products for the Treatment of Coronary Artery Disease (“CAD”):
•Our Shockwave C2 IVL catheter (“C2 catheter”) and Shockwave C2+ IVL catheter (“C2+ catheter”) are two-emitter catheters for use in our IVL System for the treatment of CAD. The C2 catheter was CE-Marked in June 2018. In August 2019, we received the Breakthrough Device Designation from the FDA for our C2 catheter using our IVL System for the treatment of CAD. We received FDA approval of our C2 catheter in February 2021. In March 2022, we received regulatory approval in Japan for our C2 catheter and commenced a limited market release in Japan in May 2022, followed by a full market release in January 2023. In May 2022, we obtained regulatory
19

approval, through our joint venture with Genesis, from the NMPA to sell our C2 catheter in the PRC. The C2+ catheter was CE-Marked in August 2022 and approved by the FDA in December 2022. In the fourth quarter of 2022, we commenced a limited market release for our C2+ catheter in select international locations, followed by a full market release in those locations in March 2023.
Our differentiated range of IVL catheters enables delivery of IVL therapy to diseased vasculature throughout the body for calcium modification. Our IVL catheters resemble in form a standard balloon angioplasty catheter, the device most commonly used by interventionalists. This familiarity makes our IVL System easy to learn, adopt and use on a day-to-day basis.
Since inception, we have focused on generating clinical data to demonstrate the safety and effectiveness of our IVL Technology. These studies have consistently shown low rates of complications regardless of which vessel was being studied. In addition to supporting our regulatory approvals or clearances, the data from our clinical studies strengthen our ability to drive adoption of our IVL Technology across multiple therapies in existing and new market segments. Our studies have also guided optimal IVL procedure technique and informed the design of our IVL System and future products in development. In addition, we have ongoing clinical programs across several products and indications, which, if successful, could allow us to expand commercialization of our products into new geographies and indications.
The first two indications that our IVL System addresses are PAD, the narrowing or blockage of vessels that carry blood from the heart to the extremities, and CAD, the narrowing or blockage of the arteries that supply blood to the heart. In the future, we see significant opportunity in the potential treatment of cardiac valvular disease, a condition where the heart’s valves become increasingly calcified with age, causing them to narrow and obstruct blood flow from the heart.
We have adapted the use of lithotripsy, which has been used to successfully treat kidney stones (deposits of hardened calcium) for over 30 years, to the cardiovascular field with the aim of creating what we believe is the safest, most effective means of addressing the growing challenge of cardiovascular calcification. By integrating lithotripsy into a device that resembles a standard balloon catheter, physicians can prepare, deliver, and treat calcified lesions using a familiar form factor, without disruption to their standard procedural workflow. Our differentiated IVL System works by delivering shockwaves through the entire depth of the artery wall, modifying both deep wall and thick calcium, not just at the thin, superficial most intimal layer. The shockwaves crack this calcium and enable the narrowed artery to expand at low pressures, thereby minimizing complications inherent to traditional balloon dilations, such as dissections or perforations. Preparing the vessel with IVL facilitates optimal outcomes with other adjacent therapies, including stents and drug-eluting technologies. Using IVL also avoids complications associated with atherectomy devices such as dissection, perforation, and embolism.
We market our products to hospitals whose interventional cardiologists, vascular surgeons and interventional radiologists treat patients with PAD and CAD. We have dedicated meaningful resources to establish a direct sales capability in the United States, Germany, Austria, Switzerland, France, Ireland, Japan and the United Kingdom and are working to build out our direct sales teams in Spain, Portugal and Canada. We have complemented our direct sales capabilities with distributors actively selling our products in over 55 countries in North and South America, Europe, the Middle East, Asia, Africa, and Australia/New Zealand. We are continuing to add new U.S. sales territories and are actively expanding our international field presence through new distributors, as well as additional sales and clinical personnel and expanded direct sales territories.
For the three months ended March 31, 2023 and 2022, we generated product revenue of $161.1 million and $93.6 million, respectively, and income from operations of $39.8 million and $15.4 million, respectively. For the three months ended March 31, 2023 and 2022, 18% and 16%, respectively, of our product revenue was generated from customers located outside of the United States.
Although we had net income for the year ended December 31, 2022 and the three months ended March 31, 2023, we may incur net losses in the future which may vary significantly from period to period. We expect to continue to incur significant expenses as we (i) expand our marketing efforts to increase adoption of our products, (ii) expand existing relationships with our customers, (iii) obtain regulatory clearances or approvals for our planned or future products, (iv) conduct clinical trials on our existing and planned or future products, and (v) develop new products or add new features to our existing products. We will need to continue to generate significant revenue in order to sustain profitability as we continue to grow our business. Even if we achieve profitability for any period, we cannot be sure that we will remain profitable for any substantial period of time.
20

To date, our principal sources of liquidity have been the net proceeds we received through the private sales of our equity securities, payments received from customers purchasing our products and proceeds from our debt financings. For the three months ended March 31, 2023, we generated positive cash flows from operations of $34.0 million. As of March 31, 2023, we had $416.9 million in cash, cash equivalents and short-term investments and retained earnings of $2.3 million.
Impact of current global economic conditions
Uncertainty in the global economy presents significant risks to our business. We are subject to continuing risks and uncertainties in connection with the current macroeconomic environment, including inflation and rising interest rates, geopolitical factors, including the ongoing conflict between Russia and Ukraine and the responses thereto, supply chain disruptions and the remaining effects of the COVID-19 pandemic. We are closely monitoring the impact of these factors on all aspects of our business, including the impacts on our customers, patients, employees, suppliers, vendors, business partners and distribution channels.
In particular, while we have not experienced material disruptions in our supply chain to date, we have been and continue to be impacted by disruptions in the operations of certain of our third-party suppliers, resulting in increased lead-times, higher component costs and lower allocations for our purchase of some components. In certain cases, we have incurred higher logistical expenses. We are continuing to work closely with our manufacturing partners and suppliers to source key components and maintain appropriate inventory levels to meet customer demand.
The ultimate extent of the impact of global economic conditions on our business remains highly uncertain and will depend on future developments and factors that continue to evolve. Most of these developments and factors are outside of our control and could exist for an extended period of time. As a result, we are subject to continuing risks and uncertainties and continue to closely monitor the impact of the current conditions on our business. For more information regarding these risks and uncertainties, see the section titled “Risk Factors” in our 2022 Annual Report, together with any updates in the section titled “Risk Factors” in this Quarterly Report on Form 10-Q.
Components of Our Results of Operations
Product revenue
Product revenue is primarily from the sale of our IVL catheters.
We sell our products to hospitals, primarily through direct sales representatives, as well as through distributors in selected international markets. For products sold through direct sales representatives, control is transferred upon delivery to customers. For products sold to distributors internationally and products sold to customers that utilize stocking orders, control is transferred upon shipment or delivery to the customer’s named location, based on the contractual shipping terms. Additionally, a portion of our revenue is generated through a consignment model under which inventory is maintained at hospitals. For consignment inventory, control is transferred at the time the catheters are consumed in a procedure.
Cost of product revenue
Cost of product revenue consists primarily of the costs of the components for use in our products, the materials and labor that are used to produce our products, the manufacturing overhead that directly supports production and the depreciation relating to the equipment used in our IVL System to the extent that we loan generators to our hospital customers, without charge to facilitate the use of our IVL catheters in their procedures. We depreciate the equipment over a three-year period. We expect costs of product revenue to increase in absolute terms as our revenue grows.
Our gross margin has been and will continue to be affected by a variety of factors, primarily production volumes, the cost of direct materials, product mix, geographic mix, discounting practices, manufacturing costs, product yields, headcount and cost-reduction strategies. We expect our gross margin percentage to marginally increase over the long term to the extent we are successful in increasing our sales volume and are therefore able to leverage our fixed costs. We intend to use our design, engineering and manufacturing capabilities to further advance and improve the efficiency of our manufacturing processes, which, if successful, we believe will reduce costs and enable us to increase our gross margin percentage. While we expect gross margin percentage to increase over the long term, it will likely fluctuate from quarter to quarter as we continue to introduce new products and adopt new manufacturing processes and technologies.
21

Research and development expenses
Research and development expenses consist of applicable personnel, consulting, materials, and clinical trial expenses. Research and development expenses include, but are not limited to:
•certain personnel-related expenses, including salaries, benefits, bonus, travel and stock-based compensation;
•cost of clinical studies to support new products and product enhancements, including expenses for clinical research organizations and site payments;
•materials and supplies used for internal research and development and clinical activities;
•allocated overhead including facilities and information technology expenses; and
•cost of outside consultants who assist with technology development, regulatory affairs, clinical affairs and quality assurance.
Research and development costs are expensed as incurred. In the future, we expect research and development expenses to increase in absolute dollars as we continue to develop new products, enhance existing products and technologies and perform activities related to obtaining additional regulatory approvals.
Sales and marketing expenses
Sales and marketing expenses consist of personnel-related expenses, including salaries, benefits, sales commissions, travel and stock-based compensation. Other sales and marketing expenses consist of marketing and promotional activities, including trade shows and market research. We expect to continue to grow our sales force and increase marketing efforts as we continue commercializing products based on our IVL Technology. As a result, we expect sales and marketing expenses to increase in absolute dollars over the long term.
General and administrative expenses
General and administrative expenses consist of personnel-related expenses, including salaries, benefits, bonus, travel and stock-based compensation. Other general and administrative expenses consist of professional services fees, including legal, audit and tax fees, insurance costs, outside consultant fees and employee recruiting and training costs. Moreover, we expect to incur additional expenses associated with operating as a public company, including legal, accounting, insurance, exchange listing and Securities and Exchange Commission (“SEC”) compliance and investor relations.
Loss from equity method investment
Loss from equity method investment, represents our proportionate share of the underlying income or loss incurred in connection with our joint venture with Genesis. Also included in loss from equity method investment is the portion of intra-entity profit which is eliminated to the extent the goods have not yet either been consumed by the JV for use in clinical trials, or sold through by the JV to an end customer at the end of the reporting period.
Interest expense
Interest expense consists of the interest and amortization expense related to our debt.
Other income (expense), net
Other income (expense), net consists of interest earned on our cash equivalents and short-term investments and the net impact of foreign exchange gains and losses.
Income tax provision
Income tax provision consists of income taxes from the U.S. and foreign jurisdictions.
22

Results of Operations
Comparison of the Three Months Ended March 31, 2023 and 2022
The following table shows our results of operations for the three months ended March 31, 2023 and 2022:
Three Months Ended March 31,Change
$ 		Change
%
20232022
(in thousands, except percentages)
Revenue:
Product revenue$161,066 $93,631 $67,435 72%
Cost of revenue:
Cost of product revenue21,066 12,890 8,176 63%
Gross profit140,000 80,741 59,259 73%
Operating expenses:
Research and development26,971 17,019 9,952 58%
Sales and marketing54,011 35,961 18,050 50%
General and administrative19,204 12,389 6,815 55%
Total operating expenses100,186 65,369 34,817 53%
Income from operations39,814 15,372 24,442 159%
Loss from equity method investment (823)(47)(776)1,651%
Interest expense(636)(297)(339)114%
Other income (expense), net2,382 (310)2,692 (868)%
Net income before taxes40,737 14,718 26,019 177%
Income tax provision1,612 197 1,415 718%
Net income$39,125 $14,521 $24,604 169%
Product revenue
Product revenue increased by $67.4 million, or 72%, from $93.6 million during the three months ended March 31, 2022 to $161.1 million during the three months ended March 31, 2023.
The following table represents our product revenue based on product line:
Three Months Ended March 31,Change
$		Change
%
20232022
(in thousands, except percentages)
Coronary$113,875 $70,337 $43,538 62%
Peripheral46,130 22,852 23,278 102%
Other 1,061 442 619 140%
Product revenue$161,066 $93,631 $67,435 72%

Coronary product revenue increased by $43.5 million, or 62%, from $70.3 million for the three months ended March 31, 2022 to $113.9 million for the three months ended March 31, 2023. The increase in coronary product revenue was due an increase in the purchase volume of our C2 catheters in the United States and increased adoption of our products internationally.
23

Peripheral product revenue increased by $23.3 million, or 102%, from $22.9 million for the three months ended March 31, 2022 to $46.1 million for the three months ended March 31, 2023 which was due to an increase in the purchase volume of our M5+ catheter, S4 catheter, and L6 catheter within the United States and internationally driven by increased adoption of our products.
We sold to a greater number of customers in the United States and to a greater number of distributors internationally for the three months ended March 31, 2023 as compared to the three months ended March 31, 2022. Product revenue, classified by the major geographic areas in which our products are shipped, was $131.6 million, or 82%, within the United States and $29.4 million, or 18%, for all other countries in the three months ended March 31, 2023 compared to $78.5 million, or 84%, within the United States and $15.1 million, or 16%, for all other countries in three months ended March 31, 2022.
Cost of product revenue, gross profit and gross margin percentage
Cost of product revenue increased by $8.2 million, or 63%, from $12.9 million during the three months ended March 31, 2022 to $21.1 million during the three months ended March 31, 2023. The increase was driven by higher product sales volume compared to the prior year. Gross margin percentage improved to 87% for the three months ended March 31, 2023, compared to 86% for the three months ended March 31, 2022. This change in gross margin percentage was primarily due to a higher average selling price and lower fixed costs per unit from increased sales volume of our IVL catheters and efficiencies from improvements to productivity and process efficiencies.
Research and development expenses
The following table summarizes our research and development expenses incurred during the periods presented:
Three Months Ended March 31,Change
$		Change
%
20232022
(in thousands)
Compensation and personnel-related costs$14,748 $10,534 $4,214 40%
Facilities and other allocated costs5,320 2,023 3,297 163%
Materials and supplies2,505 1,055 1,450 137%
Clinical-related costs2,579 1,906 673 35%
Outside consultants1,283 1,028 255 25%
Other research and development costs536 473 63 13%
Total research and development expenses$26,971 $17,019 $9,952 58%
Research and development expenses increased by $10.0 million, or 58%, from $17.0 million during the three months ended March 31, 2022 to $27.0 million during the three months ended March 31, 2023. The change was primarily due to a $4.2 million increase in compensation and personnel-related costs due to an increase in headcount, a $3.3 million increase in facilities and other allocated costs due to increased information technology, rent and building expenditures, a $1.4 million increase in materials and supplies, an increase in clinical-related costs of $0.7 million, a $0.3 million increase in outside consultants, and a $0.1 million increase in other research and development costs.
Sales and marketing expenses
Sales and marketing expenses increased by $18.0 million, or 50%, from $36.0 million during the three months ended March 31, 2022 to $54.0 million during the three months ended March 31, 2023. The change was primarily due to a $10.8 million increase in compensation and personnel-related costs, resulting from increased headcount and commissions driven by increased sales of our products. There was also a $3.9 million increase in travel related costs, a $1.3 million increase in marketing and promotional costs, a $1.0 million increase in facilities and other allocated costs, a $0.4 million increase in professional and consulting services, a $0.3 million increase in materials and supplies, a $0.2 million increase in general corporate costs, and a $0.1 million increase in recruiting and training fees.
24

General and administrative expenses
General and administrative expenses increased by $6.8 million, or 55%, from $12.4 million during the three months ended March 31, 2022 to $19.2 million during the three months ended March 31, 2023. The change was primarily due to a $3.4 million increase in compensation and personnel-related costs, a $2.1 million increase in professional services and consulting costs, a $0.8 million increase in general corporate costs, a $0.3 million increase in facilities and other allocated costs due to increased information technology, rent and building expenditures, and a $0.2 million increase in travel related costs.
Loss from equity method investment
The increase in loss from equity method investment of $0.8 million for the three months ended March 31, 2023 was due to increased sales by the JV to end customers following the NMPA approval of products in the PRC, and the elimination of intra-entity profit for goods sold by us to the JV that have not yet been sold through by the JV to an end customer at the end of the reporting period.
Interest expense
Interest expense increased by $0.3 million, or 114%, from $0.3 million during the three months ended March 31, 2022 to $0.6 million during the three months ended March 31, 2023. The increase in interest expense was related to the additional draw of $80 million under the Credit Agreement in March 2023.
Other income (expense), net
Other income (expense), net increased by $2.7 million, or 868%, from $0.3 million in other expense, net during the three months ended March 31, 2022 to $2.4 million in other income, net during the three months ended March 31, 2023. The increase in other income was primarily due to an increase in interest income from increased interest rates, partially offset by an increase in foreign exchange losses.
Income tax provision
Income tax provision of $1.6 million for the three months ended March 31, 2023 primarily consisted of U.S. federal, state, and foreign income taxes. The income tax expense for the three months ended March 31, 2023 reflected the impact of a change in U.S. tax law, effective January 1, 2022, which requires the capitalization and amortization of research and experimental expenditures incurred after December 31, 2022. Income tax provision of $0.2 million for the three months ended March 31, 2022 primarily consisted of foreign income taxes.
Liquidity and Capital Resources
To date, our principal sources of liquidity have been the net proceeds of $280.0 million that we received through the sale of our common stock in our public offerings, $10.0 million from private sales of our equity securities, payments received from customers using our products and proceeds from our debt financings.
On October 19, 2022, we entered into the Credit Agreement with Wells Fargo Bank, National Association, as administrative agent, Wells Fargo Bank, National Association, as swingline lender and an issuing lender, Wells Fargo Securities, LLC and Silicon Valley Bank, as joint lead arrangers and joint bookrunners, Silicon Valley Bank, as syndication agent, and the several lenders party thereto (the “Credit Agreement”). The Credit Agreement provides for a revolving credit facility in an aggregate principal amount of $175 million with the right to request increases to the revolving commitments (subject to certain conditions) of up to the greater of (x) $100 million or (y) our consolidated EBITDA for the four fiscal quarter period most recently ended prior to the date of such increase.
Concurrent with entering into a Credit Agreement, we drew down $25.0 million and prepaid in full all outstanding amounts and related expenses under the previous Credit Agreement with Silicon Valley Bank, totaling $14.6 million, and terminated the credit facility thereunder. We drew down an additional $80.0 million under the Credit Agreement during the three months ended March 31, 2023. On April 26, 2023, we repaid the $80.0 million drawn under the Credit Agreement in March 2023.
Since the completion of the acquisition, we have paid a total of $107.2 million to Neovasc shareholders.
25

We have a number of ongoing clinical trials and expect to continue to make substantial investments in these trials as well as additional clinical trials designed to provide clinical evidence of the safety and efficacy of our existing products. We intend to continue to make significant investments in our sales and marketing organization by increasing the number of U.S. sales representatives and expanding our international marketing programs to help facilitate further adoption among existing hospital accounts and physicians as well as broaden awareness of our products to new hospitals. We also expect to continue to make investments in research and development, regulatory affairs, and clinical studies to develop future generations of products based on our IVL Technology, support regulatory submissions, and demonstrate the clinical efficacy of our products. Moreover, we expect to continue to incur expenses associated with operating as a public company, including legal, accounting, insurance, exchange listing and SEC compliance, investor relations and other expenses. Because of these and other factors, although we had net income and generated cash flows from operations for the three months ended March 31, 2023 and for the year ended December 31, 2022, we may incur net losses and have negative cash flows from operations in the future.
As of March 31, 2023, we had $416.9 million in cash, cash equivalents and short-term investments and retained earnings of $2.3 million.
In the short term, we believe that our cash, cash equivalents and short-term investments will be sufficient for at least the next 12 months to meet our requirements and plans for cash, including supporting working capital, capital expenditure requirements, investments, acquisitions or repayments of credit facilities. In the long term, our ability to support our working capital and capital expenditure requirements will depend on many factors, including:
•the cost, timing and results of our clinical trials and regulatory reviews;
•the cost of our research and development activities for new and modified products;
•the cost and timing of establishing sales, marketing and distribution capabilities;
•the terms and timing of any other collaborative, licensing and other arrangements that we may establish including any contract manufacturing arrangements;
•the timing, receipt and amount of sales from our current and potential products;
•the degree of success we experience in commercializing our products;
•the emergence of competing or complementary technologies;
•macroeconomic conditions, including a potential recession, inflation, rising interest rates and instability in the global banking system;
•the cost of preparing, filing, prosecuting, maintaining, defending and enforcing any patent claims and other intellectual property rights; and
•the extent to which we acquire or invest in businesses, products or technologies, although we currently have no commitments or agreements relating to any of these types of transactions.
To the extent that current and anticipated future sources of liquidity are insufficient to fund our future business activities and cash and other requirements, we may be required to seek additional equity or debt financing. The sale of additional equity would result in additional dilution to our stockholders. The incurrence of additional debt financing would result in debt service obligations and the instruments governing such debt could provide for operating and financing covenants that would restrict our operations. In the event that additional financing is required from outside sources, there is a possibility we may not be able to raise it on terms acceptable to us or at all. Further, the current macroeconomic environment may make it difficult for us to raise capital on terms favorable to us or at all. If we are unable to raise additional capital when desired, our business, operating results, and financial condition could be adversely affected.
26

Our material cash requirements include the following contractual and other obligations:
Debt, Principal, and Interest
As of March 31, 2023, our debt, principal and interest commitments consist of our debt obligations under the Credit Agreement.
As discussed above, on October 19, 2022, we entered into the Credit Agreement, which provides for a revolving credit facility in an aggregate principal amount of $175 million with the right to request increases to the revolving commitments (subject to certain conditions) of up to the greater of (x) $100 million or (y) our consolidated EBITDA for the four fiscal quarter period most recently ended prior to the date of such increase.
Concurrent with entering into the Credit Agreement, we drew down $25.0 million. We drew down an additional $80.0 million under the Credit Agreement during the three months ended March 31, 2023.
The Credit Agreement is secured by all of our assets, excluding intellectual property and certain other assets. The Credit Agreement is subject to customary affirmative and restrictive covenants, including with respect to our ability to enter into fundamental transactions, incur additional indebtedness, grant liens, and pay any dividend or make any distributions to stockholders.
As of March 31, 2023, we had $104.2 million of outstanding principal, net of unamortized debt issuance costs which matures in October 2027. On April 26, 2023, we repaid the $80.0 million drawn under the Credit Agreement in March 2023.
Manufacturing Purchase Obligations
We have engaged a contract manufacturer to produce and supply us with certain products. We have fixed commitments of approximately $14.7 million within the next twelve months.
Operating Leases
Our operating lease commitments mostly consist of our lease obligations for our Santa Clara headquarter office spaces, as well as for laboratory and manufacturing space. Our total operating lease commitments as of March 31, 2023 are approximately $51.3 million, of which $5.3 million is expected to be paid within the next twelve months.
There were no other material changes during the three months ended March 31, 2023 to our contractual obligations as compared to those disclosed in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our 2022 Annual Report.
We did not have during the periods presented, and we do not currently have, any commitments or obligations, including contingent obligations, arising from arrangements with unconsolidated entities or persons that have or are reasonably likely to have a material current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, cash requirements or capital resources.
27

Cash Flows
The following table summarizes our cash flows for the periods indicated:
Three Months Ended March 31,
20232022
Net cash provided by (used in):(in thousands)
Operating activities$33,962 $1,937 
Investing activities6,182 (27,414)
Financing activities83,409 2,520 
Effect of exchange rate changes on cash and cash equivalents792 — 
Net increase (decrease) in cash, cash equivalents and restricted cash$124,345 $(22,957)
Operating activities
During the three months ended March 31, 2023, cash provided by operating activities was $34.0 million, attributable to a net income of $39.1 million, and non-cash charges of $17.4 million, partially offset by a net change in our net operating assets and liabilities of $22.5 million. Non-cash charges of $17.4 million primarily consisted of $16.0 million in stock-based compensation, $1.7 million in depreciation and amortization, and $0.7 million in non-cash lease expense. The change in our net operating assets and liabilities of $22.5 million was primarily due to a $13.0 million increase in accounts receivable due to an increase in sales, a $7.8 million increase in inventory driven by an increase in raw materials and finished goods inventory, and a $6.7 million decrease in accrued and other current liabilities from payment of accrued bonuses and other compensation in the current quarter,
During the three months ended March 31, 2022, cash provided by operating activities was $1.9 million, attributable to a net income of $14.5 million and non-cash charges of $11.6 million, partially offset by a net change in our net operating assets and liabilities of $24.2 million. Non-cash charges of $11.6 million primarily consisted of $9.5 million in stock-based compensation, $1.0 million in depreciation and amortization, and $0.8 million in non-cash lease expense. The change in our net operating assets and liabilities of $24.2 million was primarily due to a $10.4 million increase in accounts receivable due to an increase in sales, a $10.1 million increase in inventory driven by an increase in raw materials and finished goods inventory, and a $9.1 million decrease in accrued and other current liabilities resulting from payment of accrued bonuses and other compensation in the three months ended March 31, 2022. These changes were partially offset by a $4.9 million increase in accounts payable due to the timing of vendor billings.
Investing activities
During the three months ended March 31, 2023, cash provided by investing activities was $6.2 million, attributable to proceeds from maturities of available-for-sale investments of $34.5 million, partially offset by purchases of available-for-sale investments of $21.1 million and purchases of property and equipment of $7.2 million.
During the three months ended March 31, 2022, cash used in investing activities was $27.4 million, attributable to purchases of available-for-sale investments of $42.1 million and purchases of property and equipment of $3.3 million, partially offset by proceeds from maturities of available-for-sale investments of $18.0 million.
Financing activities
During the three months ended March 31, 2023, cash provided by financing activities was $83.4 million, attributable to proceeds of $80.0 million from debt financing, net of issuance costs, $3.1 million from the issuance of shares under our employee stock purchase plan, and proceeds of $0.3 million from stock option exercises.
During the three months ended March 31, 2022, cash provided by financing activities was $2.5 million, attributable to proceeds of $2.1 million from the issuance of shares under our employee stock purchase plan and proceeds of $0.4 million from stock option exercises.
28

Critical Accounting Policies and Estimates
Management’s discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). The preparation of these condensed consolidated financial statements requires us to make estimates and assumptions for the reported amounts of assets, liabilities, revenue, expenses and related disclosures. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions and any such differences may be material.
There have been no significant changes in our critical accounting policies and assumptions associated with the greatest potential impact on our consolidated financial statements as disclosed in our 2022 Annual Report in the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
There have been no material changes to our quantitative and qualitative disclosures about market risk as compared to the quantitative and qualitative disclosures about market risk described in our 2022 Annual Report.
Item 4. Controls and Procedures.
Evaluation of disclosure controls and procedures
Our management, with the participation and supervision of our Chief Executive Officer and our Chief Financial Officer, have evaluated our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this Quarterly Report on Form 10-Q, our disclosure controls and procedures are effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.
Changes in internal control over financial reporting
There was no change in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the period covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
Inherent limitation on the effectiveness of internal control
Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.
29

PART II—OTHER INFORMATION
Item 1. Legal Proceedings.
A petition for inter partes review (“IPR”) of U.S. Pat. No. 8,956,371 (the “’371 patent”), which is one of our issued U.S. patents that relates to our current IVL technology, was filed in December 2018 at the U.S. Patent and Trademark Office’s (the “USPTO”) Patent Trial and Appeal Board (the “PTAB”) by Cardiovascular Systems, Inc. (“CSI”), one of our competitors. The PTAB instituted IPR proceedings for this patent and held oral hearings in April 2020. On July 8, 2020, the PTAB ruled that one claim (“Claim 5”) in the ’371 patent is valid and ruled that all other claims in the ’371 patent are invalid. On August 27, 2020, further briefing by the parties was requested by the PTAB in the ’371 patent proceeding to assess whether recent guidance from the USPTO relating to “applicant admitted prior art” impacted the PTAB’s decision in the ’371 patent proceeding. In addition, the PTAB reset the time for commencement of an appeal in the ’371 patent proceeding pending the entry of a final decision after the requested briefing. The requested briefing is complete and the PTAB’s decision is pending. On March 9, 2022, the PTAB issued an order authorizing us to file a motion for additional discovery. On March 23, 2022, we filed a motion for additional discovery, relating to additional information publicized by CSI after the PTAB's decision on the patents. On February 2, 2023, the PTAB denied the motion for additional discovery and issued a final decision, ruling again that Claim 5 is valid and that all other claims are invalid. We will be pursuing an appeal of this ruling. Accordingly, Claim 5 and all other claims remain valid and enforceable until all appeals have been exhausted. Upon the conclusion of such appeals, if we are unsuccessful in whole or in part, the ’371 patent proceedings could result in the loss or narrowing in scope of the ’371 patent, which could further limit our ability to stop others from using or commercializing products and technology similar or identical to ours.
For more information regarding the risks presented by such proceedings, please see the section of our 2022 Annual Report, titled “Risk Factors—Risks Related to Our Intellectual Property.”
From time to time, we may become involved in various legal proceedings that arise in the ordinary course of our business. We have received, and may from time to time receive, letters from third parties alleging patent infringement, violation of employment practices or trademark infringement, and we may in the future participate in litigation to defend ourselves. We cannot predict the results of any such disputes, and despite the potential outcomes, the existence thereof may have an adverse material impact on us due to diversion of management time and attention as well as the financial costs related to resolving such disputes.
Item 1A. Risk Factors.
The following risk factor supplements and, to the extent inconsistent, supersedes, the risk factors disclosed in Part I, Item 1A. “Risk Factors” of our 2022 Annual Report. The risk factor included herein as well as the risk factors described in our 2022 Annual Report, and other information set forth in this Quarterly Report on Form 10-Q, could materially adversely affect our business, financial condition, results of operations and prospects, and should be carefully considered. The risks and uncertainties that we face, however, are not limited to those described herein or in the 2022 Annual Report. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also adversely affect our business and the trading price of our securities.
Unfavorable global economic conditions could adversely affect our business, financial condition, or results of operations.
Our results of operations could be adversely affected by general conditions in the global economy and financial markets. If the conditions in the general economy deteriorate, including as a result of changes in gross domestic product growth, recent volatility and disruptions in the capital and credit markets, rising interest rates, increasing effects of inflation, the COVID-19 pandemic and the responses thereto, the ongoing conflict between Russia and Ukraine and the responses thereto, global supply-chain disruptions or the tightening of the global labor market, or otherwise, our business, financial condition, and operating results could be adversely affected. Moreover, there has been recent turmoil in the global banking system. For example, on March 10, 2023, Silicon Valley Bank, which was one of four lenders under the Credit Agreement, was closed by the California Department of Financial Protection & Innovation and the Federal Deposit Insurance Corporation (the “FDIC”) was named receiver for Silicon Valley Bank. At the time of closing on March 10, 2023, we had cash, cash equivalents and short-term and long-term investments at Silicon Valley Bank or under Silicon Valley Bank management. While the majority of these assets were not restricted by the FDIC action to take control of Silicon Valley Bank as most of these assets resided in a custodial account with a third-party bank for which Silicon Valley Bank acted as advisor and the FDIC has taken steps to make whole all depositors of Silicon Valley Bank, there is no
30

assurance that similar guarantees will be made in the event of further bank closures and continued instability in the global banking system. Our ongoing cash management strategy is to maintain diversity in our deposit accounts across financial institutions, but deposits in these institutions may exceed the amount of insurance provided on such deposits and there can be no assurance that this strategy will be successful. If other banks and financial institutions enter receivership or become insolvent in the future in response to financial conditions affecting the banking system and financial markets, then our ability to access our cash, cash equivalents and short-term and long-term investments may be threatened, which could have a material adverse effect on our business and financial condition. Moreover, events such as the closure of Silicon Valley Bank, in addition to other global macroeconomic conditions, may cause further turbulence and uncertainty in the capital markets. A severe or prolonged economic downturn, could result in a variety of risks to our business, including driving hospitals to tighten budgets and curtail spending, which would negatively impact our sales and business. A significant change in the liquidity or financial condition of our customers could cause unfavorable trends in their purchases and also in our receivable collections, and additional allowances may be required, which could adversely affect our business, financial condition and results of operations. Adverse worldwide economic conditions may also adversely impact our suppliers’ ability to provide us with materials and components, which could have a material adverse effect on our business, financial condition, and results of operations.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
None.
Item 3. Defaults Upon Senior Securities.
None.
Item 4. Mine Safety Disclosures.
Not applicable.
Item 5. Other Information.
None.
31

Item 6. Exhibits.
Furnish the exhibits required by Item 601 of Regulation S-K (§ 229.601 of this chapter).
Exhibit
Number		DescriptionFormFile No.Exhibit(s)Filing Date
31.1*
31.2*
32.1*#
32.2*#
101.INS*Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH*Inline XBRL Taxonomy Extension Schema Document
101.CAL*Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*Inline Taxonomy Extension Presentation Linkbase Document
104
The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 has been formatted in Inline XBRL and contained in Exhibit 101
_______________________________
*Filed herewith.
#    This certification is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act.
32

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Shockwave Medical, Inc.
Date: May 8, 2023
By:/s/ Douglas Godshall
Douglas Godshall
President, Chief Executive Officer and Director
(principal executive officer)
Date: May 8, 2023
By:/s/ Trinh Phung
Trinh Phung
Vice President of Finance
(principal accounting officer)
33
 EX-31.1 2 swav-ex31_1xq123.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO
RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Douglas Godshall, certify that:
1.I have reviewed this quarterly report on Form 10-Q of Shockwave Medical, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date: May 8, 2023

By:/s/ Douglas Godshall
Douglas Godshall
President, Chief Executive Officer and Director
(Principal Executive Officer)


 EX-31.2 3 swav-ex31_2xq123.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO
RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Dan Puckett, certify that:
1.I have reviewed this quarterly report on Form 10-Q of Shockwave Medical, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date: May 8, 2023

By:/s/ Daniel K. Puckett
Daniel K. Puckett
Chief Financial Officer
(Principal Financial Officer)


 EX-32.1 4 swav-ex32_1xq123.htm EX-32.1 Document

Exhibit 32.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Shockwave Medical, Inc. (the “Company”) on Form 10-Q for the period ending March 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: May 8, 2023

By:/s/ Douglas Godshall
Douglas Godshall
President, Chief Executive Officer and Director
(Principal Executive Officer)


 EX-32.2 5 swav-ex32_2xq123.htm EX-32.2 Document

Exhibit 32.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Shockwave Medical, Inc. (the “Company”) on Form 10-Q for the period ending March 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: May 8, 2023

By:/s/ Daniel K. Puckett
Daniel K. Puckett
Chief Financial Officer
(Principal Financial Officer)


 EX-101.SCH 6 swav-20230331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Condensed Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 0000006 - Disclosure - Organization and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 0000007 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - Financial Instruments and Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Cash Equivalents and Short-Term Investments link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Balance Sheet Components link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Term Notes link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Net Income (Loss) Per Share link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Equity Method Investments link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Financial Instruments and Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Cash Equivalents and Short-Term Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Balance Sheet Components (Tables) link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Term Notes (Tables) link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - Net Income (Loss) Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 0000027 - Disclosure - Organization and Basis of Presentation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000028 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 0000029 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000030 - Disclosure - Financial Instruments and Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 0000031 - Disclosure - Cash Equivalents and Short-Term Investments - Summary of Cash Equivalents and Short-Term Investments (Details) link:presentationLink link:calculationLink link:definitionLink 0000032 - Disclosure - Cash Equivalents and Short-Term Investments - Summary of Remaining Contractual Maturities for Available-for-sale Securities (Details) link:presentationLink link:calculationLink link:definitionLink 0000033 - Disclosure - Cash Equivalents and Short-Term Investments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000034 - Disclosure - Balance Sheet Components - Schedule of Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 0000035 - Disclosure - Balance Sheet Components - Schedule of Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 0000036 - Disclosure - Term Notes - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000037 - Disclosure - Term Notes - Schedule of Current and Noncurrent Debt and Net Discount or Premium Balances (Details) link:presentationLink link:calculationLink link:definitionLink 0000037 - Disclosure - Term Notes - Schedule of Current and Noncurrent Debt and Net Discount or Premium Balances (Details) link:presentationLink link:calculationLink link:definitionLink 0000038 - Disclosure - Stock-Based Compensation - Schedule of Total Stock-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 0000039 - Disclosure - Stock-Based Compensation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000040 - Disclosure - Stock-Based Compensation - Schedule of Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 0000041 - Disclosure - Stock-Based Compensation - Schedule of RSU Activity (Details) link:presentationLink link:calculationLink link:definitionLink 0000042 - Disclosure - Net Income (Loss) Per Share - Components of Basic and Diluted Net Income (Loss) Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 0000043 - Disclosure - Revenue - Schedule of Product Revenue Based on Product Line (Details) link:presentationLink link:calculationLink link:definitionLink 0000044 - Disclosure - Revenue - Schedule of Product Revenue Based on Location (Details) link:presentationLink link:calculationLink link:definitionLink 0000045 - Disclosure - Equity Method Investments - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000046 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 0000047 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 swav-20230331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 swav-20230331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 swav-20230331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Business Acquisition [Axis] Business Acquisition [Axis] Incremental revolving commitments, maximum Line Of Credit Facility, Accordion Feature, Increase Limit Line Of Credit Facility, Accordion Feature, Increase Limit One year or less Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Type of Revenue [Extensible List] Revenue, Product and Service [Extensible Enumeration] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Schedule of Cash and Cash Equivalents Schedule of Cash and Cash Equivalents [Table Text Block] Net income (loss) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Share Subscription Agreement Share Subscription Agreement [Member] Share subscription agreement. Deferred tax assets Deferred Income Tax Assets, Net JV Agreement with Genesis MedTech J V Agreement With Genesis Med Tech [Member] JV agreement with Genesis MedTech Entity Address, Postal Zip Code Entity Address, Postal Zip Code Greater than one year and less than two years Available For Sale Securities Debt Maturities Within Greater Than One Year And Less Than Two Years Fair Value Available for sale securities debt maturities within greater than one year and less than two years fair value. Debt Instrument Debt Instrument [Axis] Line of credit facility, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Income Tax Disclosure [Abstract] Summary of Cash Equivalents and Short-Term Investments Cash, Cash Equivalents and Investments [Table Text Block] Financial Instruments Financial Instruments [Domain] Debt interest rate basis Debt Instrument, Basis Spread on Variable Rate Statistical Measurement Statistical Measurement [Domain] Proceeds of supplemental term loan Proceeds from Issuance of Debt Exercise of stock options (in shares) Options exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Issuance of common stock in connection with vesting of restricted stock (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Short-term Debt, Type Short-Term Debt, Type [Axis] Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Additional paid-in capital Additional Paid in Capital, Common Stock Income tax paid Income Taxes Paid Net income Net income (loss) Net Income (Loss) Attributable to Parent Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Fed Funds Effective Rate Overnight Index Swap Rate Fed Funds Effective Rate Overnight Index Swap Rate [Member] Adjustment for net gain realized and included in other income Adjustment for net gain realized and included in other income Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax Equity Component Equity Component [Domain] All other countries All Other Countries [Member] All other countries. Subsequent Event Type [Domain] Subsequent Event Type [Domain] Total assets Assets, Fair Value Disclosure Investment, Name Investment, Name [Domain] Vesting percentage Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Related Party Related Party [Domain] Business Acquisition, Share Price Business Acquisition, Share Price Short-term investments, fair value Debt Securities, Available-for-Sale SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: Supplemental Cash Flow Information [Abstract] Options cancelled (USD per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Entity Address, State or Province Entity Address, State or Province Level 1 Fair Value, Inputs, Level 1 [Member] Employee Stock Employee Stock [Member] Other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax [Abstract] Balance (USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Award Type Award Type [Axis] Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Lease liability, current portion Operating Lease, Liability, Current Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Summary of Remaining Contractual Maturities for Available-for-sale Securities Debt Securities, Available-for-Sale [Table Text Block] Debt Instrument, Periodic Payment [Abstract] Debt Instrument, Periodic Payment [Abstract] Schedule Of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Options cancelled (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Cash equivalents and short-term investments, fair value Cash Equivalents And Short-Term Investments, Fair Value Disclosure Cash Equivalents And Short-Term Investments, Fair Value Disclosure Debt, noncurrent portion Long-Term Debt, Excluding Current Maturities Schedule Of Cash And Cash Equivalents [Table] Schedule of Cash and Cash Equivalents [Table] TOTAL LIABILITIES Liabilities Geographical Geographical [Axis] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] CASH FLOWS FROM INVESTING ACTIVITIES: Net Cash Provided by (Used in) Investing Activities [Abstract] Accrued and other current liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Domain] Revolving Credit Facility Revolving Credit Facility [Member] Revenue Revenue from Contract with Customer [Policy Text Block] Document Type Document Type Weighted- Average Exercise Price Per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Beginning balance of period (USD per share) Ending balance of period (USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Term Notes Debt Disclosure [Text Block] Cost of revenue: Cost of Revenue [Abstract] Product and Service Product and Service [Domain] Entity Shell Company Entity Shell Company Financial Instruments Financial Instrument [Axis] Subsequent Event Subsequent Event [Member] Document Period End Date Document Period End Date TOTAL ASSETS Assets Debt Disclosure [Abstract] Debt Disclosure [Abstract] Net income per share Earnings Per Share [Abstract] Income Statement Location Income Statement Location [Axis] Performance-Based Restricted Stock Units Performance Shares [Member] Accrued liabilities Total accrued liabilities Accrued Liabilities, Current Less: debt, current portion Long-Term Debt, Current Maturities Numerator: Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Options exercised (USD per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Accounting Policies [Abstract] Accounting Policies [Abstract] Employee compensation Employee-related Liabilities, Current Line of Credit Line of Credit [Member] Net income before taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest STOCKHOLDERS’ EQUITY: Stockholders' Equity Attributable to Parent [Abstract] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Deferred income taxes Deferred Income Taxes and Tax Credits Net Income (Loss) Per Share Earnings Per Share [Text Block] Cash, Cash Equivalents and Restricted Cash Cash and Cash Equivalents, Policy [Policy Text Block] Balance Sheet Components Supplemental Balance Sheet Disclosures [Text Block] Lease liabilities Increase (Decrease) in Operating Lease Liability Award Type Award Type [Domain] Vested and exercisable, March 31, 2023 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Payments to Acquire Businesses, Gross Payments to Acquire Businesses, Gross Gross profit Gross Profit Entity Registrant Name Entity Registrant Name Ordinary shares issued (in shares) Stock Issued During Period, Shares, New Issues Percentage of cash contribution received from exchange of equity upon signing of agreement Percentage Of Cash Contribution Received From Exchange Of Equity Current Percentage of cash contribution received from exchange of equity current. Subsequent Events Subsequent Events [Text Block] Cash Equivalents and Short-Term Investments Cash, Cash Equivalents, and Short-Term Investments [Text Block] Entity Address, City or Town Entity Address, City or Town Unrealized gain (loss) on available-for-sale securities OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax Percentage of cash contribution receivable from exchange of equity within one year Percentage Of Cash Contribution Receivable From Exchange Of Equity Within One Year Percentage of cash contribution receivable from exchange of equity within one year. Operating expenses: Operating Expenses [Abstract] Asset Class Asset Class [Domain] Minimum Minimum Minimum [Member] Earnings Per Share [Table] Earnings Per Share [Table] Earnings Per Share [Table] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Business Combination, Contingent Consideration Arrangements, Maximum Value Per Share Business Combination, Contingent Consideration Arrangements, Maximum Value Per Share [Member] Business Combination, Contingent Consideration Arrangements, Maximum Value Per Share Raw material Inventory, Raw Materials, Net of Reserves Investment, Name Investment, Name [Axis] Financial Instruments and Fair Value Measurements Fair Value Disclosures [Text Block] Trading Symbol Trading Symbol Entity File Number Entity File Number Related party contract liability, noncurrent portion Contract with Customer, Liability, Noncurrent Coronary Coronary [Member] Coronary. Research and development Research and Development Expense RSUs granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Restricted Stock Units Restricted Stock Units (RSUs) [Member] Vested and expected to vest shares (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Share Based Compensation Arrangement By Share Based Payment Award Options Shares Available For Grant Roll Forward Share Based Compensation Arrangement By Share Based Payment Award Options Shares Available For Grant Roll Forward Share based compensation arrangement by share based payment award options shares available for grant. Accounts payable Increase (Decrease) in Accounts Payable Equity Method Investments and Joint Ventures [Abstract] Equity Method Investments and Joint Ventures [Abstract] Subsequent Events [Abstract] Peripheral Peripheral [Member] Peripheral. Income Tax Disclosure Income Tax Disclosure [Text Block] Finished goods Inventory, Finished Goods, Net of Reserves Credit Facility Credit Facility [Domain] Total Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value Interest paid Interest Paid, Excluding Capitalized Interest, Operating Activities Basic (USD per share) Earnings Per Share, Basic Schedule Of Equity Method Investments [Table] Schedule of Equity Method Investments [Table] Cash equivalents and short-term investments, amortized cost basis Cash Equivalents And Short Term Investments Cash equivalents and short term investments. Restrictions on Cash and Cash Equivalents Restrictions on Cash and Cash Equivalents [Table Text Block] Sales and marketing Selling and Marketing Expense TOTAL STOCKHOLDERS’ EQUITY Beginning balance Ending balance Stockholders' Equity Attributable to Parent Total cash, cash equivalents, and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations RSUs forfeited (USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Entity Interactive Data Current Entity Interactive Data Current Restricted Stock, Value, Shares Issued Net of Tax Withholdings Restricted Stock, Value, Shares Issued Net of Tax Withholdings Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Money market funds Money Market Funds [Member] Accumulated Deficit Retained Earnings [Member] Cash And Cash Equivalents [Line Items] Cash and Cash Equivalents [Line Items] Cash contribution from exchange of equity Cash Contribution From Exchange Of Equity Cash contribution from exchange of equity. Common Stock Common Stock [Member] Schedule of Total Stock-Based Compensation Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Shares available for issuance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Statement [Table] Statement [Table] Cash, cash equivalents and short-term investments Cash, Cash Equivalents, and Short-Term Investments RSUs vested (USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Loss on write down of fixed assets Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down Document Quarterly Report Document Quarterly Report CURRENT ASSETS: Assets, Current [Abstract] Lease liability, noncurrent portion Operating Lease, Liability, Noncurrent License Agreement License Agreement [Member] License agreement. Statistical Measurement Statistical Measurement [Axis] Retained earnings (accumulated deficit) Retained Earnings (Accumulated Deficit) Money market funds Cash Equivalents, at Carrying Value Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Equity Components Equity Components [Axis] Aggregate Intrinsic Value Share Based Compensation Arrangement By Share Based Payment Award Options Intrinsic Value [Abstract] Share based compensation arrangement by share based payment award options intrinsic value. Recurring Fair Value, Recurring [Member] Vested and exercisable shares (USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Document Fiscal Year Focus Document Fiscal Year Focus CASH FLOWS FROM OPERATING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities [Abstract] Statement [Line Items] Statement [Line Items] Beginning balance of period (in shares) Ending balance of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Variable Rate Variable Rate [Domain] Net income per share: EPS, Basic and Diluted [Abstract] Earnings Per Share , Basic and Diluted Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Axis] Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Accumulated Other Comprehensive Income AOCI Attributable to Parent [Member] Maximum period of automatic annual increase in common stock reserved for issuance Maximum Period Of Automatic Annual Increase In Common Stock Reserved For Issuance Maximum period of automatic annual increase in common stock reserved for issuance. Vested and expected to vest shares (USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Document Transition Report Document Transition Report Local Phone Number Local Phone Number Schedule of Option Activity under 2009 Plan and 2019 Plan Share-Based Payment Arrangement, Option, Activity [Table Text Block] Income from operations Operating Income (Loss) Inventory Increase (Decrease) in Inventories Debt issuance costs Debt Instrument, Unamortized Discount (Premium), Net Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Number of foreign subsidiaries Number Of Foreign Subsidiaries Number Of Foreign Subsidiaries Income tax expense Income Tax Expense (Benefit) Geographical Geographical [Domain] Income Statement [Abstract] Income Statement [Abstract] Additional Paid-In Capital Additional Paid-in Capital [Member] Document Fiscal Period Focus Document Fiscal Period Focus Cost of product revenue Cost of Goods and Services Sold Diluted (in shares) Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Unrealized gain on available-for-sale securities, net of tax OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax Schedule of Inventory Schedule of Inventory, Current [Table Text Block] Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Debt, current portion Notes Payable, Current Asset purchases Accrued Asset Purchases Current Accrued asset purchases current. Base Rate Base Rate [Member] Common stock Common Stock, Value, Issued Debt Instrument, Name Debt Instrument, Name [Domain] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Taxes withheld on net settled vesting of restricted stock units (in shares) Restricted Stock, Shares Issued Net of Shares for Tax Withholdings RSUs granted (USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Schedule of Financial Assets and Liabilities Measured at Fair Value Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Vested and exercisable, March 31, 2023 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents CURRENT LIABILITIES: Liabilities, Current [Abstract] Proceeds from debt financing, net of issuance costs Proceeds from Issuance of Long-Term Debt Proceeds from stock option exercises Proceeds from Stock Options Exercised Vested and expected to vest,  March 31, 2023 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Equity method investment Equity Method Investments Property and equipment purchases included in accounts payable and accrued liabilities Capital Expenditures Incurred but Not yet Paid Income Statement Location Income Statement Location [Domain] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Debt Securities, Available-for-Sale, Unrealized Loss Position Debt Securities, Available-for-Sale, Unrealized Loss Position Amendment Flag Amendment Flag Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Principal amount of debt Debt Instrument, Face Amount Issuance of common stock under employee stock purchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan Total comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Entity Current Reporting Status Entity Current Reporting Status Other assets Other Assets, Noncurrent Notice period for cancellation of agreement Notice Period For Cancellation Of Agreement Notice period for cancellation of agreement. Weighted- Average Remaining Term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Vested and exercisable shares (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Purchase shares of common stock, price per share, percentage of fair market value Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent Disaggregation Of Revenue [Table] Disaggregation of Revenue [Table] Federal statutory income tax rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Issuance of common stock under employee stock purchase plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Balance beginning of period (in shares) Balance end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Cash and Cash Equivalents Cash and Cash Equivalents [Axis] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Property and equipment, net Property, Plant and Equipment, Net Cash and Cash Equivalents [Abstract] Cash and Cash Equivalents [Abstract] Stock Options Share-Based Payment Arrangement, Option [Member] Sales and marketing Selling and Marketing Expense [Member] Exercise of stock options Stock Issued During Period, Value, Stock Options Exercised RSUs forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Debt Long-Term Debt Other income (expense), net Other Nonoperating Income (Expense) Maximum Maximum [Member] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Consigned inventory Consigned Inventory Net Of Reserves Consigned inventory, net of reserves. Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Total current assets Assets, Current Excise, sales, income and other taxes Taxes Payable, Current Revenue recognized Contract with Customer, Liability, Revenue Recognized Entity Small Business Entity Small Business Beginning balance, shares (in shares) Ending balance, shares (in shares) Shares, Outstanding Measurement Frequency Measurement Frequency [Domain] Non-cash lease expense Operating Lease, Right-of-Use Asset, Amortization Expense Revenue: Revenues [Abstract] Restricted cash Restricted Cash Purchase of available-for-sale securities Payments to Acquire Debt Securities, Available-for-Sale Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Disaggregation of Revenue [Abstract] Disaggregation of Revenue [Abstract] Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Balance Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Accounts receivable Increase (Decrease) in Accounts Receivable Title of 12(b) Security Title of 12(b) Security Organization and Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Short-term investments Short-Term Investments Total operating expenses Costs and Expenses Research and development costs Accrued Research And Development Costs Current Accrued research and development costs, current. Payables and Accruals [Abstract] Payables and Accruals [Abstract] Other Product and Service, Other [Member] Subsequent Event [Line Items] Subsequent Event [Line Items] Debt Instrument [Line Items] Debt Instrument [Line Items] US Government Agencies Debt Securities US Government Agencies Debt Securities [Member] Share-based Payment Arrangement Share-Based Payment Arrangement [Policy Text Block] Amortization of premium and discount on available-for-sale securities Accretion (Amortization) of Discounts and Premiums, Investments Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] U.S. Treasury securities US Treasury Securities [Member] Short-term investments Amortized Cost Basis Short-term investments, amortized cost basis Debt Securities, Available-for-Sale, Amortized Cost Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Fair Value, Recurring and Nonrecurring [Table] Denominator: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Neovasc Inc Neovasc Inc [Member] Neovasc Inc Inventory Total inventory Inventory, Net Accounts payable Accounts Payable, Current Other assets Increase (Decrease) in Other Operating Assets Vested and expected to vest,  March 31, 2023 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Entity Filer Category Entity Filer Category Basic (in shares) Weighted Average Number of Shares Outstanding, Basic United States UNITED STATES Foreign currency remeasurement Foreign Currency Remeasurement Gain (Loss), Before Tax Foreign Currency Remeasurement Gain (Loss), Before Tax Equity percentage Equity Method Investment, Ownership Percentage Total stock-based compensation Stock-based compensation expense Share-Based Payment Arrangement, Expense NON-CASH INVESTING AND FINANCING ACTIVITIES: Noncash Investing and Financing Items [Abstract] Security Exchange Name Security Exchange Name Beginning balance of period (USD per share) Ending balance of period (USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Preferred stock Preferred Stock, Value, Issued Schedule of Current and Noncurrent Debt and Net Discount or Premium Balances Schedule of Debt [Table Text Block] General and administrative General and Administrative Expense [Member] Short-term Debt, Type Short-Term Debt, Type [Domain] Product revenue Revenue from Contract with Customer, Excluding Assessed Tax Corporate bonds Corporate Bond Securities Corporate Bond Securities [Member] Common stock reserved for issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Cover [Abstract] Cover [Abstract] Debt Instrument [Table] Schedule of Long-Term Debt Instruments [Table] Level 3 Fair Value, Inputs, Level 3 [Member] Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Stock-Based Compensation Share-Based Payment Arrangement [Text Block] Work in progress Inventory, Work in Process, Net of Reserves Revenue Revenue from Contract with Customer [Text Block] Payments of taxes withheld on net settled vesting of restricted stock units Payment, Tax Withholding, Share-Based Payment Arrangement TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Proceeds from issuance of common stock under employee stock purchase plan Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised Type of Cost, Good Or Service [Extensible List] Cost, Product and Service [Extensible Enumeration] Amortization of debt issuance costs Amortization of Debt Issuance Costs Related Party Related Party [Axis] Long-term Debt, Type Long-Term Debt, Type [Axis] Debt extinguished Extinguishment of Debt, Amount Dilutive effect of share-based payment arrangements (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Level 2 Fair Value, Inputs, Level 2 [Member] Current Fiscal Year End Date Current Fiscal Year End Date Diluted (USD per share) Earnings Per Share, Diluted Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Joint Venture Co-venturer [Member] Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Percentage of equity stake received Percentage Of Equity Stake Received Percentage of equity stake received. Total current liabilities Liabilities, Current Debt, noncurrent portion Notes Payable, Noncurrent Schedule of RSU Activity under 2019 Plan Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Entity Address, Address Line One Entity Address, Address Line One Earnings Per Share [Line Items] Earnings Per Share [Line Items] Earnings Per Share [Line Items] Share-based compensation expenses capitalized amount Share-Based Payment Arrangement, Amount Capitalized Product and Service Product and Service [Axis] Europe Europe [Member] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Interest expense Interest Expense Interest Expense Equity Method Investments Equity Method Investments [Policy Text Block] Credit Facility Credit Facility [Axis] Proceeds from maturities of available-for-sale securities Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale Related party transaction. transaction price Related Party Transaction, Amounts of Transaction Schedule of Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] Cash and Cash Equivalents Cash and Cash Equivalents [Domain] Subsequent Event [Table] Subsequent Event [Table] RSUs vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Entity Tax Identification Number Entity Tax Identification Number Loan and Security Agreement Loan And Security Agreement [Member] Loan and security agreement. Schedule of Product Revenue Based on Product Line and Location Disaggregation of Revenue [Table Text Block] business combination, contingent consideration, per share Business Combination, Contingent Consideration, Per Share Business Combination, Contingent Consideration, Per Share Net increase (decrease) in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Commercial paper Commercial Paper [Member] Entity Central Index Key Entity Central Index Key Measurement Frequency Measurement Frequency [Axis] Weighted-Average Grant Date Fair Value Per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Other Other Accrued Liabilities, Current City Area Code City Area Code Professional services Accrued Professional Fees, Current General and administrative General and Administrative Expense ASSETS Assets: Assets [Abstract] Long-term Debt, Type Long-Term Debt, Type [Domain] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] CASH FLOWS FROM FINANCING ACTIVITIES: Net Cash Provided by (Used in) Financing Activities [Abstract] Asset Class Asset Class [Axis] Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Variable Rate Variable Rate [Axis] Equity Method Investments Equity Method Investments and Joint Ventures Disclosure [Text Block] Loss from equity method investment Loss from equity method investment Loss from equity method investment Income (Loss) from Equity Method Investments Purchase of property and equipment Payments to Acquire Property, Plant, and Equipment Disaggregation Of Revenue [Line Items] Disaggregation of Revenue [Line Items] Research and development Research and Development Expense [Member] Components of Basic and Diluted Net Income (Loss) Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Secured Overnight Financing Rate (SOFR) Secured Overnight Financing Rate (SOFR) [Member] Secured Overnight Financing Rate (SOFR) Line of Credit Facility, Interest Rate at Period End Line of Credit Facility, Interest Rate at Period End Automatic annual increase in common stock reserved for issuance Automatic Annual Increase In Common Stock Reserved For Issuance As Percentage Of Capital Stock Outstanding On Preceding Fiscal Year End Date Automatic annual increase in common stock reserved for issuance as percentage of capital stock outstanding on preceding fiscal year end date Cost of product revenue Cost of Sales [Member] Product [Member] EX-101.PRE 10 swav-20230331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover Page - shares
 3 Months Ended
Mar. 31, 2023
May 02, 2023
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2023  
Document Transition Report false  
Entity File Number 001-38829  
Entity Registrant Name Shockwave Medical, Inc.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 27-0494101  
Entity Address, Address Line One 5403 Betsy Ross Drive  
Entity Address, City or Town Santa Clara  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 95054  
City Area Code 510  
Local Phone Number 279-4262  
Title of 12(b) Security Shockwave Medical, Inc., common stock, par value $0.001 per share  
Trading Symbol SWAV  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   36,626,211
Entity Central Index Key 0001642545  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q1  
Amendment Flag false  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
CURRENT ASSETS:    
Cash and cash equivalents $ 280,932 $ 156,586 [1]
Short-term investments 135,929 147,907 [1]
Accounts receivable, net 84,309 71,366 [1]
Inventory 83,256 75,112 [1]
Prepaid expenses and other current assets 6,399 8,292 [1]
Total current assets 590,825 459,263 [1]
Operating lease right-of-use assets 31,623 32,365 [1]
Property and equipment, net 54,057 48,152 [1]
Equity method investment 2,689 3,512 [1]
Deferred tax assets 97,941 97,568
Other assets 6,112 5,229 [1]
TOTAL ASSETS 783,247 646,089 [1]
CURRENT LIABILITIES:    
Accounts payable 11,050 6,721 [1]
Debt, current portion 80,000 0 [1]
Accrued liabilities 49,640 55,375 [1]
Lease liability, current portion 1,308 1,278 [1]
Total current liabilities 141,998 63,374 [1]
Lease liability, noncurrent portion 34,058 34,928 [1]
Debt, noncurrent portion 24,231 24,198 [1]
Related party contract liability, noncurrent portion 12,273 12,273 [1]
TOTAL LIABILITIES 212,560 134,773 [1]
STOCKHOLDERS’ EQUITY:    
Preferred stock 0 0 [1]
Common stock 37 36 [1]
Additional paid-in capital 568,705 548,960 [1]
Accumulated other comprehensive loss (367) (867) [1]
Retained earnings (accumulated deficit) 2,312 (36,813) [1]
TOTAL STOCKHOLDERS’ EQUITY 570,687 511,316 [1]
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 783,247 $ 646,089 [1]
[1] The condensed consolidated balance sheet as of December 31, 2022 is derived from the audited consolidated financial statements as of that date.
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Revenue:    
Product revenue $ 161,066,000 $ 93,631,000
Cost of revenue:    
Cost of product revenue 21,066,000 12,890,000
Gross profit 140,000,000 80,741,000
Operating expenses:    
Research and development 26,971,000 17,019,000
Sales and marketing 54,011,000 35,961,000
General and administrative 19,204,000 12,389,000
Total operating expenses 100,186,000 65,369,000
Income from operations 39,814,000 15,372,000
Loss from equity method investment (823,000) (47,000)
Interest expense (636,000) (297,000)
Other income (expense), net 2,382,000 (310,000)
Net income before taxes 40,737,000 14,718,000
Income tax expense 1,612,000 197,000
Net income 39,125,000 14,521,000
Other comprehensive income (loss):    
Unrealized gain (loss) on available-for-sale securities 505,000 (815,000)
Adjustment for net gain realized and included in other income (5,000) 0
Total comprehensive income $ 39,625,000 $ 13,706,000
Net income per share    
Basic (USD per share) $ 1.07 $ 0.41
Diluted (USD per share) $ 1.03 $ 0.39
Denominator:    
Basic (in shares) 36,427,263 35,587,337
Diluted (in shares) 37,979,448 37,623,477
Type of Revenue [Extensible List] Product [Member] Product [Member]
Type of Cost, Good Or Service [Extensible List] Product [Member] Product [Member]
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Stockholders' Equity - USD ($)
Total
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Income
Accumulated Deficit
Beginning balance, shares (in shares) at Dec. 31, 2021   35,444,472,000      
Beginning balance at Dec. 31, 2021 $ 241,830,000 $ 35,000 $ 494,806,000 $ (202,000) $ (252,809,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Exercise of stock options (in shares)   54,913,000      
Exercise of stock options 391,000 $ 1,000 390,000    
Unrealized gain on available-for-sale securities, net of tax (815,000)     (815,000)  
Adjustment for net gain realized and included in other income 0        
Issuance of common stock under employee stock purchase plan (in shares)   14,172,000      
Issuance of common stock under employee stock purchase plan 2,135,000   2,135,000    
Issuance of common stock in connection with vesting of restricted stock (in shares)   210,835,000      
Taxes withheld on net settled vesting of restricted stock units (in shares)   (31,000)      
Restricted Stock, Value, Shares Issued Net of Tax Withholdings (6,000)   (6,000)    
Stock-based compensation 9,767,000   9,767,000    
Net income (loss) 14,521,000       14,521,000
Ending balance, shares (in shares) at Mar. 31, 2022   35,724,361,000      
Ending balance at Mar. 31, 2022 267,823,000 $ 36,000 507,092,000 (1,017,000) (238,288,000)
Beginning balance, shares (in shares) at Dec. 31, 2022   36,235,546,000      
Beginning balance at Dec. 31, 2022 $ 511,316,000 [1] $ 36,000 548,960,000 (867,000) (36,813,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Exercise of stock options (in shares) 77,230,000 77,230,000      
Exercise of stock options $ 320,000 $ 1,000 319,000    
Unrealized gain on available-for-sale securities, net of tax 505,000     505,000  
Adjustment for net gain realized and included in other income (5,000)     (5,000)  
Issuance of common stock under employee stock purchase plan (in shares)   19,124,000      
Issuance of common stock under employee stock purchase plan 3,092,000   3,092,000    
Issuance of common stock in connection with vesting of restricted stock (in shares)   257,624,000      
Taxes withheld on net settled vesting of restricted stock units (in shares)   (19,000)      
Restricted Stock, Value, Shares Issued Net of Tax Withholdings (3,000)   (3,000)    
Stock-based compensation 16,337,000   16,337,000    
Net income (loss) 39,125,000       39,125,000
Ending balance, shares (in shares) at Mar. 31, 2023   36,589,505,000      
Ending balance at Mar. 31, 2023 $ 570,687,000 $ 37,000 $ 568,705,000 $ (367,000) $ 2,312,000
[1] The condensed consolidated balance sheet as of December 31, 2022 is derived from the audited consolidated financial statements as of that date.
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Cash Flows - USD ($)
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net income (loss) $ 39,125,000 $ 14,521,000
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 1,708,000 953,000
Loss from equity method investment 823,000 47,000
Stock-based compensation 15,967,000 9,510,000
Non-cash lease expense 748,000 767,000
Amortization of premium and discount on available-for-sale securities (718,000) 210,000
Loss on write down of fixed assets 11,000 0
Deferred income taxes (547,000) 0
Amortization of debt issuance costs 33,000 153,000
Foreign currency remeasurement (689,000) 0
Changes in operating assets and liabilities:    
Accounts receivable (13,004,000) (10,407,000)
Inventory (7,757,000) (10,090,000)
Prepaid expenses and other current assets 1,896,000 600,000
Other assets (861,000) (119,000)
Accounts payable 4,734,000 4,911,000
Accrued and other current liabilities (6,661,000) (9,051,000)
Lease liabilities (846,000) (68,000)
Net cash provided by operating activities 33,962,000 1,937,000
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchase of available-for-sale securities (21,130,000) (42,128,000)
Proceeds from maturities of available-for-sale securities 34,500,000 18,000,000
Purchase of property and equipment (7,188,000) (3,286,000)
Net cash provided by (used in) investing activities 6,182,000 (27,414,000)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Payments of taxes withheld on net settled vesting of restricted stock units (3,000) (6,000)
Proceeds from stock option exercises 320,000 391,000
Proceeds from issuance of common stock under employee stock purchase plan 3,092,000 2,135,000
Proceeds from debt financing, net of issuance costs 80,000,000 0
Net cash provided by financing activities 83,409,000 2,520,000
Effect of exchange rate changes on cash and cash equivalents 792,000 0
Net increase (decrease) in cash, cash equivalents and restricted cash 124,345,000 (22,957,000)
Cash, cash equivalents and restricted cash at beginning of period 158,302,000 90,874,000
Cash, cash equivalents and restricted cash equivalents at end of period 282,647,000 67,917,000
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:    
Interest paid 424,000 144,000
Income tax paid 322,000 78,000
NON-CASH INVESTING AND FINANCING ACTIVITIES:    
Property and equipment purchases included in accounts payable and accrued liabilities $ 6,162,000 $ 3,159,000
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.23.1
Organization and Basis of Presentation
 3 Months Ended
Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization and Basis of Presentation Organization and Basis of Presentation
Shockwave Medical, Inc. (the “Company”) was incorporated on June 17, 2009. The Company is primarily engaged in the development of Intravascular Lithotripsy (“IVL”) technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular and heart valve disease. Built on a balloon catheter platform, the IVL technology uses lithotripsy to disrupt both superficial and deep vascular calcium, while minimizing soft tissue injury, and an integrated angioplasty balloon to dilate blockages at low pressures, restoring blood flow.
In 2016, the Company began commercial and manufacturing operations, and began selling catheters based on the IVL technology. The Company’s headquarters are in Santa Clara, California. The Company is located and operates primarily in the United States and has eleven wholly-owned foreign subsidiaries as of March 31, 2023. The unaudited condensed financial statements include the accounts of Shockwave Medical, Inc. and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated upon consolidation.
As of March 31, 2023, the Company had cash, cash equivalents and short-term investments of $416.9 million, which are available to fund future working capital requirements, investments, acquisitions, or repayments of credit facilities. The Company believes that its cash, cash equivalents, and short-term investments as of March 31, 2023, will be sufficient for the Company to continue as a going concern for at least 12 months from the date the unaudited condensed consolidated financial statements are filed with the Securities and Exchange Commission (“SEC”). The Company’s future capital requirements will depend on many factors, including its growth rate, the timing and extent of its spending to support research and development activities, and the timing and cost of establishing additional sales and marketing capabilities and the scope.
Risk and Uncertainties
The Company is subject to continuing risks and uncertainties in connection with the current macroeconomic environment, including inflation, rising interest rates, and instability in the global banking system, geopolitical factors, including the ongoing conflict between Russia and Ukraine and the responses thereto, supply chain disruptions and the remaining effects of the COVID-19 pandemic. The Company is closely monitoring the impact of these factors on all aspects of its business, including the impacts on its customers, patients, employees, suppliers, vendors, business partners and distribution channels.
In particular, while the Company has not experienced material disruptions in its supply chain to date, the Company has been and continues to be impacted by disruptions in the operations of certain of its third-party suppliers, resulting in increased lead-times, higher component costs and lower allocations for the purchase of some components. In certain cases, the Company has incurred higher logistical expenses. The Company is continuing to work closely with its manufacturing partners and suppliers to source key components and maintain appropriate inventory levels to meet customer demand.
The Company’s future results of operations and liquidity could be adversely impacted by a variety of factors, including those discussed in the section titled “Risk Factors” of the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on February 27, 2023 (the “2022 Annual Report”), together with any updates in the section titled “Risk Factors” in this Quarterly Report on Form 10-Q. As of the date of issuance of these condensed consolidated financial statements, the extent to which the current macroeconomic environment and the COVID-19 pandemic may materially impact the Company’s financial condition, liquidity, or results of operations remains uncertain.
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies
 3 Months Ended
Mar. 31, 2023
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies Summary of Significant Accounting Policies
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) and applicable rules and regulations of the SEC regarding interim financial reporting.
The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s consolidated financial position, results of operations and
cash flows. The results of operations for the three months ended March 31, 2023 are not necessarily indicative of the results to be expected for the year ending December 31, 2023 or for any other future annual or interim period. The condensed consolidated balance sheet as of December 31, 2022 included herein was derived from the audited financial statements as of that date. The unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and related notes included in the 2022 Annual Report.
Cash, Cash Equivalents, and Restricted Cash
The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts.
The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated statements of cash flows:
March 31,
2023		March 31,
2022
(in thousands)
Cash and cash equivalents$280,932 $66,252 
Restricted cash1,715 1,665 
Total cash, cash equivalents, and restricted cash$282,647 $67,917 
Restricted cash as of March 31, 2023 and December 31, 2022 relates to letters of credit established for real property leases relating to the Company’s office buildings, and is recorded as other assets on the condensed consolidated balance sheets.
See Note 12 for a discussion of the Company’s subsequent payments related to the acquisition of Neovasc, Inc. and the repayment of the credit drawn on March 16, 2023 under the Credit Agreement.
Equity Method Investments
Entities which the Company has significant influence over activities of the entity, but does not control, are accounted for under the equity method of accounting in accordance with Topic 323, Investments - Equity Method and Joint Ventures. The Company’s carrying value in the equity method investment is reported as equity method investment on the Company’s consolidated balance sheets. The Company records its proportionate share of the underlying income or loss which is recognized in earnings or loss from the equity method investment. The Company eliminates a portion of intra-entity profit to the extent the goods sold by the Company have not yet been sold through by the equity method investee to an end customer at the end of the reporting period. The profit earned by the Company from the equity method investee for items not yet sold through is eliminated through equity method earnings or loss which is recognized in income (loss) from equity method investment.
The Company assesses its equity method investment for impairment when events or circumstances suggest that the carrying amount of the investment may be impaired. The Company considers all available evidence in assessing whether a decline in fair value is other than temporary. If the decline in fair value is determined to be other than temporary, the difference between the carrying amount of the investment and estimated fair value is recognized as an impairment charge.
Revenue
To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, Revenue from Contracts with Customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.
Product Revenue
The Company records product revenue primarily from the sale of its IVL catheters. The Company sells its products to hospitals, primarily through direct sales representatives, as well as through distributors in selected international markets. Additionally, a portion of the Company’s revenue is generated through a consignment model under which inventory is maintained at hospitals.
Product revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.
For products sold through direct sales representatives, control is transferred upon delivery to customers. For products sold to distributors internationally and products sold to customers that utilize stocking orders, control is transferred upon shipment or delivery to the customer’s named location, based on the contractual shipping terms. For consignment inventory, control is transferred at the time the IVL catheters are consumed in a procedure. The Company has elected to account for shipping and handling activities that occur after the customer has obtained control as a fulfillment activity, and not a separate performance obligation.
The Company may provide for the use of an IVL generator and connector cable under an agreement to customers at no charge to facilitate use of the IVL catheters. These agreements generally do not contain contractually enforceable minimum commitments and are generally cancellable by either party with 30 days notice.
License Revenue
For arrangements that contain a license of the Company’s functional intellectual property with a customer, the Company considers whether the license grant is distinct from other performance obligations in the arrangement. A license grant of functional intellectual property is generally considered to be capable of being distinct if a customer can benefit from the license on its own or together with other readily available resources. License revenue for licenses of functional intellectual property is recognized at a point in time when the Company satisfies its performance obligation of transferring the license to the customer.
Consideration received in advance of the satisfaction of a performance obligation is recognized as a contract liability. No license revenues were recognized for the three months ended March 31, 2023 and 2022.
Stock-Based Compensation
The Company accounts for share-based payments at fair value. The fair value of stock options is measured using the Black-Scholes option-pricing model. For share-based awards that vest subject to the satisfaction of a service requirement, the fair value measurement date for stock-based compensation awards is the date of grant and the expense is recognized on a straight-line basis, over the vesting period. For share-based awards that vest upon the satisfaction of a performance target, the related compensation cost is recognized over the requisite service period based on the expected achievement of the performance target. The Company accounts for forfeitures as they occur.
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.23.1
Financial Instruments and Fair Value Measurements
 3 Months Ended
Mar. 31, 2023
Fair Value Disclosures [Abstract]  
Financial Instruments and Fair Value Measurements Financial Instruments and Fair Value Measurements
The following tables summarize the Company’s financial assets measured at fair value on a recurring basis by level within the fair value hierarchy:
March 31, 2023
Level 1Level 2Level 3Total
(in thousands)
Assets:
U.S. Treasury securities$95,282 $— $— $95,282 
Money market funds10,070 — — 10,070 
Commercial paper— 8,139 — 8,139 
Corporate bonds— 20,688 — 20,688 
U.S. agency securities— 11,820 — 11,820 
Total assets$105,352 $40,647 $— $145,999 
December 31, 2022
Level 1Level 2Level 3Total
(in thousands)
Assets:
U.S. Treasury securities$111,631 $— $— $111,631 
Money market funds12,076 — — 12,076 
Commercial paper— 8,039 — 8,039 
Corporate bonds— 18,808 — 18,808 
U.S. agency securities— 9,429 — 9,429 
Total assets$123,707 $36,276 $— $159,983 
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.23.1
Cash Equivalents and Short-Term Investments
 3 Months Ended
Mar. 31, 2023
Cash and Cash Equivalents [Abstract]  
Cash Equivalents and Short-Term Investments Cash Equivalents and Short-Term Investments
The following is a summary of the Company’s cash equivalents and short-term investments:
March 31, 2023
Amortized
Cost Basis		Unrealized
Gains		Unrealized
Losses		Fair Value
(in thousands)
U.S. Treasury securities$95,784 $18 $(520)$95,282 
Money market funds10,070 — — 10,070 
Commercial paper8,140 1 (2)8,139 
Corporate bonds20,685 22 (19)20,688 
U.S. agency securities11,804 16 — 11,820 
Total$146,483 $57 $(541)$145,999 
Reported as:
Cash equivalents$10,070 
Short-term investments135,929 
Total$145,999 
December 31, 2022
Amortized
Cost Basis		Unrealized
Gains		Unrealized
Losses		Fair Value
(in thousands)
U.S. Treasury securities$112,719 $3 $(1,091)$111,631 
Money market funds12,076 — — 12,076 
Commercial paper8,039 — — 8,039 
Corporate bonds18,876 8 (76)18,808 
U.S. agency securities9,432 4 (7)9,429 
Total$161,142 $15 $(1,174)$159,983 
Reported as:
Cash equivalents$12,076 
Short-term investments147,907 
Total$159,983 
There were $76.4 million and $123.8 million of investments in unrealized loss positions of $0.5 million and $1.2 million as of March 31, 2023 and December 31, 2022, respectively. During the three months ended March 31, 2023 and 2022, the Company did not record any other-than-temporary impairment charges on its available-for-sale securities. Based on the Company’s procedures under the expected credit loss model, including an assessment of unrealized losses on the portfolio, the Company concluded that the unrealized losses for its marketable securities were not attributable to credit and therefore an allowance for credit losses for these securities has not been recorded as of March 31, 2023 and December 31, 2022. Also, based on the scheduled maturities of the investments, the Company was more likely than not to hold these investments for a period of time sufficient for a recovery of the Company’s cost basis.
For the three months ended March 31, 2023 and 2022, the Company recognized $5,000 and nil in realized gains on cash equivalents and short-term investments.
The remaining contractual maturities of the Company’s cash equivalents and short-term investments were as follows:
March 31,
2023
Fair Value
(in thousands)
Money market funds
$10,070 
One year or less 112,680 
Greater than one year and less than two years 23,249 
Total$145,999 
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.23.1
Balance Sheet Components
 3 Months Ended
Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Balance Sheet Components Balance Sheet Components
Inventory
Inventory consists of the following:
March 31,
2023		 December 31,
2022
(in thousands)
Raw material$21,504 $18,456 
Work in progress10,722 7,666 
Finished goods50,737 48,735 
Consigned inventory293 255 
Total inventory$83,256 $75,112 
Accrued Liabilities
Accrued liabilities consist of the following:
March 31,
2023		December 31,
2022
(in thousands)
Employee compensation$22,070 $32,885 
Asset purchases6,882 4,600 
Research and development costs4,118 4,007 
Professional services3,862 4,044 
Excise, sales, income and other taxes5,123 4,036 
Other7,585 5,803 
Total accrued liabilities$49,640 $55,375 
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.23.1
Term Notes
 3 Months Ended
Mar. 31, 2023
Debt Disclosure [Abstract]  
Term Notes Debt
On October 19, 2022, the Company entered into a Credit Agreement (the “Credit Agreement”) with Wells Fargo Bank, National Association, as administrative agent, Wells Fargo Bank, National Association, as swingline lender and an issuing lender, Wells Fargo Securities, LLC and Silicon Valley Bank, as joint lead arrangers and joint bookrunners, Silicon Valley Bank, as syndication agent, and the several lenders party thereto. The Credit Agreement provides for a revolving credit facility in an aggregate principal amount of $175 million with the right to request increases to the revolving commitments (subject to certain conditions) of up to the greater of (x) $100 million or (y) the Company’s consolidated EBITDA for the four fiscal quarter period most recently ended prior to the date of such increase.
Concurrent with entering into the Credit Agreement, the Company drew down $25.0 million. On March 16, 2023, the Company drew down an additional $80.0 million under the Credit Agreement. See Note 12 for a discussion of the Company’s subsequent payment of the additional $80.0 million drawn under the Credit Agreement.
The revolving credit facility accrues for interest, at the election of the Company, at (A) the Base Rate (as defined below) plus a margin ranging from 0% to 1% depending on the Company's Consolidated Total Net Leverage Ratio (as defined in the Credit Agreement) (which rate is currently 0%) or (B) the applicable secured overnight financing rate (“SOFR”) plus a margin from 1% to 2%, depending on the Company's Consolidated Total Net Leverage Ratio (which rate is currently 1%). Base Rate means, at any time, the highest of (a) the Wells Fargo Bank, National Association's announced prime rate, (b) the federal funds rate plus 0.5% and (c) Term SOFR for a one-month tenor in effect on such day plus 1%. The Credit Agreement matures on October 19, 2027. The interest rate was 5.6% as of March 31, 2023.
The Company recorded interest expense of $0.6 million and $0.3 million for the three months ended March 31, 2023 and 2022, respectively.
Debt and debt issuance costs are as follows:
March 31,
2023		December 31,
2022
(in thousands)
Principal amount of debt$105,000 $25,000 
Debt issuance costs(769)(802)
Debt104,231 24,198 
Less: debt, current portion(80,000)— 
Debt, noncurrent portion$24,231 $24,198 
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.23.1
Stock-Based Compensation
 3 Months Ended
Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Stock-Based Compensation Stock-Based Compensation
Total stock-based compensation was as follows:
Three Months Ended
March 31,
20232022
(in thousands)
Cost of product revenue$954 $653 
Research and development3,795 2,238 
Sales and marketing6,466 3,932 
General and administrative4,752 2,687 
Total stock-based compensation$15,967 $9,510 
Stock-based compensation of $0.4 million and $0.3 million was capitalized into inventory for the three months ended March 31, 2023 and 2022, respectively. Stock-based compensation capitalized into inventory is recognized as cost of product revenue when the related product is sold.
2009 Equity Incentive Plan and 2019 Equity Incentive Plan
On June 17, 2009, the Company adopted the 2009 Equity Incentive Plan (the “2009 Plan”) under which the Company's Board of Directors (the “Board”) had the authority to issue stock options to employees, directors and consultants.
In February 2019, the Company adopted the 2019 Equity Incentive Plan (the “2019 Plan”), which became effective in connection with the Company's initial public offering (the “IPO”). As a result, effective as of March 6, 2019, the Company may not grant any additional awards under the 2009 Plan. The 2009 Plan will continue to govern outstanding equity awards granted thereunder. The Company initially reserved 2,000,430 shares of common stock for the issuance of a variety of awards under the 2019 Plan, including stock options, stock appreciation rights, awards of restricted stock and awards of restricted stock units (“RSUs”). In addition, the number of shares of common stock reserved for issuance under the 2019 Plan will automatically increase on the first day of January for a period of up to ten years, which commenced on January 1, 2020, in an amount equal to 3% of the total number of shares of the Company’s capital stock outstanding on the last day of the preceding year, or a lesser number of shares determined by the Board. As of March 31, 2023, there were 3,765,125 shares available for issuance under the 2019 Plan.
Stock Options
Option activity under the 2009 Plan and 2019 Plan is set forth below:
Number
of Shares		Weighted-
Average
Exercise
Price Per
Share		Weighted-
Average
Remaining
Term		Aggregate
Intrinsic
Value
(in years)(in thousands)
Balance, December 31, 20221,122,009 $5.87 4.60$224,115 
Awards authorized— 
Options exercised(77,230)4.12 
Options cancelled(6,133)2.41 
Balance, March 31, 20231,038,646 $6.02 4.41$218,961 
Vested and exercisable,
March 31, 2023		1,038,503 $6.01 4.41$218,935 
Vested and expected to vest, 
March 31, 2023		1,038,646 $6.02 4.41$218,961 
Restricted Stock Units
RSUs are share awards that entitle the holder to receive freely tradable shares of the Company’s common stock upon vesting. RSUs cannot be transferred and the awards are subject to forfeiture if the holder’s employment terminates prior to the release of the vesting restrictions. RSUs generally vest over a four-year period with straight-line quarterly vesting with a one year cliff or straight-line annual vesting, provided the employee remains continuously employed with the Company. The fair value of RSUs is equal to the closing price of the Company’s common stock on the grant date.
In February 2022 and 2023, the Company granted performance-based restricted stock units (“PRSUs”) to certain key executives. The vesting of these PRSUs is dependent on the achievement of certain performance targets related to the Company’s compound annual growth rate of revenue over a two or three year performance period, provided the executives remain employed with the Company at the time of vesting. The number of PRSUs that vest will vary from 0% to 200% of the target which will be determined based on the level of performance attained for each performance period. The fair value of these PRSUs is equal to the closing price of the Company’s common stock on the grant date. Compensation cost for PRSUs is recognized over the requisite service period based on the expected achievement of performance targets.
RSU and PRSU activity under the 2019 Plan is set forth below. Grant activity for all PRSUs is disclosed at target (100%):
Restricted Stock UnitsPerformance-Based Restricted Stock Units
Number
of Shares		Weighted-
Average
Grant Date
Fair Value
Per Share		Number
of Shares		Weighted-
Average
Grant Date
Fair Value
Per Share
Balance, December 31, 20221,125,991 $127.39 38,797 $165.74 
RSUs granted293,007 191.06 29,473 191.36
RSUs forfeited(19,803)145.72 (175)278.52 
RSUs vested(257,624)97.37 — — 
Balance, March 31, 20231,141,571 150.18 68,095 176.54 
Employee Stock Purchase Plan
In February 2019, the Company adopted the 2019 Employee Stock Purchase Plan (“ESPP”), which became effective in connection with the IPO on March 6, 2019. The Company initially reserved 300,650 shares of common stock for purchase under the ESPP. Each offering under the ESPP to Company employees to purchase stock under the ESPP begins on each September 1 and March 1 and ends on the following February 28 or 29 and August 31, respectively. On each purchase date, which falls on the last date of each offering period, ESPP participants will purchase shares of common stock at a price per share equal to 85% of the lesser of (1) the fair market value per share of the common stock on the offering date or (2) the fair market value of the common stock on the purchase date. The occurrence and duration of offering periods under the ESPP are subject to the determinations of the Company’s Compensation Committee of the Board, in its sole discretion.
The fair value of the ESPP shares is estimated using the Black-Scholes option pricing model. The Company recorded $1.3 million and $0.4 million of stock-based compensation expense related to the ESPP for the three months ended March 31, 2023 and 2022, respectively. At March 31, 2023, a total of 1,540,527 shares were available for issuance under the ESPP.
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.23.1
Net Income (Loss) Per Share
 3 Months Ended
Mar. 31, 2023
Earnings Per Share [Abstract]  
Net Income (Loss) Per Share Net Income Per Share
The components of basic and diluted net income per share were as follows (in thousands, except share and per share amounts):
Three Months Ended
March 31,
20232022
Numerator:
Net income $39,125 $14,521 
Denominator:
Basic:
Weighted average number of common shares outstanding - basic36,427,263 35,587,337 
Diluted:
Weighted average number of common shares outstanding - basic36,427,263 35,587,337 
Dilutive effect of outstanding common stock options1,039,985 1,437,748 
Dilutive effect of restricted stock units510,340 597,817 
Dilutive effect of common stock pursuant to employee stock purchase plan1,860 575 
Weighted average number of common shares outstanding - diluted37,979,448 37,623,477 
Net income per share:
Basic$1.07 $0.41 
Diluted$1.03 $0.39 
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue
 3 Months Ended
Mar. 31, 2023
Disaggregation of Revenue [Abstract]  
Revenue Revenue
The following table represents the Company’s product revenue based on product line:
Three Months Ended
March 31,
20232022
(in thousands)
Coronary$113,875 $70,337 
Peripheral46,130 22,852 
Other 1,061 442 
Product revenue$161,066 $93,631 
Coronary product revenue encompasses sales of the Company’s C2 catheter and C2+ catheter. Peripheral product revenue encompasses sales of the Company’s M5 catheter, M5+ catheter, S4 IVL catheter, and L6 IVL catheter. Other product revenue encompasses sales of the Company’s generators and related accessories.
The following table represents the Company’s product revenue based on the location to which the product is shipped:
Three Months Ended
March 31,
20232022
(in thousands)
United States$131,623 $78,519 
Europe16,234 12,067 
All other countries13,209 3,045 
Product revenue$161,066 $93,631 
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.23.1
Equity Method Investments
 3 Months Ended
Mar. 31, 2023
Equity Method Investments and Joint Ventures [Abstract]  
Equity Method Investments Equity Method Investments
Genesis Shockwave Private Limited
On March 19, 2021, the Company entered into the Joint Venture Deed (or “JV Agreement”) with Genesis MedTech International Private Limited (“Genesis”) to establish a long-term strategic partnership to develop, manufacture and commercialize certain of the Company’s interventional products in the People’s Republic of China, excluding the Special Administrative Regions of Hong Kong and Macau (the “PRC”). Under the JV Agreement, Genesis Shockwave Private Ltd. (the “JV”) was formed under the laws of Singapore to serve as a joint venture of Genesis and the Company for the purpose of establishing and managing the strategic partnership.
On the same date, Genesis and the Company entered into a Share Subscription Agreement pursuant to which, among other things, the JV issued (i) 54,900 ordinary shares which represents 55% of the total equity of the JV, to Genesis in exchange for a cash contribution of $15.0 million, of which 50% was due upon signing and the remaining 50% was due within one year of signing, and (ii) 45,000 ordinary shares, which represents 45% of the total equity of the JV, to the Company as consideration for the Shockwave License Agreement (the “License Agreement”). Under the License Agreement, the Company has agreed to contribute to the JV an exclusive license under certain of the Company’s intellectual property rights to develop, manufacture, distribute and commercialize certain products in the PRC and is entitled to receive royalties on the sales of the licensed products in the PRC. Further, the Company entered into a Distribution Agreement, pursuant to which the Company has agreed to sell certain Company-manufactured products to the JV or a PRC subsidiary of the JV for commercialization and distribution in the PRC. In May 2022, the JV obtained regulatory approval from the China National Medical Products Administration to sell the Company-manufactured Shockwave IVL System with the Shockwave C2 catheter, M5 catheter and S4 catheter in the PRC.
The Company has accounted for its investment in the JV under the equity method of accounting. As of March 31, 2023, the carrying value of the Company’s investment in the JV was $2.7 million and the Company owned a 45% interest in the entity. During the three months ended March 31, 2023, the Company continued to recognize product revenue on sales to the JV and eliminate a portion of intra-entity profit to the extent the goods have not yet either been consumed by the JV for use in clinical trials, or sold by the JV to an end customer at the end of the reporting period. The profit earned by the Company from the JV for items not yet sold through to an end customer is eliminated through equity method earnings or loss which is recognized in income (loss) from equity method investment.
The Company’s product revenue for products sold to the JV during the three months ended March 31, 2023 and related accounts receivable from the JV as of March 31, 2023 were immaterial. Intra-entity profit, which was recorded as a reduction to equity method investment as of and for the three months ended March 31, 2023, was also immaterial.
For the three months ended March 31, 2023 and 2022, the Company’s loss from the equity method was $0.8 million and $47,000, respectively.
Upon execution of the License Agreement, on March 19, 2021, the Company received a 45% equity stake in the JV. The Company determined that the JV met the definition of a customer under Topic 606, and that the promised goods and services of the contribution of the license of intellectual property and associated manufacturing technology transfer to the JV were considered to be a single performance obligation. The transaction price of $12.3 million was estimated by reference to the cash value of the shares that were issued at the formation of the JV.
As of March 31, 2023, the associated manufacturing technology transfer to the JV has not yet been completed. The Company maintains a related party contract liability, noncurrent, of $12.3 million for the outstanding performance obligation. The Company will satisfy the outstanding performance obligation upon the completion of training provided by the Company to the JV, and successful regulatory approval for the JV manufactured product from the China National Medical Products Administration.
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.23.1
Income Taxes
 3 Months Ended
Mar. 31, 2023
Income Tax Disclosure [Abstract]  
Income Tax Disclosure Income Taxes
On a quarterly basis, the Company provides for income taxes based upon an estimated annual effective income tax rate, adjusted for discrete items. The Company recognized income tax expense of $1.6 million and $0.2 million for the three months ended March 31, 2023 and 2022, respectively, representing an effective tax rate of 3.96% and 1.34%, respectively. The year-over-year increase in tax expense for the three-month period ended March 31, 2023 was primarily due to the valuation allowance on the U.S. federal and other-than-California state deferred tax assets as of March 31, 2022, which was released in the fourth quarter of fiscal year 2022. For the three months ended March 31, 2023, the effective tax rate differed from the U.S. federal statutory rate primarily due to stock-based compensation for tax purposes and research credits. For the three months ended March 31, 2022, the effective tax rate differed from the U.S. federal statutory rate primarily due to the valuation allowance on the U.S. deferred tax assets.
The Company’s effective tax rate may be subject to fluctuation due to several factors, including the Company’s ability to accurately predict the pre-tax earnings in the various jurisdictions, valuation allowances against deferred tax assets, the recognition or de-recognition of tax benefits related to uncertain tax positions and the effects of tax law changes.
During the fourth quarter of 2022, the Company determined that the positive evidence overcame any negative evidence, primarily due to the Company’s transition from a cumulative loss in recent years to cumulative income in 2022 and concluded that it was more likely than not that the U.S. federal and other-than-California state deferred tax assets were realizable. As a result, the Company released the valuation allowance against all of the U.S. federal deferred tax assets and other-than-California state deferred tax assets during the fourth quarter of fiscal year 2022.
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.23.1
Subsequent Events
 3 Months Ended
Mar. 31, 2023
Subsequent Events [Abstract]  
Subsequent Events Subsequent Events
Acquisition of Neovasc, Inc.
On April 11, 2023, the Company completed the previously announced acquisition of Neovasc Inc. (“Neovasc”), a corporation existing under the Canada Business Corporations Act, in accordance with the Arrangement Agreement (the “Arrangement Agreement”). Pursuant to the Arrangement Agreement, the Company acquired all of the issued and outstanding common shares of Neovasc and Neovasc became a wholly owned subsidiary of the Company by means of a
plan of arrangement under the Canada Business Corporations Act. Each common share of Neovasc that was issued and outstanding immediately prior to April 11, 2023 was transferred to the Company in exchange for $27.25 per share in cash and one contingent value right entitling the holder to receive up to $12.00 per share in cash, with such receipt and amount contingent on whether the U.S. Food and Drug Administration grants marketing approval for the device known as the Neovasc Reducer for the treatment of angina within specified timeframes set forth in the Arrangement Agreement
Since the completion of the acquisition, the Company has paid a total of $107.2 million to Neovasc shareholders.
Pay-off of Credit Agreement Draw
On April 26, 2023, the Company repaid the $80.0 million drawn under the Credit Agreement in March 2023.
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies (Policies)
 3 Months Ended
Mar. 31, 2023
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) and applicable rules and regulations of the SEC regarding interim financial reporting.
The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s consolidated financial position, results of operations and
cash flows. The results of operations for the three months ended March 31, 2023 are not necessarily indicative of the results to be expected for the year ending December 31, 2023 or for any other future annual or interim period. The condensed consolidated balance sheet as of December 31, 2022 included herein was derived from the audited financial statements as of that date. The unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and related notes included in the 2022 Annual Report.
Cash, Cash Equivalents and Restricted Cash Cash, Cash Equivalents, and Restricted Cash The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts.
Equity Method Investments
Equity Method Investments
Entities which the Company has significant influence over activities of the entity, but does not control, are accounted for under the equity method of accounting in accordance with Topic 323, Investments - Equity Method and Joint Ventures. The Company’s carrying value in the equity method investment is reported as equity method investment on the Company’s consolidated balance sheets. The Company records its proportionate share of the underlying income or loss which is recognized in earnings or loss from the equity method investment. The Company eliminates a portion of intra-entity profit to the extent the goods sold by the Company have not yet been sold through by the equity method investee to an end customer at the end of the reporting period. The profit earned by the Company from the equity method investee for items not yet sold through is eliminated through equity method earnings or loss which is recognized in income (loss) from equity method investment.
The Company assesses its equity method investment for impairment when events or circumstances suggest that the carrying amount of the investment may be impaired. The Company considers all available evidence in assessing whether a decline in fair value is other than temporary. If the decline in fair value is determined to be other than temporary, the difference between the carrying amount of the investment and estimated fair value is recognized as an impairment charge.
Revenue
Revenue
To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, Revenue from Contracts with Customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.
Product Revenue
The Company records product revenue primarily from the sale of its IVL catheters. The Company sells its products to hospitals, primarily through direct sales representatives, as well as through distributors in selected international markets. Additionally, a portion of the Company’s revenue is generated through a consignment model under which inventory is maintained at hospitals.
Product revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.
For products sold through direct sales representatives, control is transferred upon delivery to customers. For products sold to distributors internationally and products sold to customers that utilize stocking orders, control is transferred upon shipment or delivery to the customer’s named location, based on the contractual shipping terms. For consignment inventory, control is transferred at the time the IVL catheters are consumed in a procedure. The Company has elected to account for shipping and handling activities that occur after the customer has obtained control as a fulfillment activity, and not a separate performance obligation.
The Company may provide for the use of an IVL generator and connector cable under an agreement to customers at no charge to facilitate use of the IVL catheters. These agreements generally do not contain contractually enforceable minimum commitments and are generally cancellable by either party with 30 days notice.
License Revenue
For arrangements that contain a license of the Company’s functional intellectual property with a customer, the Company considers whether the license grant is distinct from other performance obligations in the arrangement. A license grant of functional intellectual property is generally considered to be capable of being distinct if a customer can benefit from the license on its own or together with other readily available resources. License revenue for licenses of functional intellectual property is recognized at a point in time when the Company satisfies its performance obligation of transferring the license to the customer.
Consideration received in advance of the satisfaction of a performance obligation is recognized as a contract liability. No license revenues were recognized for the three months ended March 31, 2023 and 2022.
Share-based Payment Arrangement Stock-Based CompensationThe Company accounts for share-based payments at fair value. The fair value of stock options is measured using the Black-Scholes option-pricing model. For share-based awards that vest subject to the satisfaction of a service requirement, the fair value measurement date for stock-based compensation awards is the date of grant and the expense is recognized on a straight-line basis, over the vesting period. For share-based awards that vest upon the satisfaction of a performance target, the related compensation cost is recognized over the requisite service period based on the expected achievement of the performance target. The Company accounts for forfeitures as they occur.
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies (Tables)
 3 Months Ended
Mar. 31, 2023
Accounting Policies [Abstract]  
Restrictions on Cash and Cash Equivalents
March 31,
2023		March 31,
2022
(in thousands)
Cash and cash equivalents$280,932 $66,252 
Restricted cash1,715 1,665 
Total cash, cash equivalents, and restricted cash$282,647 $67,917 
Schedule of Cash and Cash Equivalents
March 31,
2023		March 31,
2022
(in thousands)
Cash and cash equivalents$280,932 $66,252 
Restricted cash1,715 1,665 
Total cash, cash equivalents, and restricted cash$282,647 $67,917 
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.23.1
Financial Instruments and Fair Value Measurements (Tables)
 3 Months Ended
Mar. 31, 2023
Fair Value Disclosures [Abstract]  
Schedule of Financial Assets and Liabilities Measured at Fair Value
The following tables summarize the Company’s financial assets measured at fair value on a recurring basis by level within the fair value hierarchy:
March 31, 2023
Level 1Level 2Level 3Total
(in thousands)
Assets:
U.S. Treasury securities$95,282 $— $— $95,282 
Money market funds10,070 — — 10,070 
Commercial paper— 8,139 — 8,139 
Corporate bonds— 20,688 — 20,688 
U.S. agency securities— 11,820 — 11,820 
Total assets$105,352 $40,647 $— $145,999 
December 31, 2022
Level 1Level 2Level 3Total
(in thousands)
Assets:
U.S. Treasury securities$111,631 $— $— $111,631 
Money market funds12,076 — — 12,076 
Commercial paper— 8,039 — 8,039 
Corporate bonds— 18,808 — 18,808 
U.S. agency securities— 9,429 — 9,429 
Total assets$123,707 $36,276 $— $159,983 
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.23.1
Cash Equivalents and Short-Term Investments (Tables)
 3 Months Ended
Mar. 31, 2023
Cash and Cash Equivalents [Abstract]  
Summary of Cash Equivalents and Short-Term Investments
The following is a summary of the Company’s cash equivalents and short-term investments:
March 31, 2023
Amortized
Cost Basis		Unrealized
Gains		Unrealized
Losses		Fair Value
(in thousands)
U.S. Treasury securities$95,784 $18 $(520)$95,282 
Money market funds10,070 — — 10,070 
Commercial paper8,140 1 (2)8,139 
Corporate bonds20,685 22 (19)20,688 
U.S. agency securities11,804 16 — 11,820 
Total$146,483 $57 $(541)$145,999 
Reported as:
Cash equivalents$10,070 
Short-term investments135,929 
Total$145,999 
December 31, 2022
Amortized
Cost Basis		Unrealized
Gains		Unrealized
Losses		Fair Value
(in thousands)
U.S. Treasury securities$112,719 $3 $(1,091)$111,631 
Money market funds12,076 — — 12,076 
Commercial paper8,039 — — 8,039 
Corporate bonds18,876 8 (76)18,808 
U.S. agency securities9,432 4 (7)9,429 
Total$161,142 $15 $(1,174)$159,983 
Reported as:
Cash equivalents$12,076 
Short-term investments147,907 
Total$159,983 
Summary of Remaining Contractual Maturities for Available-for-sale Securities
The remaining contractual maturities of the Company’s cash equivalents and short-term investments were as follows:
March 31,
2023
Fair Value
(in thousands)
Money market funds
$10,070 
One year or less 112,680 
Greater than one year and less than two years 23,249 
Total$145,999 
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.23.1
Balance Sheet Components (Tables)
 3 Months Ended
Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Inventory
Inventory consists of the following:
March 31,
2023		 December 31,
2022
(in thousands)
Raw material$21,504 $18,456 
Work in progress10,722 7,666 
Finished goods50,737 48,735 
Consigned inventory293 255 
Total inventory$83,256 $75,112 
Schedule of Accrued Liabilities
Accrued liabilities consist of the following:
March 31,
2023		December 31,
2022
(in thousands)
Employee compensation$22,070 $32,885 
Asset purchases6,882 4,600 
Research and development costs4,118 4,007 
Professional services3,862 4,044 
Excise, sales, income and other taxes5,123 4,036 
Other7,585 5,803 
Total accrued liabilities$49,640 $55,375 
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.23.1
Term Notes (Tables)
 3 Months Ended
Mar. 31, 2023
Debt Disclosure [Abstract]  
Schedule of Current and Noncurrent Debt and Net Discount or Premium Balances
March 31,
2023		December 31,
2022
(in thousands)
Principal amount of debt$105,000 $25,000 
Debt issuance costs(769)(802)
Debt104,231 24,198 
Less: debt, current portion(80,000)— 
Debt, noncurrent portion$24,231 $24,198 
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.23.1
Stock-Based Compensation (Tables)
 3 Months Ended
Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Schedule of Total Stock-Based Compensation
Total stock-based compensation was as follows:
Three Months Ended
March 31,
20232022
(in thousands)
Cost of product revenue$954 $653 
Research and development3,795 2,238 
Sales and marketing6,466 3,932 
General and administrative4,752 2,687 
Total stock-based compensation$15,967 $9,510 
Schedule of Option Activity under 2009 Plan and 2019 Plan
Stock Options
Option activity under the 2009 Plan and 2019 Plan is set forth below:
Number
of Shares		Weighted-
Average
Exercise
Price Per
Share		Weighted-
Average
Remaining
Term		Aggregate
Intrinsic
Value
(in years)(in thousands)
Balance, December 31, 20221,122,009 $5.87 4.60$224,115 
Awards authorized— 
Options exercised(77,230)4.12 
Options cancelled(6,133)2.41 
Balance, March 31, 20231,038,646 $6.02 4.41$218,961 
Vested and exercisable,
March 31, 2023		1,038,503 $6.01 4.41$218,935 
Vested and expected to vest, 
March 31, 2023		1,038,646 $6.02 4.41$218,961 
Schedule of RSU Activity under 2019 Plan
RSU and PRSU activity under the 2019 Plan is set forth below. Grant activity for all PRSUs is disclosed at target (100%):
Restricted Stock UnitsPerformance-Based Restricted Stock Units
Number
of Shares		Weighted-
Average
Grant Date
Fair Value
Per Share		Number
of Shares		Weighted-
Average
Grant Date
Fair Value
Per Share
Balance, December 31, 20221,125,991 $127.39 38,797 $165.74 
RSUs granted293,007 191.06 29,473 191.36
RSUs forfeited(19,803)145.72 (175)278.52 
RSUs vested(257,624)97.37 — — 
Balance, March 31, 20231,141,571 150.18 68,095 176.54 
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.23.1
Net Income (Loss) Per Share (Tables)
 3 Months Ended
Mar. 31, 2023
Earnings Per Share [Abstract]  
Components of Basic and Diluted Net Income (Loss) Per Share
The components of basic and diluted net income per share were as follows (in thousands, except share and per share amounts):
Three Months Ended
March 31,
20232022
Numerator:
Net income $39,125 $14,521 
Denominator:
Basic:
Weighted average number of common shares outstanding - basic36,427,263 35,587,337 
Diluted:
Weighted average number of common shares outstanding - basic36,427,263 35,587,337 
Dilutive effect of outstanding common stock options1,039,985 1,437,748 
Dilutive effect of restricted stock units510,340 597,817 
Dilutive effect of common stock pursuant to employee stock purchase plan1,860 575 
Weighted average number of common shares outstanding - diluted37,979,448 37,623,477 
Net income per share:
Basic$1.07 $0.41 
Diluted$1.03 $0.39 
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue (Tables)
 3 Months Ended
Mar. 31, 2023
Disaggregation of Revenue [Abstract]  
Schedule of Product Revenue Based on Product Line and Location
The following table represents the Company’s product revenue based on product line:
Three Months Ended
March 31,
20232022
(in thousands)
Coronary$113,875 $70,337 
Peripheral46,130 22,852 
Other 1,061 442 
Product revenue$161,066 $93,631 
Three Months Ended
March 31,
20232022
(in thousands)
United States$131,623 $78,519 
Europe16,234 12,067 
All other countries13,209 3,045 
Product revenue$161,066 $93,631 
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.23.1
Organization and Basis of Presentation - Additional Information (Details)
$ in Millions
Mar. 31, 2023
USD ($)
subsidiary
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Number of foreign subsidiaries | subsidiary 11
Cash, cash equivalents and short-term investments | $ $ 416.9
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
 [1]
Mar. 31, 2022
Accounting Policies [Abstract]      
Cash and cash equivalents $ 280,932 $ 156,586 $ 66,252
Restricted cash 1,715   1,665
Total cash, cash equivalents, and restricted cash $ 282,647   $ 67,917
[1] The condensed consolidated balance sheet as of December 31, 2022 is derived from the audited consolidated financial statements as of that date.
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies - Additional Information (Details)
 3 Months Ended
Mar. 31, 2023
USD ($)
Accounting Policies [Abstract]  
Notice period for cancellation of agreement 30 days
Revenue recognized $ 0
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.23.1
Financial Instruments and Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Assets:    
Unrealized Gains $ 57 $ 15
US Government Agencies Debt Securities | Level 1    
Assets:    
Total assets 0 0
US Government Agencies Debt Securities | Level 2    
Assets:    
Total assets 11,820 9,429
Recurring    
Assets:    
Total assets 145,999 159,983
Recurring | Level 1    
Assets:    
Total assets 105,352 123,707
Recurring | Level 2    
Assets:    
Total assets 40,647 36,276
Recurring | Level 3    
Assets:    
Total assets 0 0
Recurring | U.S. Treasury securities    
Assets:    
Total assets 95,282 111,631
Recurring | U.S. Treasury securities | Level 1    
Assets:    
Total assets 95,282 111,631
Recurring | U.S. Treasury securities | Level 2    
Assets:    
Total assets 0 0
Recurring | U.S. Treasury securities | Level 3    
Assets:    
Total assets 0 0
Recurring | Money market funds    
Assets:    
Total assets 10,070 12,076
Recurring | Money market funds | Level 1    
Assets:    
Total assets 10,070 12,076
Recurring | Money market funds | Level 2    
Assets:    
Total assets 0 0
Recurring | Money market funds | Level 3    
Assets:    
Total assets 0 0
Recurring | Commercial paper    
Assets:    
Total assets 8,139 8,039
Recurring | Commercial paper | Level 1    
Assets:    
Total assets 0 0
Recurring | Commercial paper | Level 2    
Assets:    
Total assets 8,139 8,039
Recurring | Commercial paper | Level 3    
Assets:    
Total assets 0 0
Recurring | Corporate bonds    
Assets:    
Total assets 20,688 18,808
Recurring | Corporate bonds | Level 1    
Assets:    
Total assets 0 0
Recurring | Corporate bonds | Level 2    
Assets:    
Total assets 20,688 18,808
Recurring | Corporate bonds | Level 3    
Assets:    
Total assets 0 0
Recurring | US Government Agencies Debt Securities    
Assets:    
Total assets 11,820 9,429
Recurring | US Government Agencies Debt Securities | Level 3    
Assets:    
Total assets $ 0 $ 0
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.23.1
Cash Equivalents and Short-Term Investments - Summary of Cash Equivalents and Short-Term Investments (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Cash And Cash Equivalents [Line Items]    
Money market funds $ 10,070 $ 12,076
Cash equivalents and short-term investments, amortized cost basis 146,483 161,142
Unrealized Gains 57 15
Unrealized Losses (541) (1,174)
Short-term investments, fair value 11,820 9,429
Cash equivalents and short-term investments, fair value 145,999 159,983
Short-term investments 135,929 147,907 [1]
U.S. Treasury securities    
Cash And Cash Equivalents [Line Items]    
Short-term investments, amortized cost basis 95,784 112,719
Unrealized Gains 18 3
Unrealized Losses (520) (1,091)
Short-term investments, fair value 95,282 111,631
Money market funds    
Cash And Cash Equivalents [Line Items]    
Money market funds 10,070 12,076
Corporate Bond Securities    
Cash And Cash Equivalents [Line Items]    
Short-term investments, amortized cost basis 20,685 18,876
Unrealized Gains 22 8
Unrealized Losses (19) (76)
Short-term investments, fair value 20,688 18,808
Commercial paper    
Cash And Cash Equivalents [Line Items]    
Short-term investments, amortized cost basis 8,140 8,039
Unrealized Gains 1 0
Unrealized Losses (2) 0
Short-term investments, fair value 8,139 8,039
US Government Agencies Debt Securities    
Cash And Cash Equivalents [Line Items]    
Short-term investments, amortized cost basis 11,804 9,432
Unrealized Gains 16 4
Unrealized Losses $ 0 $ (7)
[1] The condensed consolidated balance sheet as of December 31, 2022 is derived from the audited consolidated financial statements as of that date.
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.23.1
Cash Equivalents and Short-Term Investments - Summary of Remaining Contractual Maturities for Available-for-sale Securities (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Cash and Cash Equivalents [Abstract]    
Money market funds $ 10,070 $ 12,076
One year or less 112,680  
Greater than one year and less than two years 23,249  
Total $ 145,999  
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.23.1
Cash Equivalents and Short-Term Investments - Narrative (Details) - USD ($)
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Cash and Cash Equivalents [Abstract]      
Debt Securities, Available-for-Sale, Unrealized Loss Position $ 76,400,000   $ 123,800,000
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss 500,000   $ 1,200,000
Adjustment for net gain realized and included in other income $ 5,000 $ 0  
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.23.1
Balance Sheet Components - Schedule of Inventory (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Inventory Disclosure [Abstract]    
Raw material $ 21,504 $ 18,456
Work in progress 10,722 7,666
Finished goods 50,737 48,735
Consigned inventory 293 255
Total inventory $ 83,256 $ 75,112 [1]
[1] The condensed consolidated balance sheet as of December 31, 2022 is derived from the audited consolidated financial statements as of that date.
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.23.1
Balance Sheet Components - Schedule of Accrued Liabilities (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Payables and Accruals [Abstract]    
Employee compensation $ 22,070 $ 32,885
Research and development costs 4,118 4,007
Asset purchases 6,882 4,600
Professional services 3,862 4,044
Excise, sales, income and other taxes 5,123 4,036
Other 7,585 5,803
Total accrued liabilities $ 49,640 $ 55,375 [1]
[1] The condensed consolidated balance sheet as of December 31, 2022 is derived from the audited consolidated financial statements as of that date.
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.23.1
Term Notes - Additional Information (Details) - USD ($)
 3 Months Ended
Apr. 26, 2023
Mar. 16, 2023
Oct. 19, 2022
Mar. 31, 2023
Mar. 31, 2022
Debt Instrument [Line Items]          
Interest Expense       $ 636,000 $ 297,000
Subsequent Event | Loan and Security Agreement          
Debt Instrument [Line Items]          
Debt extinguished $ 80,000,000.0        
Revolving Credit Facility | Line of Credit          
Debt Instrument [Line Items]          
Proceeds of supplemental term loan   $ 80,000,000.0      
Line of Credit | Revolving Credit Facility          
Debt Instrument [Line Items]          
Line of credit facility, maximum borrowing capacity     $ 175,000,000    
Incremental revolving commitments, maximum     100,000,000    
Proceeds of supplemental term loan     $ 25,000,000.0    
Line of Credit Facility, Interest Rate at Period End       5.60%  
Secured Overnight Financing Rate (SOFR) | Line of Credit | Revolving Credit Facility          
Debt Instrument [Line Items]          
Debt interest rate basis     1.00%    
Fed Funds Effective Rate Overnight Index Swap Rate | Line of Credit | Revolving Credit Facility          
Debt Instrument [Line Items]          
Debt interest rate basis     0.50%    
Minimum | Line of Credit | Revolving Credit Facility          
Debt Instrument [Line Items]          
Debt interest rate basis     0.00%    
Minimum | Base Rate | Line of Credit | Revolving Credit Facility          
Debt Instrument [Line Items]          
Debt interest rate basis     0.00%    
Minimum | Secured Overnight Financing Rate (SOFR) | Line of Credit | Revolving Credit Facility          
Debt Instrument [Line Items]          
Debt interest rate basis     1.00%    
Maximum | Line of Credit | Revolving Credit Facility          
Debt Instrument [Line Items]          
Debt interest rate basis     1.00%    
Maximum | Base Rate | Line of Credit | Revolving Credit Facility          
Debt Instrument [Line Items]          
Debt interest rate basis     1.00%    
Maximum | Secured Overnight Financing Rate (SOFR) | Line of Credit | Revolving Credit Facility          
Debt Instrument [Line Items]          
Debt interest rate basis     2.00%    
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.23.1
Term Notes - Schedule of Current and Noncurrent Debt and Net Discount or Premium Balances (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Debt Instrument, Periodic Payment [Abstract]    
Principal amount of debt $ 105,000 $ 25,000
Debt issuance costs (769) (802)
Debt 104,231 24,198
Less: debt, current portion (80,000) 0
Debt, noncurrent portion $ 24,231 $ 24,198
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.23.1
Stock-Based Compensation - Schedule of Total Stock-Based Compensation (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]    
Total stock-based compensation $ 15,967 $ 9,510
Cost of product revenue    
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]    
Total stock-based compensation 954 653
Research and development    
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]    
Total stock-based compensation 3,795 2,238
Sales and marketing    
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]    
Total stock-based compensation 6,466 3,932
General and administrative    
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]    
Total stock-based compensation $ 4,752 $ 2,687
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.23.1
Stock-Based Compensation - Additional Information (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended
Feb. 28, 2019
Mar. 31, 2023
Mar. 31, 2022
Mar. 06, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Share-based compensation expenses capitalized amount   $ 400 $ 300  
Common stock reserved for issuance (in shares) 2,000,430      
Maximum period of automatic annual increase in common stock reserved for issuance 10 years      
Automatic annual increase in common stock reserved for issuance 3.00%      
Shares available for issuance (in shares)   3,765,125    
Stock-based compensation expense   $ 15,967 9,510  
Employee Stock        
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Common stock reserved for issuance (in shares)       300,650
Shares available for issuance (in shares)   1,540,527    
Purchase shares of common stock, price per share, percentage of fair market value   85.00%    
Stock-based compensation expense   $ 1,300 $ 400  
Performance-Based Restricted Stock Units        
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Vesting percentage   100.00%    
Performance-Based Restricted Stock Units | Minimum        
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Vesting period   2 years    
Vesting percentage   0.00%    
Performance-Based Restricted Stock Units | Maximum        
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Vesting period   3 years    
Vesting percentage   200.00%    
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.23.1
Stock-Based Compensation - Schedule of Option Activity (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2023
Dec. 31, 2022
Number of Shares    
Balance beginning of period (in shares) 1,122,009,000  
Options exercised (in shares) 77,230,000  
Options cancelled (in shares) (6,133,000)  
Balance end of period (in shares) 1,038,646,000 1,122,009,000
Vested and exercisable shares (in shares) 1,038,503,000  
Vested and expected to vest shares (in shares) 1,038,646,000  
Weighted- Average Exercise Price Per Share    
Beginning balance of period (USD per share) $ 5,870  
Options exercised (USD per share) 4,120  
Options cancelled (USD per share) 2,410  
Ending balance of period (USD per share) 6,020.00 $ 5,870
Vested and exercisable shares (USD per share) 6,010.00  
Vested and expected to vest shares (USD per share) $ 6,020.00  
Weighted- Average Remaining Term    
Balance (USD per share) 4 years 4 months 28 days 4 years 7 months 6 days
Vested and exercisable, March 31, 2023 4 years 4 months 28 days  
Vested and expected to vest,  March 31, 2023 4 years 4 months 28 days  
Aggregate Intrinsic Value    
Balance $ 218,961 $ 224,115
Vested and exercisable, March 31, 2023 218,935  
Vested and expected to vest,  March 31, 2023 $ 218,961  
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.23.1
Stock-Based Compensation - Schedule of RSU Activity (Details)
 3 Months Ended
Mar. 31, 2023
$ / shares
shares
Restricted Stock Units  
Number of Shares  
Beginning balance of period (in shares) | shares 1,125,991,000
RSUs granted (in shares) | shares 293,007,000
RSUs forfeited (in shares) | shares (19,803,000)
RSUs vested (in shares) | shares (257,624,000)
Ending balance of period (in shares) | shares 1,141,571,000
Weighted-Average Grant Date Fair Value Per Share  
Beginning balance of period (USD per share) | $ / shares $ 127,390
RSUs granted (USD per share) | $ / shares 191,060.00
RSUs forfeited (USD per share) | $ / shares 145,720
RSUs vested (USD per share) | $ / shares 97,370
Ending balance of period (USD per share) | $ / shares $ 150,180
Performance-Based Restricted Stock Units  
Number of Shares  
Beginning balance of period (in shares) | shares 38,797,000
RSUs granted (in shares) | shares 29,473,000
RSUs forfeited (in shares) | shares (175,000)
RSUs vested (in shares) | shares 0
Ending balance of period (in shares) | shares 68,095,000
Weighted-Average Grant Date Fair Value Per Share  
Beginning balance of period (USD per share) | $ / shares $ 165,740
RSUs granted (USD per share) | $ / shares 191,360
RSUs forfeited (USD per share) | $ / shares 278,520
RSUs vested (USD per share) | $ / shares 0
Ending balance of period (USD per share) | $ / shares $ 176,540
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.23.1
Net Income (Loss) Per Share - Components of Basic and Diluted Net Income (Loss) Per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Numerator:    
Net income (loss) $ 39,125 $ 14,521
Denominator:    
Basic (in shares) 36,427,263 35,587,337
Diluted (in shares) 37,979,448 37,623,477
Net income per share:    
Basic (USD per share) $ 1.07 $ 0.41
Diluted (USD per share) $ 1.03 $ 0.39
Stock Options    
Denominator:    
Dilutive effect of share-based payment arrangements (in shares) 1,039,985 1,437,748
Restricted Stock Units    
Denominator:    
Dilutive effect of share-based payment arrangements (in shares) 510,340 597,817
Employee Stock    
Denominator:    
Dilutive effect of share-based payment arrangements (in shares) 1,860 575
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue - Schedule of Product Revenue Based on Product Line (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Disaggregation Of Revenue [Line Items]    
Product revenue $ 161,066 $ 93,631
Coronary    
Disaggregation Of Revenue [Line Items]    
Product revenue 113,875 70,337
Peripheral    
Disaggregation Of Revenue [Line Items]    
Product revenue 46,130 22,852
Other    
Disaggregation Of Revenue [Line Items]    
Product revenue $ 1,061 $ 442
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue - Schedule of Product Revenue Based on Location (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Disaggregation Of Revenue [Line Items]    
Product revenue $ 161,066 $ 93,631
United States    
Disaggregation Of Revenue [Line Items]    
Product revenue 131,623 78,519
Europe    
Disaggregation Of Revenue [Line Items]    
Product revenue 16,234 12,067
All other countries    
Disaggregation Of Revenue [Line Items]    
Product revenue $ 13,209 $ 3,045
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.23.1
Equity Method Investments - Additional Information (Details) - USD ($)
 3 Months Ended
Mar. 19, 2021
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
 [1]
Schedule Of Equity Method Investments [Line Items]        
Equity method investment   $ 2,689,000   $ 3,512,000
Loss from equity method investment   823,000 $ 47,000  
Related party contract liability, noncurrent portion   12,273,000   $ 12,273,000
Joint Venture        
Schedule Of Equity Method Investments [Line Items]        
Percentage of equity stake received 45.00%      
Related party transaction. transaction price $ 12,300,000      
Related party contract liability, noncurrent portion $ 12,300,000      
JV Agreement with Genesis MedTech        
Schedule Of Equity Method Investments [Line Items]        
Equity method investment   $ 2,700,000    
JV Agreement with Genesis MedTech | Share Subscription Agreement        
Schedule Of Equity Method Investments [Line Items]        
Ordinary shares issued (in shares) 54,900      
Equity percentage 55.00%      
Cash contribution from exchange of equity $ 15,000,000.0      
Percentage of cash contribution received from exchange of equity upon signing of agreement 50.00%      
Percentage of cash contribution receivable from exchange of equity within one year 50.00%      
JV Agreement with Genesis MedTech | License Agreement        
Schedule Of Equity Method Investments [Line Items]        
Ordinary shares issued (in shares) 45,000      
Equity percentage 45.00%      
[1] The condensed consolidated balance sheet as of December 31, 2022 is derived from the audited consolidated financial statements as of that date.
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.23.1
Income Taxes (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Income Tax Disclosure [Abstract]    
Income tax expense $ 1,612 $ 197
Federal statutory income tax rate 3.96% 1.34%
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.23.1
Subsequent Events (Details) - USD ($)
$ / shares in Units, $ in Millions
 1 Months Ended
Apr. 26, 2023
Apr. 11, 2023
Mar. 16, 2023
May 03, 2023
Revolving Credit Facility | Line of Credit        
Subsequent Event [Line Items]        
Proceeds of supplemental term loan     $ 80.0  
Subsequent Event | Loan and Security Agreement        
Subsequent Event [Line Items]        
Debt extinguished $ 80.0      
Subsequent Event | Neovasc Inc        
Subsequent Event [Line Items]        
Business Acquisition, Share Price   $ 27.25    
Payments to Acquire Businesses, Gross       $ 107.2
Subsequent Event | Neovasc Inc | Business Combination, Contingent Consideration Arrangements, Maximum Value Per Share        
Subsequent Event [Line Items]        
business combination, contingent consideration, per share   $ 12.00    
XML 58 swav-20230331_htm.xml IDEA: XBRL DOCUMENT 0001642545 2023-01-01 2023-03-31 0001642545 2023-05-02 0001642545 2023-03-31 0001642545 2022-12-31 0001642545 2022-01-01 2022-03-31 0001642545 us-gaap:CommonStockMember 2022-12-31 0001642545 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001642545 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001642545 us-gaap:RetainedEarningsMember 2022-12-31 0001642545 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001642545 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001642545 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001642545 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001642545 us-gaap:CommonStockMember 2023-03-31 0001642545 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001642545 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001642545 us-gaap:RetainedEarningsMember 2023-03-31 0001642545 us-gaap:CommonStockMember 2021-12-31 0001642545 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001642545 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001642545 us-gaap:RetainedEarningsMember 2021-12-31 0001642545 2021-12-31 0001642545 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001642545 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001642545 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001642545 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001642545 us-gaap:CommonStockMember 2022-03-31 0001642545 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001642545 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001642545 us-gaap:RetainedEarningsMember 2022-03-31 0001642545 2022-03-31 0001642545 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001642545 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001642545 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001642545 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001642545 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001642545 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001642545 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001642545 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001642545 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001642545 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001642545 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001642545 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001642545 us-gaap:CorporateBondSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001642545 us-gaap:CorporateBondSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001642545 us-gaap:CorporateBondSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001642545 us-gaap:CorporateBondSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001642545 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member 2023-03-31 0001642545 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2023-03-31 0001642545 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001642545 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001642545 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001642545 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001642545 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001642545 us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001642545 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001642545 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001642545 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001642545 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001642545 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001642545 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001642545 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001642545 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001642545 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001642545 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001642545 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001642545 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001642545 us-gaap:CorporateBondSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001642545 us-gaap:CorporateBondSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001642545 us-gaap:CorporateBondSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001642545 us-gaap:CorporateBondSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001642545 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member 2022-12-31 0001642545 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2022-12-31 0001642545 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001642545 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001642545 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001642545 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001642545 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001642545 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001642545 us-gaap:USTreasurySecuritiesMember 2023-03-31 0001642545 us-gaap:MoneyMarketFundsMember 2023-03-31 0001642545 us-gaap:CommercialPaperMember 2023-03-31 0001642545 us-gaap:CorporateBondSecuritiesMember 2023-03-31 0001642545 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-03-31 0001642545 us-gaap:USTreasurySecuritiesMember 2022-12-31 0001642545 us-gaap:MoneyMarketFundsMember 2022-12-31 0001642545 us-gaap:CommercialPaperMember 2022-12-31 0001642545 us-gaap:CorporateBondSecuritiesMember 2022-12-31 0001642545 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0001642545 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2022-10-19 0001642545 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2022-10-19 2022-10-19 0001642545 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2023-03-16 2023-03-16 0001642545 swav:LoanAndSecurityAgreementMember us-gaap:SubsequentEventMember 2023-04-26 2023-04-26 0001642545 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember 2022-10-19 2022-10-19 0001642545 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember 2022-10-19 2022-10-19 0001642545 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2022-10-19 2022-10-19 0001642545 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember swav:SecuredOvernightFinancingRateSOFRMember 2022-10-19 2022-10-19 0001642545 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember swav:SecuredOvernightFinancingRateSOFRMember 2022-10-19 2022-10-19 0001642545 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2022-10-19 2022-10-19 0001642545 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:FederalFundsEffectiveSwapRateMember 2022-10-19 2022-10-19 0001642545 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember swav:SecuredOvernightFinancingRateSOFRMember 2022-10-19 2022-10-19 0001642545 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2023-03-31 0001642545 us-gaap:CostOfSalesMember 2023-01-01 2023-03-31 0001642545 us-gaap:CostOfSalesMember 2022-01-01 2022-03-31 0001642545 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-03-31 0001642545 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-03-31 0001642545 us-gaap:SellingAndMarketingExpenseMember 2023-01-01 2023-03-31 0001642545 us-gaap:SellingAndMarketingExpenseMember 2022-01-01 2022-03-31 0001642545 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-03-31 0001642545 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-03-31 0001642545 2019-02-28 0001642545 2019-02-01 2019-02-28 0001642545 2022-01-01 2022-12-31 0001642545 srt:MinimumMember us-gaap:PerformanceSharesMember 2023-01-01 2023-03-31 0001642545 srt:MaximumMember us-gaap:PerformanceSharesMember 2023-01-01 2023-03-31 0001642545 us-gaap:PerformanceSharesMember 2023-01-01 2023-03-31 0001642545 us-gaap:RestrictedStockUnitsRSUMember 2022-12-31 0001642545 us-gaap:PerformanceSharesMember 2022-12-31 0001642545 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0001642545 us-gaap:RestrictedStockUnitsRSUMember 2023-03-31 0001642545 us-gaap:PerformanceSharesMember 2023-03-31 0001642545 us-gaap:EmployeeStockMember 2019-03-06 0001642545 us-gaap:EmployeeStockMember 2023-01-01 2023-03-31 0001642545 us-gaap:EmployeeStockMember 2022-01-01 2022-03-31 0001642545 us-gaap:EmployeeStockMember 2023-03-31 0001642545 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0001642545 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0001642545 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-03-31 0001642545 swav:CoronaryMember 2023-01-01 2023-03-31 0001642545 swav:CoronaryMember 2022-01-01 2022-03-31 0001642545 swav:PeripheralMember 2023-01-01 2023-03-31 0001642545 swav:PeripheralMember 2022-01-01 2022-03-31 0001642545 us-gaap:ProductAndServiceOtherMember 2023-01-01 2023-03-31 0001642545 us-gaap:ProductAndServiceOtherMember 2022-01-01 2022-03-31 0001642545 country:US 2023-01-01 2023-03-31 0001642545 country:US 2022-01-01 2022-03-31 0001642545 srt:EuropeMember 2023-01-01 2023-03-31 0001642545 srt:EuropeMember 2022-01-01 2022-03-31 0001642545 swav:AllOtherCountriesMember 2023-01-01 2023-03-31 0001642545 swav:AllOtherCountriesMember 2022-01-01 2022-03-31 0001642545 swav:JVAgreementWithGenesisMedTechMember swav:ShareSubscriptionAgreementMember 2021-03-19 2021-03-19 0001642545 swav:JVAgreementWithGenesisMedTechMember swav:ShareSubscriptionAgreementMember 2021-03-19 0001642545 swav:JVAgreementWithGenesisMedTechMember swav:LicenseAgreementMember 2021-03-19 2021-03-19 0001642545 swav:JVAgreementWithGenesisMedTechMember swav:LicenseAgreementMember 2021-03-19 0001642545 swav:JVAgreementWithGenesisMedTechMember 2023-03-31 0001642545 us-gaap:CoVenturerMember 2021-03-19 0001642545 us-gaap:CoVenturerMember 2021-03-19 2021-03-19 0001642545 swav:NeovascIncMember us-gaap:SubsequentEventMember 2023-04-11 0001642545 swav:NeovascIncMember swav:BusinessCombinationContingentConsiderationArrangementsMaximumValuePerShareMember us-gaap:SubsequentEventMember 2023-04-11 2023-04-11 0001642545 swav:NeovascIncMember us-gaap:SubsequentEventMember 2023-04-11 2023-05-03 shares iso4217:USD iso4217:USD shares swav:subsidiary pure 0001642545 --12-31 2023 Q1 false http://fasb.org/us-gaap/2022#ProductMember http://fasb.org/us-gaap/2022#ProductMember http://fasb.org/us-gaap/2022#ProductMember http://fasb.org/us-gaap/2022#ProductMember http://fasb.org/us-gaap/2022#ProductMember http://fasb.org/us-gaap/2022#ProductMember http://fasb.org/us-gaap/2022#ProductMember http://fasb.org/us-gaap/2022#ProductMember P2Y P3Y 10-Q true 2023-03-31 false 001-38829 Shockwave Medical, Inc. DE 27-0494101 5403 Betsy Ross Drive Santa Clara CA 95054 510 279-4262 Shockwave Medical, Inc., common stock, par value $0.001 per share SWAV NASDAQ Yes Yes Large Accelerated Filer false false false 36626211 280932000 156586000 135929000 147907000 84309000 71366000 83256000 75112000 6399000 8292000 590825000 459263000 31623000 32365000 54057000 48152000 2689000 3512000 97941000 97568000 6112000 5229000 783247000 646089000 11050000 6721000 80000000 0 49640000 55375000 1308000 1278000 141998000 63374000 34058000 34928000 24231000 24198000 12273000 12273000 212560000 134773000 0 0 37000 36000 568705000 548960000 -367000 -867000 2312000 -36813000 570687000 511316000 783247000 646089000 161066000 93631000 21066000 12890000 140000000 80741000 26971000 17019000 54011000 35961000 19204000 12389000 100186000 65369000 39814000 15372000 -823000 -47000 636000 297000 2382000 -310000 40737000 14718000 1612000 197000 39125000 14521000 505000 -815000 5000 0 39625000 13706000 1.07 0.41 1.03 0.39 36427263 35587337 37979448 37623477 36235546000 36000 548960000 -867000 -36813000 511316000 77230000 1000 319000 320000 505000 505000 5000 5000 19124000 3092000 3092000 257624000 19000 3000 3000 16337000 16337000 39125000 39125000 36589505000 37000 568705000 -367000 2312000 570687000 35444472000 35000 494806000 -202000 -252809000 241830000 54913000 1000 390000 391000 -815000 -815000 14172000 2135000 2135000 210835000 31000 6000 6000 9767000 9767000 14521000 14521000 35724361000 36000 507092000 -1017000 -238288000 267823000 39125000 14521000 1708000 953000 -823000 -47000 15967000 9510000 748000 767000 718000 -210000 11000 0 -547000 0 33000 153000 689000 0 13004000 10407000 7757000 10090000 -1896000 -600000 861000 119000 4734000 4911000 -6661000 -9051000 -846000 -68000 33962000 1937000 21130000 42128000 34500000 18000000 7188000 3286000 6182000 -27414000 3000 6000 320000 391000 3092000 2135000 80000000 0 83409000 2520000 792000 0 124345000 -22957000 158302000 90874000 282647000 67917000 424000 144000 322000 78000 6162000 3159000 Organization and Basis of Presentation <div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shockwave Medical, Inc. (the “Company”) was incorporated on June 17, 2009. The Company is primarily engaged in the development of Intravascular Lithotripsy (“IVL”) technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular and heart valve disease. Built on a balloon catheter platform, the IVL technology uses lithotripsy to disrupt both superficial and deep vascular calcium, while minimizing soft tissue injury, and an integrated angioplasty balloon to dilate blockages at low pressures, restoring blood flow.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the Company began commercial and manufacturing operations, and began selling catheters based on the IVL technology. The Company’s headquarters are in Santa Clara, California. The Company is located and operates primarily in the United States and h</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as eleven wholly-owned foreign subsidiaries as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The unaudited condensed financial statements include the accounts of Shockwave Medical, Inc. and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated upon consolidation.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, the Company had cash, cash equivalents and short-term investments of $416.9 million, which are available to fund future working capital requirements, investments, acquisitions, or repayments of credit facilities. The Company believes that its cash, cash equivalents, and short-term investments as of March 31, 2023, will be sufficient for the Company to continue as a going concern for at least 12 months from the date the unaudited condensed consolidated financial statements are filed with the Securities and Exchange Commission (“SEC”). The Company’s future capital requirements will depend on many factors, including its growth rate, the timing and extent of its spending to support research and development activities, and the timing and cost of establishing additional sales and marketing capabilities and the scope.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risk and Uncertainties </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to continuing risks and uncertainties in connection with the current macroeconomic environment, including inflation, rising interest rates, and instability in the global banking system, geopolitical factors, including the ongoing conflict between Russia and Ukraine and the responses thereto, supply chain disruptions and the remaining effects of the COVID-19 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pandemic</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company is closely monitoring the impact of these factors on all aspects of its business, including the impacts on its customers, patients, employees, suppliers, vendors, business partners and distribution channels.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, while the Company has not experienced material disruptions in its supply chain to date, the Company has been and continues to be impacted by disruptions in the operations of certain of its third-party </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">suppliers, resulting in increased lead-times, higher component costs and lower allocations for the purchase of some components. In certain cases, the Company has incurred higher logistical expenses. The Company is continuing to work closely with its manufacturing partners and suppliers to source key components and maintain appropriate inventory levels to meet customer demand. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s future results of operations and liquidity could be adversely impacted by a variety of factors, including those discussed in the section titled “Risk Factors” of the Company’s Annual Report on Form 10-K for the year ended December 31, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">filed with the SEC on February 27, 2023 (the “2022 Annual Report”), together with any updates in the section titled “Risk Factors” in this Quarterly Report on Form 10-Q. As of the date of issuance of these condensed consolidated financial statements, the extent to which the current macroeconomic environment and the COVID-19 pandemic may materially impact the Company’s financial condition, liquidity, or results of operations remains uncertain.</span></div> 11 416900000 Summary of Significant Accounting Policies <div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) and applicable rules and regulations of the SEC regarding interim financial reporting. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s consolidated financial position, results of operations and </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cash flows. The results of operations for the three months ended March 31, 2023 are not necessarily indicative of the results to be expected for the year ending December 31, 2023 or for any other future annual or interim period. The condensed consolidated balance sheet as of December 31, 2022 included herein was derived from the audited financial statements as of that date. The unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and related notes included in the 2022 Annual Report.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents, and Restricted Cash </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated statements of cash flows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.112%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.992%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">280,932 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">66,252 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,715 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,665 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total cash, cash equivalents, and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">282,647 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">67,917 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash as of March 31, 2023 and December 31, 2022 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">relates to letters of credit established for real property leases relating to the Company’s office buildings, and is recorded as other assets on the condensed consolidated balance sheets.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 12 for a discussion of the Company’s subsequent payments related to the acquisition of Neovasc, Inc. and the repayment of the credit drawn on March 16, 2023 under the Credit Agreement.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Method Investments </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Entities which the Company has significant influence over activities of the entity, but does not control, are accounted for under the equity method of accounting in accordance with Topic 323, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments - Equity Method and Joint Ventures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company’s carrying value in the equity method investment is reported as equity method investment on the Company’s consolidated balance sheets. The Company records its proportionate share of the underlying income or loss which is recognized in earnings or loss from the equity method investment. The Company eliminates a portion of intra-entity profit to the extent the goods sold by the Company have not yet been sold through by the equity method investee to an end customer at the end of the reporting period. The profit earned by the Company from the equity method investee for items not yet sold through is eliminated through equity method earnings or loss which is recognized in income (loss) from equity method investment. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses its equity method investment for impairment when events or circumstances suggest that the carrying amount of the investment may be impaired. The Company considers all available evidence in assessing whether a decline in fair value is other than temporary. If the decline in fair value is determined to be other than temporary, the difference between the carrying amount of the investment and estimated fair value is recognized as an impairment charge.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, Revenue from Contracts with Customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Revenue</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records product revenue primarily from the sale of its IVL catheters. The Company sells its products to hospitals, primarily through direct sales representatives, as well as through distributors in selected international markets. Additionally, a portion of the Company’s revenue is generated through a consignment model under which inventory is maintained at hospitals.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For products sold through direct sales representatives, control is transferred upon delivery to customers. For products sold to distributors internationally and products sold to customers that utilize stocking orders, control is transferred upon shipment or delivery to the customer’s named location, based on the contractual shipping terms. For consignment inventory, control is transferred at the time the IVL catheters are consumed in a procedure. The Company has elected to account for shipping and handling activities that occur after the customer has obtained control as a fulfillment activity, and not a separate performance obligation.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may provide for the use of an IVL generator and connector cable under an agreement to customers at no charge to facilitate use of the IVL catheters. These agreements generally do not contain contractually enforceable minimum commitments and are generally cancellable by either party with 30 days notice.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Revenue</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that contain a license of the Company’s functional intellectual property with a customer, the Company considers whether the license grant is distinct from other performance obligations in the arrangement. A license grant of functional intellectual property is generally considered to be capable of being distinct if a customer can benefit from the license on its own or together with other readily available resources. License revenue for licenses of functional intellectual property is recognized at a point in time when the Company satisfies its performance obligation of transferring the license to the customer.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration received in advance of the satisfaction of a performance obligation is recognized as a contract </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">liability. No license revenues were recognized for the three months ended March 31, 2023 and 2022.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div>The Company accounts for share-based payments at fair value. The fair value of stock options is measured using the Black-Scholes option-pricing model. For share-based awards that vest subject to the satisfaction of a service requirement, the fair value measurement date for stock-based compensation awards is the date of grant and the expense is recognized on a straight-line basis, over the vesting period. For share-based awards that vest upon the satisfaction of a performance target, the related compensation cost is recognized over the requisite service period based on the expected achievement of the performance target. The Company accounts for forfeitures as they occur. <div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) and applicable rules and regulations of the SEC regarding interim financial reporting. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s consolidated financial position, results of operations and </span></div>cash flows. The results of operations for the three months ended March 31, 2023 are not necessarily indicative of the results to be expected for the year ending December 31, 2023 or for any other future annual or interim period. The condensed consolidated balance sheet as of December 31, 2022 included herein was derived from the audited financial statements as of that date. The unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and related notes included in the 2022 Annual Report. Cash, Cash Equivalents, and Restricted Cash The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts. <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.112%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.992%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">280,932 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">66,252 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,715 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,665 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total cash, cash equivalents, and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">282,647 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">67,917 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.112%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.992%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">280,932 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">66,252 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,715 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,665 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total cash, cash equivalents, and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">282,647 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">67,917 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 280932000 66252000 1715000 1665000 282647000 67917000 <div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Method Investments </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Entities which the Company has significant influence over activities of the entity, but does not control, are accounted for under the equity method of accounting in accordance with Topic 323, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments - Equity Method and Joint Ventures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company’s carrying value in the equity method investment is reported as equity method investment on the Company’s consolidated balance sheets. The Company records its proportionate share of the underlying income or loss which is recognized in earnings or loss from the equity method investment. The Company eliminates a portion of intra-entity profit to the extent the goods sold by the Company have not yet been sold through by the equity method investee to an end customer at the end of the reporting period. The profit earned by the Company from the equity method investee for items not yet sold through is eliminated through equity method earnings or loss which is recognized in income (loss) from equity method investment. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses its equity method investment for impairment when events or circumstances suggest that the carrying amount of the investment may be impaired. The Company considers all available evidence in assessing whether a decline in fair value is other than temporary. If the decline in fair value is determined to be other than temporary, the difference between the carrying amount of the investment and estimated fair value is recognized as an impairment charge.</span></div> <div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, Revenue from Contracts with Customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Revenue</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records product revenue primarily from the sale of its IVL catheters. The Company sells its products to hospitals, primarily through direct sales representatives, as well as through distributors in selected international markets. Additionally, a portion of the Company’s revenue is generated through a consignment model under which inventory is maintained at hospitals.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For products sold through direct sales representatives, control is transferred upon delivery to customers. For products sold to distributors internationally and products sold to customers that utilize stocking orders, control is transferred upon shipment or delivery to the customer’s named location, based on the contractual shipping terms. For consignment inventory, control is transferred at the time the IVL catheters are consumed in a procedure. The Company has elected to account for shipping and handling activities that occur after the customer has obtained control as a fulfillment activity, and not a separate performance obligation.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may provide for the use of an IVL generator and connector cable under an agreement to customers at no charge to facilitate use of the IVL catheters. These agreements generally do not contain contractually enforceable minimum commitments and are generally cancellable by either party with 30 days notice.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Revenue</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that contain a license of the Company’s functional intellectual property with a customer, the Company considers whether the license grant is distinct from other performance obligations in the arrangement. A license grant of functional intellectual property is generally considered to be capable of being distinct if a customer can benefit from the license on its own or together with other readily available resources. License revenue for licenses of functional intellectual property is recognized at a point in time when the Company satisfies its performance obligation of transferring the license to the customer.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration received in advance of the satisfaction of a performance obligation is recognized as a contract </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">liability. No license revenues were recognized for the three months ended March 31, 2023 and 2022.</span></div> P30D 0 0 Stock-Based CompensationThe Company accounts for share-based payments at fair value. The fair value of stock options is measured using the Black-Scholes option-pricing model. For share-based awards that vest subject to the satisfaction of a service requirement, the fair value measurement date for stock-based compensation awards is the date of grant and the expense is recognized on a straight-line basis, over the vesting period. For share-based awards that vest upon the satisfaction of a performance target, the related compensation cost is recognized over the requisite service period based on the expected achievement of the performance target. The Company accounts for forfeitures as they occur. Financial Instruments and Fair Value Measurements <div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company’s financial assets measured at fair value on a recurring basis by level within the fair value hierarchy:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.994%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,282 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,282 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,070 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,070 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,139 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,139 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,688 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,688 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,820 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,820 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,352 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,647 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,999 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.994%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,631 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,631 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,076 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,076 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,039 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,039 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,808 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,808 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,429 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,429 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,707 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,276 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,983 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company’s financial assets measured at fair value on a recurring basis by level within the fair value hierarchy:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.994%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,282 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,282 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,070 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,070 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,139 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,139 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,688 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,688 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,820 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,820 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,352 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,647 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,999 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.994%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,631 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,631 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,076 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,076 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,039 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,039 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,808 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,808 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,429 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,429 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,707 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,276 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,983 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 95282000 0 0 95282000 10070000 0 0 10070000 0 8139000 0 8139000 0 20688000 0 20688000 0 11820000 0 11820000 105352000 40647000 0 145999000 111631000 0 0 111631000 12076000 0 0 12076000 0 8039000 0 8039000 0 18808000 0 18808000 0 9429000 0 9429000 123707000 36276000 0 159983000 Cash Equivalents and Short-Term Investments<div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company’s cash equivalents and short-term investments: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.994%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortized<br/>Cost Basis</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,784 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(520)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,282 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,070 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,070 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,140 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,139 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,685 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,688 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,804 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,820 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,483 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(541)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,999 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported as:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,070 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,929 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,999 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.994%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortized<br/>Cost Basis</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,719 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,091)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,631 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,076 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,076 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,039 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,039 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,876 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,808 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,432 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,429 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,142 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,174)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,983 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported as:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,076 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,907 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,983 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were $76.4 million and $123.8 million of investments in unrealized loss positions of $0.5 million and $1.2 million as of March 31, 2023 and December 31, 2022, respectively. During the three months ended March 31, 2023 and 2022, the Company did not record any other-than-temporary impairment charges on its available-for-sale securities. Based on the Company’s procedures under the expected credit loss model, including an assessment of unrealized losses on the portfolio, the Company concluded that the unrealized losses for its marketable securities were not attributable to credit and therefore an allowance for credit losses for these securities has not been recorded as of March 31, 2023 and December 31, 2022. Also, based on the scheduled maturities of the investments, the Company was more likely than not to hold these investments for a period of time sufficient for a recovery of the Company’s cost basis.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2023 and 2022, the Company recognized $5,000 and nil in realized gains on cash equivalents and short-term investments.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The remaining contractual maturities of the Company’s cash equivalents and short-term investments were as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.809%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.991%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,070 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One year or less </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,680 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater than one year and less than two years </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,249 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,999 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company’s cash equivalents and short-term investments: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.994%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortized<br/>Cost Basis</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,784 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(520)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,282 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,070 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,070 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,140 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,139 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,685 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,688 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,804 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,820 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,483 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(541)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,999 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported as:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,070 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,929 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,999 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.994%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortized<br/>Cost Basis</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,719 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,091)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,631 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,076 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,076 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,039 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,039 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,876 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,808 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,432 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,429 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,142 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,174)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,983 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported as:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,076 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,907 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,983 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 95784000 18000 520000 95282000 10070000 10070000 8140000 1000 2000 8139000 20685000 22000 19000 20688000 11804000 16000 0 11820000 146483000 57000 541000 145999000 10070000 135929000 145999000 112719000 3000 1091000 111631000 12076000 12076000 8039000 0 0 8039000 18876000 8000 76000 18808000 9432000 4000 7000 9429000 161142000 15000 1174000 159983000 12076000 147907000 159983000 76400000 123800000 500000 1200000 5000 0 <div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The remaining contractual maturities of the Company’s cash equivalents and short-term investments were as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.809%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.991%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,070 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One year or less </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,680 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater than one year and less than two years </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,249 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,999 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 10070000 112680000 23249000 145999000 Balance Sheet Components <div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consists of the following: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.112%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.992%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw material</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,504 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,456 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,722 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,666 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,737 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,735 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consigned inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total inventory</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,256 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,112 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Liabilities </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consist of the following: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.112%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.992%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,070 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,885 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,882 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,118 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,007 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,862 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,044 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Excise, sales, income and other taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,123 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,036 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,585 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,803 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,640 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,375 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consists of the following: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.112%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.992%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw material</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,504 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,456 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,722 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,666 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,737 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,735 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consigned inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total inventory</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,256 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,112 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 21504000 18456000 10722000 7666000 50737000 48735000 293000 255000 83256000 75112000 <div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consist of the following: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.112%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.992%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,070 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,885 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,882 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,118 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,007 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,862 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,044 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Excise, sales, income and other taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,123 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,036 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,585 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,803 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,640 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,375 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 22070000 32885000 6882000 4600000 4118000 4007000 3862000 4044000 5123000 4036000 7585000 5803000 49640000 55375000 Debt<div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 19, 2022, the Company entered into a Credit Agreement (the “Credit Agreement”) with Wells Fargo Bank, National Association, as administrative agent, Wells Fargo Bank, National Association, as swingline lender and an issuing lender, Wells Fargo Securities, LLC and Silicon Valley Bank, as joint lead arrangers and joint bookrunners, Silicon Valley Bank, as syndication agent, and the several lenders party thereto. The Credit Agreement provides for a revolving credit facility in an aggregate principal amount of $175 million with the right to request increases to the revolving commitments (subject to certain conditions) of up to the greater of (x) $100 million or (y) the Company’s consolidated EBITDA for the four fiscal quarter period most recently ended prior to the date of such increase.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrent with entering into the Credit Agreement, the Company drew down $25.0 million. On March 16, 2023, the Company drew down an additional $80.0 million under the Credit Agreement. See Note 12 for a discussion of the Company’s subsequent payment of the additional $80.0 million drawn under the Credit Agreement.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The revolving credit facility accrues for interest, at the election of the Company, at (A) the Base Rate (as defined below) plus a margin ranging from 0% to 1% depending on the Company's Consolidated Total Net Leverage Ratio (as defined in the Credit Agreement) (which rate is currently 0%) or (B) the applicable secured overnight financing rate (“SOFR”) plus a margin from 1% to 2%, depending on the Company's Consolidated Total Net Leverage Ratio (which rate is currently 1%). Base Rate means, at any time, the highest of (a) the Wells Fargo Bank, National Association's announced prime rate, (b) the federal funds rate plus 0.5% and (c) Term SOFR for a one-month tenor in effect on such day plus 1%. The Credit Agreement matures on October 19, 2027. The interest rate was 5.6% as of March 31, 2023. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded interest expense of $0.6 million and $0.3 million for the three months ended March 31, 2023 and 2022, respectively.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt and debt issuance costs are as follows: </span></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.112%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.992%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount of debt</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(769)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(802)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,231 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,198 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: debt, current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt, noncurrent portion</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,231 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,198 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 175000000 100000000 25000000.0 80000000.0 80000000.0 0 0.01 0 0.01 0.02 0.01 0.005 0.01 0.056 600000 300000 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.112%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.992%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount of debt</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(769)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(802)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,231 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,198 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: debt, current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt, noncurrent portion</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,231 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,198 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 105000000 25000000 769000 802000 104231000 24198000 80000000 0 24231000 24198000 Stock-Based Compensation <div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation was as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"><tr><td style="width:1.0%"/><td style="width:69.579%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.251%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.253%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">954 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">653 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,795 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,238 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,466 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,932 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,752 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,687 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,967 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,510 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation of $0.4 million and $0.3 million was capitalized into inventory for the three months ended March 31, 2023 and 2022, respectively. Stock-based compensation capitalized into inventory is recognized as cost of product revenue when the related product is sold.</span></div><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2009 Equity Incentive Plan and 2019 Equity Incentive Plan</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 17, 2009, the Company adopted the 2009 Equity Incentive Plan (the “2009 Plan”) under which the Company's Board of Directors (the “Board”) had the authority to issue stock options to employees, directors and consultants. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, the Company adopted the 2019 Equity Incentive Plan (the “2019 Plan”), which became effective in connection with the Company's initial public offering (the “IPO”). As a result, effective as of March 6, 2019, the Company may not grant any additional awards under the 2009 Plan. The 2009 Plan will continue to govern outstanding equity awards granted thereunder. The Company initially reserved 2,000,430 shares of common stock for the issuance of a variety of awards under the 2019 Plan, including stock options, stock appreciation rights, awards of restricted stock and awards of restricted stock units (“RSUs”). In addition, the number of shares of common stock reserved for issuance under the 2019 Plan will automatically increase on the first day of January for a period of up to ten years, which commenced on January 1, 2020, in an amount equal to 3% of the total number of shares of the Company’s capital stock outstanding on the last day of the preceding year, or a lesser number of shares determined by the Board. As of March 31, 2023, there were 3,765,125 shares available for issuance under the 2019 Plan.</span></div><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Option activity under the 2009 Plan and 2019 Plan is set forth below: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.545%"><tr><td style="width:1.0%"/><td style="width:39.843%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.055%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.055%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.055%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.060%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number<br/>of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Exercise<br/>Price Per<br/>Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Remaining<br/>Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,122,009 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.60</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224,115 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards authorized</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,230)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options cancelled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,133)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038,646 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.02 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.41</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218,961 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable,<br/>March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038,503 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.01 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.41</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218,935 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest, <br/>March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038,646 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.02 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.41</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218,961 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs are share awards that entitle the holder to receive freely tradable shares of the Company’s common stock upon vesting. RSUs cannot be transferred and the awards are subject to forfeiture if the holder’s employment terminates prior to the release of the vesting restrictions. RSUs generally vest over a four-year period with straight-line quarterly vesting with a one year cliff or straight-line annual vesting, provided the employee remains continuously employed with the Company. The fair value of RSUs is equal to the closing price of the Company’s common stock on the grant date.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022 and 2023, the Company granted performance-based restricted stock units (“PRSUs”) to certain key executives. The vesting of these PRSUs is dependent on the achievement of certain performance targets related to the Company’s compound annual growth rate of revenue over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIzMGUxMDU2MjBkYzQyMjVhNmIzZTViYTQxZmRkOWI5L3NlYzpiMzBlMTA1NjIwZGM0MjI1YTZiM2U1YmE0MWZkZDliOV81NS9mcmFnOmE2Y2MxNjk1Nzc1NjQ2N2Q4ZGNjNmQ4ZDUyODFiM2JlL3RleHRyZWdpb246YTZjYzE2OTU3NzU2NDY3ZDhkY2M2ZDhkNTI4MWIzYmVfMjczMA_63316ef6-ed46-430e-a675-06cb5737fd81">two</span> or <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIzMGUxMDU2MjBkYzQyMjVhNmIzZTViYTQxZmRkOWI5L3NlYzpiMzBlMTA1NjIwZGM0MjI1YTZiM2U1YmE0MWZkZDliOV81NS9mcmFnOmE2Y2MxNjk1Nzc1NjQ2N2Q4ZGNjNmQ4ZDUyODFiM2JlL3RleHRyZWdpb246YTZjYzE2OTU3NzU2NDY3ZDhkY2M2ZDhkNTI4MWIzYmVfMjczNg_1728af0b-50ed-4b23-ba4d-e64164fd2f86">three</span> year performance period, provided the executives remain employed with the Company at the time of vesting. The number of PRSUs that vest will vary from 0% to 200% of the target which will be determined based on the level of performance attained for each performance period. The fair value of these PRSUs is equal to the closing price of the Company’s common stock on the grant date. Compensation cost for PRSUs is recognized over the requisite service period based on the expected achievement of performance targets.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSU and PRSU activity under the 2019 Plan is set forth below. Grant activity for all PRSUs is disclosed at target (100%):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.994%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance-Based Restricted Stock Units</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number<br/>of Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Grant Date<br/>Fair Value<br/>Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number<br/>of Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Grant Date<br/>Fair Value<br/>Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,125,991 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.39 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,797 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165.74 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293,007 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191.06 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,473 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191.36</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,803)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145.72 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(175)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278.52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(257,624)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,141,571 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150.18 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,095 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176.54 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, the Company adopted the 2019 Employee Stock Purchase Plan (“ESPP”), which became effective in connection with the IPO on March 6, 2019. The Company initially reserved 300,650 shares of common stock for purchase under the ESPP. Each offering under the ESPP to Company employees to purchase stock under the ESPP begins on each September 1 and March 1 and ends on the following February 28 or 29 and August 31, respectively. On each purchase date, which falls on the last date of each offering period, ESPP participants will purchase shares of common stock at a price per share equal to 85% of the lesser of (1) the fair market value per share of the common stock on the offering date or (2) the fair market value of the common stock on the purchase date. The occurrence and duration of offering periods under the ESPP are subject to the determinations of the Company’s Compensation Committee of the Board, in its sole discretion.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the ESPP shares is estimated using the Black-Scholes option pricing model. The Company recorded $1.3 million and $0.4 million of stock-based compensation expense related to the ESPP for the three months ended March 31, 2023 and 2022, respectively. At March 31, 2023, a total of 1,540,527 shares were available for issuance under the ESPP.</span></div> <div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation was as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"><tr><td style="width:1.0%"/><td style="width:69.579%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.251%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.253%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">954 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">653 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,795 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,238 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,466 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,932 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,752 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,687 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,967 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,510 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 954000 653000 3795000 2238000 6466000 3932000 4752000 2687000 15967000 9510000 400000 300000 2000430 P10Y 0.03 3765125 <div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Option activity under the 2009 Plan and 2019 Plan is set forth below: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.545%"><tr><td style="width:1.0%"/><td style="width:39.843%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.055%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.055%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.055%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.060%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number<br/>of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Exercise<br/>Price Per<br/>Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Remaining<br/>Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,122,009 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.60</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224,115 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards authorized</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,230)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options cancelled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,133)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038,646 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.02 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.41</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218,961 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable,<br/>March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038,503 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.01 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.41</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218,935 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest, <br/>March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038,646 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.02 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.41</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218,961 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1122009000 5870 P4Y7M6D 224115000 77230000 4120 6133000 2410 1038646000 6020.00 P4Y4M28D 218961000 1038503000 6010.00 P4Y4M28D 218935000 1038646000 6020.00 P4Y4M28D 218961000 0 2 <div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSU and PRSU activity under the 2019 Plan is set forth below. Grant activity for all PRSUs is disclosed at target (100%):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.994%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance-Based Restricted Stock Units</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number<br/>of Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Grant Date<br/>Fair Value<br/>Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number<br/>of Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Grant Date<br/>Fair Value<br/>Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,125,991 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.39 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,797 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165.74 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293,007 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191.06 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,473 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191.36</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,803)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145.72 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(175)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278.52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(257,624)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,141,571 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150.18 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,095 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176.54 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1 1125991000 127390 38797000 165740 293007000 191060.00 29473000 191360 19803000 145720 175000 278520 257624000 97370 0 0 1141571000 150180 68095000 176540 300650 0.85 1300000 400000 1540527 Net Income Per Share <div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of basic and diluted net income per share were as follows (in thousands, except share and per share amounts): </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.878%"><tr><td style="width:1.0%"/><td style="width:68.068%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.071%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.452%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.909%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net income </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,125 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,521 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted average number of common shares outstanding - basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,427,263 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,587,337 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted average number of common shares outstanding - basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,427,263 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,587,337 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Dilutive effect of outstanding common stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,039,985 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,437,748 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Dilutive effect of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510,340 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597,817 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Dilutive effect of common stock pursuant to employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,860 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted average number of common shares outstanding - diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,979,448 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,623,477 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income per share:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.07 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.03 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.39 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of basic and diluted net income per share were as follows (in thousands, except share and per share amounts): </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.878%"><tr><td style="width:1.0%"/><td style="width:68.068%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.071%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.452%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.909%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net income </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,125 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,521 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted average number of common shares outstanding - basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,427,263 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,587,337 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted average number of common shares outstanding - basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,427,263 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,587,337 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Dilutive effect of outstanding common stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,039,985 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,437,748 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Dilutive effect of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510,340 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597,817 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Dilutive effect of common stock pursuant to employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,860 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted average number of common shares outstanding - diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,979,448 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,623,477 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income per share:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.07 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.03 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.39 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 39125000 14521000 36427263 35587337 36427263 35587337 1039985 1437748 510340 597817 1860 575 37979448 37623477 1.07 0.41 1.03 0.39 Revenue <div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the Company’s product revenue based on product line:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"/><td style="width:68.181%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.096%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.770%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Coronary</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,875 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,337 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peripheral</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,852 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,061 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Product revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,066 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,631 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Coronary product revenue encompasses sales of the Company’s C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> catheter and C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">2+</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> catheter. Peripheral product revenue encompasses sales of the Company’s M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> catheter, M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">5+</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> catheter, S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> IVL catheter, and L</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> IVL catheter. Other product revenue encompasses sales of the Company’s generators and related accessories.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the Company’s product revenue based on the location to which the product is shipped: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"/><td style="width:69.025%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.525%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,623 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,519 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,234 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,067 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other countries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,209 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,045 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,066 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,631 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the Company’s product revenue based on product line:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"/><td style="width:68.181%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.096%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.770%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Coronary</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,875 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,337 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peripheral</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,852 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,061 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Product revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,066 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,631 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"/><td style="width:69.025%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.525%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,623 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,519 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,234 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,067 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other countries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,209 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,045 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,066 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,631 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 113875000 70337000 46130000 22852000 1061000 442000 161066000 93631000 131623000 78519000 16234000 12067000 13209000 3045000 161066000 93631000 Equity Method Investments <div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Genesis Shockwave Private Limited </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 19, 2021, the Company entered into the Joint Venture Deed (or “JV Agreement”) with Genesis MedTech International Private Limited (“Genesis”) to establish a long-term strategic partnership to develop, manufacture and commercialize certain of the Company’s interventional products in the People’s Republic of China, excluding the Special Administrative Regions of Hong Kong and Macau (the “PRC”). Under the JV Agreement, Genesis Shockwave Private Ltd. (the “JV”) was formed under the laws of Singapore to serve as a joint venture of Genesis and the Company for the purpose of establishing and managing the strategic partnership. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On the same date, Genesis and the Company entered into a Share Subscription Agreement pursuant to which, among other things, the JV issued (i) 54,900 ordinary shares which represents 55% of the total equity of the JV, to Genesis in exchange for a cash contribution of $15.0 million, of which 50% was due upon signing and the remaining 50% was due within one year of signing, and (ii) 45,000 ordinary shares, which represents 45% of the total equity of the JV, to the Company as consideration for the Shockwave License Agreement (the “License Agreement”). Under the License Agreement, the Company has agreed to contribute to the JV an exclusive license under certain of the Company’s intellectual property rights to develop, manufacture, distribute and commercialize certain products in the PRC and is entitled to receive royalties on the sales of the licensed products in the PRC. Further, the Company entered into a Distribution Agreement, pursuant to which the Company has agreed to sell certain Company-manufactured products to the JV or a PRC subsidiary of the JV for commercialization and distribution in the PRC. In May 2022, the JV obtained regulatory approval from the China National Medical Products Administration to sell the Company-manufactured Shockwave IVL System with the Shockwave C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> catheter, M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> catheter and S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> catheter in the PRC.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has accounted for its investment in the JV under the equity method of accounting. As of March 31, 2023, the carrying value of the Company’s investment in the JV was $2.7 million and the Company owned a 45% interest in the entity. During the three months ended March 31, 2023, the Company continued to recognize product revenue on sales to the JV and eliminate a portion of intra-entity profit to the extent the goods have not yet either been consumed by the JV for use in clinical trials, or sold by the JV to an end customer at the end of the reporting period. The profit earned by the Company from the JV for items not yet sold through to an end customer is eliminated through equity method earnings or loss which is recognized in income (loss) from equity method investment.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s product revenue for products sold to the JV during the three months ended March 31, 2023 and related accounts receivable from the JV as of March 31, 2023 were immaterial. Intra-entity profit, which was recorded as a reduction to equity method investment as of and for the three months ended March 31, 2023, was also immaterial. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2023 and 2022, the Company’s loss from the equity method was $0.8 million and $47,000, respectively. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon execution of the License Agreement, on March 19, 2021, the Company received a 45% equity stake in the JV. The Company determined that the JV met the definition of a customer under Topic 606, and that the promised goods and services of the contribution of the license of intellectual property and associated manufacturing technology transfer to the JV were considered to be a single performance obligation. The transaction price of $12.3 million was estimated by reference to the cash value of the shares that were issued at the formation of the JV. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, the associated manufacturing technology transfer to the JV has not yet been completed. The Company maintains a related party contract liability, noncurrent, of $12.3 million for the outstanding performance obligation. The Company will satisfy the outstanding performance obligation upon the completion of training provided by the Company to the JV, and successful regulatory approval for the JV manufactured product from the China National Medical Products Administration.</span></div> 54900 0.55 15000000.0 0.50 0.50 45000 0.45 2700000 0.45 -800000 -47000 0.45 12300000 12300000 Income Taxes<div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a quarterly basis, the Company provides for income taxes based upon an estimated annual effective income tax rate, adjusted for discrete items. The Company recognized income tax expense of $1.6 million and $0.2 million for the three months ended March 31, 2023 and 2022, respectively, representing an effective tax rate of 3.96% and 1.34%, respectively. The year-over-year increase in tax expense for the three-month period ended March 31, 2023 was primarily due to the valuation allowance on the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. federal and other-than-California state deferred tax assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as of March 31, 2022, which was released in the fourth quarter of fiscal year 2022. For the three months ended March 31, 2023, the effective tax rate differed from the U.S. federal statutory rate primarily due to stock-based compensation for tax purposes and research credits. For the three months ended March 31, 2022, the effective tax rate differed from the U.S. federal statutory rate primarily due to the valuation allowance on the U.S. deferred tax assets.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s effective tax rate may be subject to fluctuation due to several factors, including the Company’s ability to accurately predict the pre-tax earnings in the various jurisdictions, valuation allowances against deferred tax assets, the recognition or de-recognition of tax benefits related to uncertain tax positions and the effects of tax law changes. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2022, the Company determined that the positive evidence overcame any negative evidence, primarily due to the Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s transition from a cumulative loss in recent years to cumulative income in 2022 and concluded that it was more likely than not that the U.S. federal and other-than-California state deferred tax assets were realizable. As a result, the Company released the valuation allowance against all of the U.S. federal deferred tax assets and other-than-California state deferred tax assets during the fourth quarter of fiscal year 2022.</span></div> 1600000 200000 0.0396 0.0134 Subsequent Events<div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition of Neovasc, Inc.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 11, 2023, the Company completed the previously announced acquisition of Neovasc Inc. (“Neovasc”), a corporation existing under the Canada Business Corporations Act, in accordance with the Arrangement Agreement (the “Arrangement Agreement”). Pursuant to the Arrangement Agreement, the Company acquired all of the issued and outstanding common shares of Neovasc and Neovasc became a wholly owned subsidiary of the Company by means of a </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">plan of arrangement under the Canada Business Corporations Act. Each common share of Neovasc that was issued and outstanding immediately prior to April 11, 2023 was transferred to the Company in exchange for $27.25 per share in cash and one contingent value right entitling the holder to receive up to $12.00 per share in cash, with such receipt and amount contingent on whether the U.S. Food and Drug Administration grants marketing approval for the device known as the Neovasc Reducer for the treatment of angina within specified timeframes set forth in the Arrangement Agreement</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the completion of the acquisition, the Company has paid a total of $107.2 million to Neovasc shareholders.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pay-off of Credit Agreement Draw</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 26, 2023, the Company repaid the $80.0 million drawn under the Credit Agreement in March 2023.</span></div> 27.25 12.00 107200000 80000000.0 The condensed consolidated balance sheet as of December 31, 2022 is derived from the audited consolidated financial statements as of that date. EXCEL 59 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

,"2*ZG/PX#P*M^=4V/UR-/D-4$L#!!0 M ( .J#J%:7BKL

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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 61 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 62 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 150 236 1 true 48 0 false 5 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.shockwavemedical.com/role/CoverPage Cover Page Cover 1 false false R2.htm 0000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 0000003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) Sheet http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) Statements 3 false false R4.htm 0000004 - Statement - Condensed Consolidated Statements of Stockholders' Equity Sheet http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofStockholdersEquity Condensed Consolidated Statements of Stockholders' Equity Statements 4 false false R5.htm 0000005 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows Condensed Consolidated Statements of Cash Flows Statements 5 false false R6.htm 0000006 - Disclosure - Organization and Basis of Presentation Sheet http://www.shockwavemedical.com/role/OrganizationandBasisofPresentation Organization and Basis of Presentation Notes 6 false false R7.htm 0000007 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.shockwavemedical.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 7 false false R8.htm 0000008 - Disclosure - Financial Instruments and Fair Value Measurements Sheet http://www.shockwavemedical.com/role/FinancialInstrumentsandFairValueMeasurements Financial Instruments and Fair Value Measurements Notes 8 false false R9.htm 0000009 - Disclosure - Cash Equivalents and Short-Term Investments Sheet http://www.shockwavemedical.com/role/CashEquivalentsandShortTermInvestments Cash Equivalents and Short-Term Investments Notes 9 false false R10.htm 0000010 - Disclosure - Balance Sheet Components Sheet http://www.shockwavemedical.com/role/BalanceSheetComponents Balance Sheet Components Notes 10 false false R11.htm 0000011 - Disclosure - Term Notes Notes http://www.shockwavemedical.com/role/TermNotes Term Notes Notes 11 false false R12.htm 0000012 - Disclosure - Stock-Based Compensation Sheet http://www.shockwavemedical.com/role/StockBasedCompensation Stock-Based Compensation Notes 12 false false R13.htm 0000013 - Disclosure - Net Income (Loss) Per Share Sheet http://www.shockwavemedical.com/role/NetIncomeLossPerShare Net Income (Loss) Per Share Notes 13 false false R14.htm 0000014 - Disclosure - Revenue Sheet http://www.shockwavemedical.com/role/Revenue Revenue Notes 14 false false R15.htm 0000015 - Disclosure - Equity Method Investments Sheet http://www.shockwavemedical.com/role/EquityMethodInvestments Equity Method Investments Notes 15 false false R16.htm 0000016 - Disclosure - Income Taxes Sheet http://www.shockwavemedical.com/role/IncomeTaxes Income Taxes Notes 16 false false R17.htm 0000017 - Disclosure - Subsequent Events Sheet http://www.shockwavemedical.com/role/SubsequentEvents Subsequent Events Notes 17 false false R18.htm 0000018 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.shockwavemedical.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.shockwavemedical.com/role/SummaryofSignificantAccountingPolicies 18 false false R19.htm 0000019 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.shockwavemedical.com/role/SummaryofSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.shockwavemedical.com/role/SummaryofSignificantAccountingPolicies 19 false false R20.htm 0000020 - Disclosure - Financial Instruments and Fair Value Measurements (Tables) Sheet http://www.shockwavemedical.com/role/FinancialInstrumentsandFairValueMeasurementsTables Financial Instruments and Fair Value Measurements (Tables) Tables http://www.shockwavemedical.com/role/FinancialInstrumentsandFairValueMeasurements 20 false false R21.htm 0000021 - Disclosure - Cash Equivalents and Short-Term Investments (Tables) Sheet http://www.shockwavemedical.com/role/CashEquivalentsandShortTermInvestmentsTables Cash Equivalents and Short-Term Investments (Tables) Tables http://www.shockwavemedical.com/role/CashEquivalentsandShortTermInvestments 21 false false R22.htm 0000022 - Disclosure - Balance Sheet Components (Tables) Sheet http://www.shockwavemedical.com/role/BalanceSheetComponentsTables Balance Sheet Components (Tables) Tables http://www.shockwavemedical.com/role/BalanceSheetComponents 22 false false R23.htm 0000023 - Disclosure - Term Notes (Tables) Notes http://www.shockwavemedical.com/role/TermNotesTables Term Notes (Tables) Tables http://www.shockwavemedical.com/role/TermNotes 23 false false R24.htm 0000024 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.shockwavemedical.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.shockwavemedical.com/role/StockBasedCompensation 24 false false R25.htm 0000025 - Disclosure - Net Income (Loss) Per Share (Tables) Sheet http://www.shockwavemedical.com/role/NetIncomeLossPerShareTables Net Income (Loss) Per Share (Tables) Tables http://www.shockwavemedical.com/role/NetIncomeLossPerShare 25 false false R26.htm 0000026 - Disclosure - Revenue (Tables) Sheet http://www.shockwavemedical.com/role/RevenueTables Revenue (Tables) Tables http://www.shockwavemedical.com/role/Revenue 26 false false R27.htm 0000027 - Disclosure - Organization and Basis of Presentation - Additional Information (Details) Sheet http://www.shockwavemedical.com/role/OrganizationandBasisofPresentationAdditionalInformationDetails Organization and Basis of Presentation - Additional Information (Details) Details 27 false false R28.htm 0000028 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) Sheet http://www.shockwavemedical.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) Details 28 false false R29.htm 0000029 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) Sheet http://www.shockwavemedical.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails Summary of Significant Accounting Policies - Additional Information (Details) Details 29 false false R30.htm 0000030 - Disclosure - Financial Instruments and Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value (Details) Sheet http://www.shockwavemedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails Financial Instruments and Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value (Details) Details 30 false false R31.htm 0000031 - Disclosure - Cash Equivalents and Short-Term Investments - Summary of Cash Equivalents and Short-Term Investments (Details) Sheet http://www.shockwavemedical.com/role/CashEquivalentsandShortTermInvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails Cash Equivalents and Short-Term Investments - Summary of Cash Equivalents and Short-Term Investments (Details) Details 31 false false R32.htm 0000032 - Disclosure - Cash Equivalents and Short-Term Investments - Summary of Remaining Contractual Maturities for Available-for-sale Securities (Details) Sheet http://www.shockwavemedical.com/role/CashEquivalentsandShortTermInvestmentsSummaryofRemainingContractualMaturitiesforAvailableforsaleSecuritiesDetails Cash Equivalents and Short-Term Investments - Summary of Remaining Contractual Maturities for Available-for-sale Securities (Details) Details 32 false false R33.htm 0000033 - Disclosure - Cash Equivalents and Short-Term Investments - Narrative (Details) Sheet http://www.shockwavemedical.com/role/CashEquivalentsandShortTermInvestmentsNarrativeDetails Cash Equivalents and Short-Term Investments - Narrative (Details) Details 33 false false R34.htm 0000034 - Disclosure - Balance Sheet Components - Schedule of Inventory (Details) Sheet http://www.shockwavemedical.com/role/BalanceSheetComponentsScheduleofInventoryDetails Balance Sheet Components - Schedule of Inventory (Details) Details 34 false false R35.htm 0000035 - Disclosure - Balance Sheet Components - Schedule of Accrued Liabilities (Details) Sheet http://www.shockwavemedical.com/role/BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails Balance Sheet Components - Schedule of Accrued Liabilities (Details) Details 35 false false R36.htm 0000036 - Disclosure - Term Notes - Additional Information (Details) Notes http://www.shockwavemedical.com/role/TermNotesAdditionalInformationDetails Term Notes - Additional Information (Details) Details 36 false false R37.htm 0000037 - Disclosure - Term Notes - Schedule of Current and Noncurrent Debt and Net Discount or Premium Balances (Details) Notes http://www.shockwavemedical.com/role/TermNotesScheduleofCurrentandNoncurrentDebtandNetDiscountorPremiumBalancesDetails Term Notes - Schedule of Current and Noncurrent Debt and Net Discount or Premium Balances (Details) Details 37 false false R38.htm 0000038 - Disclosure - Stock-Based Compensation - Schedule of Total Stock-Based Compensation (Details) Sheet http://www.shockwavemedical.com/role/StockBasedCompensationScheduleofTotalStockBasedCompensationDetails Stock-Based Compensation - Schedule of Total Stock-Based Compensation (Details) Details 38 false false R39.htm 0000039 - Disclosure - Stock-Based Compensation - Additional Information (Details) Sheet http://www.shockwavemedical.com/role/StockBasedCompensationAdditionalInformationDetails Stock-Based Compensation - Additional Information (Details) Details 39 false false R40.htm 0000040 - Disclosure - Stock-Based Compensation - Schedule of Option Activity (Details) Sheet http://www.shockwavemedical.com/role/StockBasedCompensationScheduleofOptionActivityDetails Stock-Based Compensation - Schedule of Option Activity (Details) Details 40 false false R41.htm 0000041 - Disclosure - Stock-Based Compensation - Schedule of RSU Activity (Details) Sheet http://www.shockwavemedical.com/role/StockBasedCompensationScheduleofRSUActivityDetails Stock-Based Compensation - Schedule of RSU Activity (Details) Details 41 false false R42.htm 0000042 - Disclosure - Net Income (Loss) Per Share - Components of Basic and Diluted Net Income (Loss) Per Share (Details) Sheet http://www.shockwavemedical.com/role/NetIncomeLossPerShareComponentsofBasicandDilutedNetIncomeLossPerShareDetails Net Income (Loss) Per Share - Components of Basic and Diluted Net Income (Loss) Per Share (Details) Details http://www.shockwavemedical.com/role/NetIncomeLossPerShareTables 42 false false R43.htm 0000043 - Disclosure - Revenue - Schedule of Product Revenue Based on Product Line (Details) Sheet http://www.shockwavemedical.com/role/RevenueScheduleofProductRevenueBasedonProductLineDetails Revenue - Schedule of Product Revenue Based on Product Line (Details) Details 43 false false R44.htm 0000044 - Disclosure - Revenue - Schedule of Product Revenue Based on Location (Details) Sheet http://www.shockwavemedical.com/role/RevenueScheduleofProductRevenueBasedonLocationDetails Revenue - Schedule of Product Revenue Based on Location (Details) Details 44 false false R45.htm 0000045 - Disclosure - Equity Method Investments - Additional Information (Details) Sheet http://www.shockwavemedical.com/role/EquityMethodInvestmentsAdditionalInformationDetails Equity Method Investments - Additional Information (Details) Details 45 false false R46.htm 0000046 - Disclosure - Income Taxes (Details) Sheet http://www.shockwavemedical.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.shockwavemedical.com/role/IncomeTaxes 46 false false R47.htm 0000047 - Disclosure - Subsequent Events (Details) Sheet http://www.shockwavemedical.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://www.shockwavemedical.com/role/SubsequentEvents 47 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 - swav-20230331.htm 4 swav-20230331.htm swav-20230331.xsd swav-20230331_cal.xml swav-20230331_def.xml swav-20230331_lab.xml swav-20230331_pre.xml swav-ex31_1xq123.htm swav-ex31_2xq123.htm swav-ex32_1xq123.htm swav-ex32_2xq123.htm http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 65 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "swav-20230331.htm": { "axisCustom": 0, "axisStandard": 21, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 529, "http://xbrl.sec.gov/dei/2022": 29 }, "contextCount": 150, "dts": { "calculationLink": { "local": [ "swav-20230331_cal.xml" ] }, "definitionLink": { "local": [ "swav-20230331_def.xml" ] }, "inline": { "local": [ "swav-20230331.htm" ] }, "labelLink": { "local": [ "swav-20230331_lab.xml" ] }, "presentationLink": { "local": [ "swav-20230331_pre.xml" ] }, "schema": { "local": [ "swav-20230331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 388, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 10, "http://xbrl.sec.gov/dei/2022": 5, "total": 15 }, "keyCustom": 17, "keyStandard": 219, "memberCustom": 10, "memberStandard": 32, "nsprefix": "swav", "nsuri": "http://www.shockwavemedical.com/20230331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i4e3c37cdda724a1892f2d809160537ac_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover Page", "menuCat": "Cover", "order": "1", "role": "http://www.shockwavemedical.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i4e3c37cdda724a1892f2d809160537ac_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i4e3c37cdda724a1892f2d809160537ac_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000010 - Disclosure - Balance Sheet Components", "menuCat": "Notes", "order": "10", "role": "http://www.shockwavemedical.com/role/BalanceSheetComponents", "shortName": "Balance Sheet Components", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i4e3c37cdda724a1892f2d809160537ac_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i4e3c37cdda724a1892f2d809160537ac_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000011 - Disclosure - Term Notes", "menuCat": "Notes", "order": "11", "role": "http://www.shockwavemedical.com/role/TermNotes", "shortName": "Term Notes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i4e3c37cdda724a1892f2d809160537ac_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i4e3c37cdda724a1892f2d809160537ac_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000012 - Disclosure - Stock-Based Compensation", "menuCat": "Notes", "order": "12", "role": "http://www.shockwavemedical.com/role/StockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i4e3c37cdda724a1892f2d809160537ac_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i4e3c37cdda724a1892f2d809160537ac_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000013 - Disclosure - Net Income (Loss) Per Share", "menuCat": "Notes", "order": "13", "role": "http://www.shockwavemedical.com/role/NetIncomeLossPerShare", "shortName": "Net Income (Loss) Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i4e3c37cdda724a1892f2d809160537ac_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i4e3c37cdda724a1892f2d809160537ac_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000014 - Disclosure - Revenue", "menuCat": "Notes", "order": "14", "role": "http://www.shockwavemedical.com/role/Revenue", "shortName": "Revenue", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i4e3c37cdda724a1892f2d809160537ac_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i4e3c37cdda724a1892f2d809160537ac_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000015 - Disclosure - Equity Method Investments", "menuCat": "Notes", "order": "15", "role": "http://www.shockwavemedical.com/role/EquityMethodInvestments", "shortName": "Equity Method Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i4e3c37cdda724a1892f2d809160537ac_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i4e3c37cdda724a1892f2d809160537ac_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000016 - Disclosure - Income Taxes", "menuCat": "Notes", "order": "16", "role": "http://www.shockwavemedical.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i4e3c37cdda724a1892f2d809160537ac_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i4e3c37cdda724a1892f2d809160537ac_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000017 - Disclosure - Subsequent Events", "menuCat": "Notes", "order": "17", "role": "http://www.shockwavemedical.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i4e3c37cdda724a1892f2d809160537ac_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i4e3c37cdda724a1892f2d809160537ac_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000018 - Disclosure - Summary of Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "18", "role": "http://www.shockwavemedical.com/role/SummaryofSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i4e3c37cdda724a1892f2d809160537ac_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i4e3c37cdda724a1892f2d809160537ac_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000019 - Disclosure - Summary of Significant Accounting Policies (Tables)", "menuCat": "Tables", "order": "19", "role": "http://www.shockwavemedical.com/role/SummaryofSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i4e3c37cdda724a1892f2d809160537ac_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i8980b54e7d9c4cc7870832ab6b16c278_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets", "menuCat": "Statements", "order": "2", "role": "http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i8980b54e7d9c4cc7870832ab6b16c278_I20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i4e3c37cdda724a1892f2d809160537ac_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000020 - Disclosure - Financial Instruments and Fair Value Measurements (Tables)", "menuCat": "Tables", "order": "20", "role": "http://www.shockwavemedical.com/role/FinancialInstrumentsandFairValueMeasurementsTables", "shortName": "Financial Instruments and Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i4e3c37cdda724a1892f2d809160537ac_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i4e3c37cdda724a1892f2d809160537ac_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000021 - Disclosure - Cash Equivalents and Short-Term Investments (Tables)", "menuCat": "Tables", "order": "21", "role": "http://www.shockwavemedical.com/role/CashEquivalentsandShortTermInvestmentsTables", "shortName": "Cash Equivalents and Short-Term Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i4e3c37cdda724a1892f2d809160537ac_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i4e3c37cdda724a1892f2d809160537ac_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000022 - Disclosure - Balance Sheet Components (Tables)", "menuCat": "Tables", "order": "22", "role": "http://www.shockwavemedical.com/role/BalanceSheetComponentsTables", "shortName": "Balance Sheet Components (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i4e3c37cdda724a1892f2d809160537ac_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i4e3c37cdda724a1892f2d809160537ac_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000023 - Disclosure - Term Notes (Tables)", "menuCat": "Tables", "order": "23", "role": "http://www.shockwavemedical.com/role/TermNotesTables", "shortName": "Term Notes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i4e3c37cdda724a1892f2d809160537ac_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i4e3c37cdda724a1892f2d809160537ac_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000024 - Disclosure - Stock-Based Compensation (Tables)", "menuCat": "Tables", "order": "24", "role": "http://www.shockwavemedical.com/role/StockBasedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i4e3c37cdda724a1892f2d809160537ac_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i4e3c37cdda724a1892f2d809160537ac_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000025 - Disclosure - Net Income (Loss) Per Share (Tables)", "menuCat": "Tables", "order": "25", "role": "http://www.shockwavemedical.com/role/NetIncomeLossPerShareTables", "shortName": "Net Income (Loss) Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i4e3c37cdda724a1892f2d809160537ac_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i4e3c37cdda724a1892f2d809160537ac_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000026 - Disclosure - Revenue (Tables)", "menuCat": "Tables", "order": "26", "role": "http://www.shockwavemedical.com/role/RevenueTables", "shortName": "Revenue (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i4e3c37cdda724a1892f2d809160537ac_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i8980b54e7d9c4cc7870832ab6b16c278_I20230331", "decimals": "INF", "first": true, "lang": "en-US", "name": "swav:NumberOfForeignSubsidiaries", "reportCount": 1, "unique": true, "unitRef": "subsidiary", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000027 - Disclosure - Organization and Basis of Presentation - Additional Information (Details)", "menuCat": "Details", "order": "27", "role": "http://www.shockwavemedical.com/role/OrganizationandBasisofPresentationAdditionalInformationDetails", "shortName": "Organization and Basis of Presentation - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i8980b54e7d9c4cc7870832ab6b16c278_I20230331", "decimals": "INF", "first": true, "lang": "en-US", "name": "swav:NumberOfForeignSubsidiaries", "reportCount": 1, "unique": true, "unitRef": "subsidiary", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i8980b54e7d9c4cc7870832ab6b16c278_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000028 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)", "menuCat": "Details", "order": "28", "role": "http://www.shockwavemedical.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails", "shortName": "Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i07e903dd2cda4d89abf241c1de4c0b17_I20220331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i4e3c37cdda724a1892f2d809160537ac_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "swav:NoticePeriodForCancellationOfAgreement", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000029 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)", "menuCat": "Details", "order": "29", "role": "http://www.shockwavemedical.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails", "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i4e3c37cdda724a1892f2d809160537ac_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "swav:NoticePeriodForCancellationOfAgreement", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i4e3c37cdda724a1892f2d809160537ac_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)", "menuCat": "Statements", "order": "3", "role": "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i4e3c37cdda724a1892f2d809160537ac_D20230101-20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i8980b54e7d9c4cc7870832ab6b16c278_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000030 - Disclosure - Financial Instruments and Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value (Details)", "menuCat": "Details", "order": "30", "role": "http://www.shockwavemedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails", "shortName": "Financial Instruments and Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i40daaf23f1cf4a16a8514c16e7095d1a_I20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i8980b54e7d9c4cc7870832ab6b16c278_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000031 - Disclosure - Cash Equivalents and Short-Term Investments - Summary of Cash Equivalents and Short-Term Investments (Details)", "menuCat": "Details", "order": "31", "role": "http://www.shockwavemedical.com/role/CashEquivalentsandShortTermInvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails", "shortName": "Cash Equivalents and Short-Term Investments - Summary of Cash Equivalents and Short-Term Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i8980b54e7d9c4cc7870832ab6b16c278_I20230331", "decimals": "-3", "lang": "en-US", "name": "swav:CashEquivalentsAndShortTermInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i8980b54e7d9c4cc7870832ab6b16c278_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000032 - Disclosure - Cash Equivalents and Short-Term Investments - Summary of Remaining Contractual Maturities for Available-for-sale Securities (Details)", "menuCat": "Details", "order": "32", "role": "http://www.shockwavemedical.com/role/CashEquivalentsandShortTermInvestmentsSummaryofRemainingContractualMaturitiesforAvailableforsaleSecuritiesDetails", "shortName": "Cash Equivalents and Short-Term Investments - Summary of Remaining Contractual Maturities for Available-for-sale Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i8980b54e7d9c4cc7870832ab6b16c278_I20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i8980b54e7d9c4cc7870832ab6b16c278_I20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000033 - Disclosure - Cash Equivalents and Short-Term Investments - Narrative (Details)", "menuCat": "Details", "order": "33", "role": "http://www.shockwavemedical.com/role/CashEquivalentsandShortTermInvestmentsNarrativeDetails", "shortName": "Cash Equivalents and Short-Term Investments - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i8980b54e7d9c4cc7870832ab6b16c278_I20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i8980b54e7d9c4cc7870832ab6b16c278_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000034 - Disclosure - Balance Sheet Components - Schedule of Inventory (Details)", "menuCat": "Details", "order": "34", "role": "http://www.shockwavemedical.com/role/BalanceSheetComponentsScheduleofInventoryDetails", "shortName": "Balance Sheet Components - Schedule of Inventory (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i8980b54e7d9c4cc7870832ab6b16c278_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i8980b54e7d9c4cc7870832ab6b16c278_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000035 - Disclosure - Balance Sheet Components - Schedule of Accrued Liabilities (Details)", "menuCat": "Details", "order": "35", "role": "http://www.shockwavemedical.com/role/BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails", "shortName": "Balance Sheet Components - Schedule of Accrued Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i8980b54e7d9c4cc7870832ab6b16c278_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i4e3c37cdda724a1892f2d809160537ac_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InterestExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000036 - Disclosure - Term Notes - Additional Information (Details)", "menuCat": "Details", "order": "36", "role": "http://www.shockwavemedical.com/role/TermNotesAdditionalInformationDetails", "shortName": "Term Notes - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i23e8a0b108d94e93a2391b6806fb14b7_I20221019", "decimals": "INF", "lang": "en-US", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i8980b54e7d9c4cc7870832ab6b16c278_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000037 - Disclosure - Term Notes - Schedule of Current and Noncurrent Debt and Net Discount or Premium Balances (Details)", "menuCat": "Details", "order": "37", "role": "http://www.shockwavemedical.com/role/TermNotesScheduleofCurrentandNoncurrentDebtandNetDiscountorPremiumBalancesDetails", "shortName": "Term Notes - Schedule of Current and Noncurrent Debt and Net Discount or Premium Balances (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i8980b54e7d9c4cc7870832ab6b16c278_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i4e3c37cdda724a1892f2d809160537ac_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000038 - Disclosure - Stock-Based Compensation - Schedule of Total Stock-Based Compensation (Details)", "menuCat": "Details", "order": "38", "role": "http://www.shockwavemedical.com/role/StockBasedCompensationScheduleofTotalStockBasedCompensationDetails", "shortName": "Stock-Based Compensation - Schedule of Total Stock-Based Compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i856f6123e1cf4ee084d2ba06b45a60ec_D20230101-20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i4e3c37cdda724a1892f2d809160537ac_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000039 - Disclosure - Stock-Based Compensation - Additional Information (Details)", "menuCat": "Details", "order": "39", "role": "http://www.shockwavemedical.com/role/StockBasedCompensationAdditionalInformationDetails", "shortName": "Stock-Based Compensation - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i4e3c37cdda724a1892f2d809160537ac_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i2972a418ace24f74bd72ecef4d9343d4_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000004 - Statement - Condensed Consolidated Statements of Stockholders' Equity", "menuCat": "Statements", "order": "4", "role": "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "shortName": "Condensed Consolidated Statements of Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i2972a418ace24f74bd72ecef4d9343d4_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "ib655861ca7a74380a8bc643c1cdcd335_I20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000040 - Disclosure - Stock-Based Compensation - Schedule of Option Activity (Details)", "menuCat": "Details", "order": "40", "role": "http://www.shockwavemedical.com/role/StockBasedCompensationScheduleofOptionActivityDetails", "shortName": "Stock-Based Compensation - Schedule of Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i4e3c37cdda724a1892f2d809160537ac_D20230101-20230331", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i501066eaadab4efaad6ee7c3c32f6b85_I20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000041 - Disclosure - Stock-Based Compensation - Schedule of RSU Activity (Details)", "menuCat": "Details", "order": "41", "role": "http://www.shockwavemedical.com/role/StockBasedCompensationScheduleofRSUActivityDetails", "shortName": "Stock-Based Compensation - Schedule of RSU Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i501066eaadab4efaad6ee7c3c32f6b85_I20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i4e3c37cdda724a1892f2d809160537ac_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000042 - Disclosure - Net Income (Loss) Per Share - Components of Basic and Diluted Net Income (Loss) Per Share (Details)", "menuCat": "Details", "order": "42", "role": "http://www.shockwavemedical.com/role/NetIncomeLossPerShareComponentsofBasicandDilutedNetIncomeLossPerShareDetails", "shortName": "Net Income (Loss) Per Share - Components of Basic and Diluted Net Income (Loss) Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i91a1bd7acbdc4afeb722c67c5b2b872c_D20230101-20230331", "decimals": "0", "lang": "en-US", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i4e3c37cdda724a1892f2d809160537ac_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000043 - Disclosure - Revenue - Schedule of Product Revenue Based on Product Line (Details)", "menuCat": "Details", "order": "43", "role": "http://www.shockwavemedical.com/role/RevenueScheduleofProductRevenueBasedonProductLineDetails", "shortName": "Revenue - Schedule of Product Revenue Based on Product Line (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i11792879fbda45b5a02d0169b34032b9_D20230101-20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i4e3c37cdda724a1892f2d809160537ac_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000044 - Disclosure - Revenue - Schedule of Product Revenue Based on Location (Details)", "menuCat": "Details", "order": "44", "role": "http://www.shockwavemedical.com/role/RevenueScheduleofProductRevenueBasedonLocationDetails", "shortName": "Revenue - Schedule of Product Revenue Based on Location (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "ib0cfd419a81b4842853fdfbb00ef86df_D20230101-20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i8980b54e7d9c4cc7870832ab6b16c278_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000045 - Disclosure - Equity Method Investments - Additional Information (Details)", "menuCat": "Details", "order": "45", "role": "http://www.shockwavemedical.com/role/EquityMethodInvestmentsAdditionalInformationDetails", "shortName": "Equity Method Investments - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i4941c134306f43a895a4c44375349336_I20210319", "decimals": "2", "lang": "en-US", "name": "swav:PercentageOfEquityStakeReceived", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i4e3c37cdda724a1892f2d809160537ac_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000046 - Disclosure - Income Taxes (Details)", "menuCat": "Details", "order": "46", "role": "http://www.shockwavemedical.com/role/IncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i4e3c37cdda724a1892f2d809160537ac_D20230101-20230331", "decimals": "INF", "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "ie07f4a5cf6444185b7731de020104e2f_D20230316-20230316", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ProceedsFromIssuanceOfDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000047 - Disclosure - Subsequent Events (Details)", "menuCat": "Details", "order": "47", "role": "http://www.shockwavemedical.com/role/SubsequentEventsDetails", "shortName": "Subsequent Events (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i9db37cf02924439f830ff06fd23ca0dd_I20230411", "decimals": "2", "lang": "en-US", "name": "us-gaap:BusinessAcquisitionSharePrice", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i4e3c37cdda724a1892f2d809160537ac_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000005 - Statement - Condensed Consolidated Statements of Cash Flows", "menuCat": "Statements", "order": "5", "role": "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i4e3c37cdda724a1892f2d809160537ac_D20230101-20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i4e3c37cdda724a1892f2d809160537ac_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000006 - Disclosure - Organization and Basis of Presentation", "menuCat": "Notes", "order": "6", "role": "http://www.shockwavemedical.com/role/OrganizationandBasisofPresentation", "shortName": "Organization and Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i4e3c37cdda724a1892f2d809160537ac_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i4e3c37cdda724a1892f2d809160537ac_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000007 - Disclosure - Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "7", "role": "http://www.shockwavemedical.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i4e3c37cdda724a1892f2d809160537ac_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i4e3c37cdda724a1892f2d809160537ac_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000008 - Disclosure - Financial Instruments and Fair Value Measurements", "menuCat": "Notes", "order": "8", "role": "http://www.shockwavemedical.com/role/FinancialInstrumentsandFairValueMeasurements", "shortName": "Financial Instruments and Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i4e3c37cdda724a1892f2d809160537ac_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i4e3c37cdda724a1892f2d809160537ac_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000009 - Disclosure - Cash Equivalents and Short-Term Investments", "menuCat": "Notes", "order": "9", "role": "http://www.shockwavemedical.com/role/CashEquivalentsandShortTermInvestments", "shortName": "Cash Equivalents and Short-Term Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "swav-20230331.htm", "contextRef": "i4e3c37cdda724a1892f2d809160537ac_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 48, "tag": { "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://www.shockwavemedical.com/role/RevenueScheduleofProductRevenueBasedonLocationDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.shockwavemedical.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.shockwavemedical.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.shockwavemedical.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "verboseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.shockwavemedical.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.shockwavemedical.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.shockwavemedical.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r541" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.shockwavemedical.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r542" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.shockwavemedical.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "verboseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.shockwavemedical.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.shockwavemedical.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.shockwavemedical.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.shockwavemedical.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.shockwavemedical.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r539" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.shockwavemedical.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.shockwavemedical.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.shockwavemedical.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r539" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.shockwavemedical.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.shockwavemedical.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r539" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.shockwavemedical.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.shockwavemedical.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r543" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.shockwavemedical.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r539" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.shockwavemedical.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r539" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.shockwavemedical.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r539" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.shockwavemedical.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r539" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.shockwavemedical.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.shockwavemedical.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r538" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.shockwavemedical.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r540" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.shockwavemedical.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.shockwavemedical.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment, Name [Domain]", "terseLabel": "Investment, Name" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.shockwavemedical.com/role/EquityMethodInvestmentsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_EuropeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Europe [Member]", "terseLabel": "Europe" } } }, "localname": "EuropeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.shockwavemedical.com/role/RevenueScheduleofProductRevenueBasedonLocationDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r251", "r252", "r253", "r254", "r326", "r458", "r482", "r499", "r500", "r517", "r530", "r537", "r574", "r588", "r589", "r590", "r591", "r592", "r593" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.shockwavemedical.com/role/StockBasedCompensationAdditionalInformationDetails", "http://www.shockwavemedical.com/role/TermNotesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r251", "r252", "r253", "r254", "r326", "r458", "r482", "r499", "r500", "r517", "r530", "r537", "r574", "r588", "r589", "r590", "r591", "r592", "r593" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum", "verboseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.shockwavemedical.com/role/StockBasedCompensationAdditionalInformationDetails", "http://www.shockwavemedical.com/role/TermNotesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r221", "r459", "r518", "r535", "r570", "r571", "r576", "r599" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.shockwavemedical.com/role/RevenueScheduleofProductRevenueBasedonProductLineDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r221", "r459", "r518", "r535", "r570", "r571", "r576", "r599" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.shockwavemedical.com/role/RevenueScheduleofProductRevenueBasedonProductLineDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r251", "r252", "r253", "r254", "r318", "r326", "r357", "r358", "r359", "r434", "r458", "r482", "r499", "r500", "r517", "r530", "r537", "r569", "r574", "r589", "r590", "r591", "r592", "r593" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.shockwavemedical.com/role/StockBasedCompensationAdditionalInformationDetails", "http://www.shockwavemedical.com/role/TermNotesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r251", "r252", "r253", "r254", "r318", "r326", "r357", "r358", "r359", "r434", "r458", "r482", "r499", "r500", "r517", "r530", "r537", "r569", "r574", "r589", "r590", "r591", "r592", "r593" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.shockwavemedical.com/role/StockBasedCompensationAdditionalInformationDetails", "http://www.shockwavemedical.com/role/TermNotesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r234" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]", "terseLabel": "Investment, Name" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.shockwavemedical.com/role/EquityMethodInvestmentsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r222", "r223", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r519", "r536", "r576" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.shockwavemedical.com/role/RevenueScheduleofProductRevenueBasedonLocationDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r222", "r223", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r519", "r536", "r576" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.shockwavemedical.com/role/RevenueScheduleofProductRevenueBasedonLocationDetails" ], "xbrltype": "stringItemType" }, "swav_AccruedAssetPurchasesCurrent": { "auth_ref": [], "calculation": { "http://www.shockwavemedical.com/role/BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued asset purchases current.", "label": "Accrued Asset Purchases Current", "terseLabel": "Asset purchases" } } }, "localname": "AccruedAssetPurchasesCurrent", "nsuri": "http://www.shockwavemedical.com/20230331", "presentation": [ "http://www.shockwavemedical.com/role/BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "swav_AccruedResearchAndDevelopmentCostsCurrent": { "auth_ref": [], "calculation": { "http://www.shockwavemedical.com/role/BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued research and development costs, current.", "label": "Accrued Research And Development Costs Current", "terseLabel": "Research and development costs" } } }, "localname": "AccruedResearchAndDevelopmentCostsCurrent", "nsuri": "http://www.shockwavemedical.com/20230331", "presentation": [ "http://www.shockwavemedical.com/role/BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "swav_AllOtherCountriesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All other countries.", "label": "All Other Countries [Member]", "terseLabel": "All other countries" } } }, "localname": "AllOtherCountriesMember", "nsuri": "http://www.shockwavemedical.com/20230331", "presentation": [ "http://www.shockwavemedical.com/role/RevenueScheduleofProductRevenueBasedonLocationDetails" ], "xbrltype": "domainItemType" }, "swav_AutomaticAnnualIncreaseInCommonStockReservedForIssuanceAsPercentageOfCapitalStockOutstandingOnPrecedingFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Automatic annual increase in common stock reserved for issuance as percentage of capital stock outstanding on preceding fiscal year end date", "label": "Automatic Annual Increase In Common Stock Reserved For Issuance As Percentage Of Capital Stock Outstanding On Preceding Fiscal Year End Date", "terseLabel": "Automatic annual increase in common stock reserved for issuance" } } }, "localname": "AutomaticAnnualIncreaseInCommonStockReservedForIssuanceAsPercentageOfCapitalStockOutstandingOnPrecedingFiscalYearEndDate", "nsuri": "http://www.shockwavemedical.com/20230331", "presentation": [ "http://www.shockwavemedical.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "swav_AvailableForSaleSecuritiesDebtMaturitiesWithinGreaterThanOneYearAndLessThanTwoYearsFairValue": { "auth_ref": [], "calculation": { "http://www.shockwavemedical.com/role/CashEquivalentsandShortTermInvestmentsSummaryofRemainingContractualMaturitiesforAvailableforsaleSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Available for sale securities debt maturities within greater than one year and less than two years fair value.", "label": "Available For Sale Securities Debt Maturities Within Greater Than One Year And Less Than Two Years Fair Value", "terseLabel": "Greater than one year and less than two years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinGreaterThanOneYearAndLessThanTwoYearsFairValue", "nsuri": "http://www.shockwavemedical.com/20230331", "presentation": [ "http://www.shockwavemedical.com/role/CashEquivalentsandShortTermInvestmentsSummaryofRemainingContractualMaturitiesforAvailableforsaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "swav_BusinessCombinationContingentConsiderationArrangementsMaximumValuePerShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Combination, Contingent Consideration Arrangements, Maximum Value Per Share", "label": "Business Combination, Contingent Consideration Arrangements, Maximum Value Per Share [Member]", "terseLabel": "Business Combination, Contingent Consideration Arrangements, Maximum Value Per Share" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsMaximumValuePerShareMember", "nsuri": "http://www.shockwavemedical.com/20230331", "presentation": [ "http://www.shockwavemedical.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "swav_BusinessCombinationContingentConsiderationPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Combination, Contingent Consideration, Per Share", "label": "Business Combination, Contingent Consideration, Per Share", "terseLabel": "business combination, contingent consideration, per share" } } }, "localname": "BusinessCombinationContingentConsiderationPerShare", "nsuri": "http://www.shockwavemedical.com/20230331", "presentation": [ "http://www.shockwavemedical.com/role/SubsequentEventsDetails" ], "xbrltype": "perShareItemType" }, "swav_CashContributionFromExchangeOfEquity": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash contribution from exchange of equity.", "label": "Cash Contribution From Exchange Of Equity", "terseLabel": "Cash contribution from exchange of equity" } } }, "localname": "CashContributionFromExchangeOfEquity", "nsuri": "http://www.shockwavemedical.com/20230331", "presentation": [ "http://www.shockwavemedical.com/role/EquityMethodInvestmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "swav_CashEquivalentsAndShortTermInvestments": { "auth_ref": [], "calculation": { "http://www.shockwavemedical.com/role/CashEquivalentsandShortTermInvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash equivalents and short term investments.", "label": "Cash Equivalents And Short Term Investments", "totalLabel": "Cash equivalents and short-term investments, amortized cost basis" } } }, "localname": "CashEquivalentsAndShortTermInvestments", "nsuri": "http://www.shockwavemedical.com/20230331", "presentation": [ "http://www.shockwavemedical.com/role/CashEquivalentsandShortTermInvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "swav_CashEquivalentsAndShortTermInvestmentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.shockwavemedical.com/role/CashEquivalentsandShortTermInvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails": { "order": 2.0, "parentTag": "swav_CashEquivalentsAndShortTermInvestments", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash Equivalents And Short-Term Investments, Fair Value Disclosure", "label": "Cash Equivalents And Short-Term Investments, Fair Value Disclosure", "totalLabel": "Cash equivalents and short-term investments, fair value" } } }, "localname": "CashEquivalentsAndShortTermInvestmentsFairValueDisclosure", "nsuri": "http://www.shockwavemedical.com/20230331", "presentation": [ "http://www.shockwavemedical.com/role/CashEquivalentsandShortTermInvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "swav_ConsignedInventoryNetOfReserves": { "auth_ref": [], "calculation": { "http://www.shockwavemedical.com/role/BalanceSheetComponentsScheduleofInventoryDetails": { "order": 4.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Consigned inventory, net of reserves.", "label": "Consigned Inventory Net Of Reserves", "terseLabel": "Consigned inventory" } } }, "localname": "ConsignedInventoryNetOfReserves", "nsuri": "http://www.shockwavemedical.com/20230331", "presentation": [ "http://www.shockwavemedical.com/role/BalanceSheetComponentsScheduleofInventoryDetails" ], "xbrltype": "monetaryItemType" }, "swav_CoronaryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Coronary.", "label": "Coronary [Member]", "terseLabel": "Coronary" } } }, "localname": "CoronaryMember", "nsuri": "http://www.shockwavemedical.com/20230331", "presentation": [ "http://www.shockwavemedical.com/role/RevenueScheduleofProductRevenueBasedonProductLineDetails" ], "xbrltype": "domainItemType" }, "swav_EPSBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Earnings Per Share , Basic and Diluted", "label": "EPS, Basic and Diluted [Abstract]", "terseLabel": "Net income per share:" } } }, "localname": "EPSBasicAndDilutedAbstract", "nsuri": "http://www.shockwavemedical.com/20230331", "presentation": [ "http://www.shockwavemedical.com/role/NetIncomeLossPerShareComponentsofBasicandDilutedNetIncomeLossPerShareDetails" ], "xbrltype": "stringItemType" }, "swav_EarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Earnings Per Share [Line Items]", "label": "Earnings Per Share [Line Items]", "terseLabel": "Earnings Per Share [Line Items]" } } }, "localname": "EarningsPerShareLineItems", "nsuri": "http://www.shockwavemedical.com/20230331", "presentation": [ "http://www.shockwavemedical.com/role/NetIncomeLossPerShareComponentsofBasicandDilutedNetIncomeLossPerShareDetails" ], "xbrltype": "stringItemType" }, "swav_EarningsPerShareTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Earnings Per Share [Table]", "label": "Earnings Per Share [Table]", "terseLabel": "Earnings Per Share [Table]" } } }, "localname": "EarningsPerShareTable", "nsuri": "http://www.shockwavemedical.com/20230331", "presentation": [ "http://www.shockwavemedical.com/role/NetIncomeLossPerShareComponentsofBasicandDilutedNetIncomeLossPerShareDetails" ], "xbrltype": "stringItemType" }, "swav_ForeignCurrencyRemeasurementGainLossBeforeTax": { "auth_ref": [], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Foreign Currency Remeasurement Gain (Loss), Before Tax", "label": "Foreign Currency Remeasurement Gain (Loss), Before Tax", "negatedTerseLabel": "Foreign currency remeasurement" } } }, "localname": "ForeignCurrencyRemeasurementGainLossBeforeTax", "nsuri": "http://www.shockwavemedical.com/20230331", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "swav_JVAgreementWithGenesisMedTechMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "JV agreement with Genesis MedTech", "label": "J V Agreement With Genesis Med Tech [Member]", "terseLabel": "JV Agreement with Genesis MedTech" } } }, "localname": "JVAgreementWithGenesisMedTechMember", "nsuri": "http://www.shockwavemedical.com/20230331", "presentation": [ "http://www.shockwavemedical.com/role/EquityMethodInvestmentsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "swav_LicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License agreement.", "label": "License Agreement [Member]", "terseLabel": "License Agreement" } } }, "localname": "LicenseAgreementMember", "nsuri": "http://www.shockwavemedical.com/20230331", "presentation": [ "http://www.shockwavemedical.com/role/EquityMethodInvestmentsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "swav_LineOfCreditFacilityAccordionFeatureIncreaseLimit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Line Of Credit Facility, Accordion Feature, Increase Limit", "label": "Line Of Credit Facility, Accordion Feature, Increase Limit", "terseLabel": "Incremental revolving commitments, maximum" } } }, "localname": "LineOfCreditFacilityAccordionFeatureIncreaseLimit", "nsuri": "http://www.shockwavemedical.com/20230331", "presentation": [ "http://www.shockwavemedical.com/role/TermNotesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "swav_LoanAndSecurityAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loan and security agreement.", "label": "Loan And Security Agreement [Member]", "terseLabel": "Loan and Security Agreement" } } }, "localname": "LoanAndSecurityAgreementMember", "nsuri": "http://www.shockwavemedical.com/20230331", "presentation": [ "http://www.shockwavemedical.com/role/SubsequentEventsDetails", "http://www.shockwavemedical.com/role/TermNotesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "swav_MaximumPeriodOfAutomaticAnnualIncreaseInCommonStockReservedForIssuance": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum period of automatic annual increase in common stock reserved for issuance.", "label": "Maximum Period Of Automatic Annual Increase In Common Stock Reserved For Issuance", "terseLabel": "Maximum period of automatic annual increase in common stock reserved for issuance" } } }, "localname": "MaximumPeriodOfAutomaticAnnualIncreaseInCommonStockReservedForIssuance", "nsuri": "http://www.shockwavemedical.com/20230331", "presentation": [ "http://www.shockwavemedical.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "swav_NeovascIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Neovasc Inc", "label": "Neovasc Inc [Member]", "terseLabel": "Neovasc Inc" } } }, "localname": "NeovascIncMember", "nsuri": "http://www.shockwavemedical.com/20230331", "presentation": [ "http://www.shockwavemedical.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "swav_NoticePeriodForCancellationOfAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Notice period for cancellation of agreement.", "label": "Notice Period For Cancellation Of Agreement", "terseLabel": "Notice period for cancellation of agreement" } } }, "localname": "NoticePeriodForCancellationOfAgreement", "nsuri": "http://www.shockwavemedical.com/20230331", "presentation": [ "http://www.shockwavemedical.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "swav_NumberOfForeignSubsidiaries": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Foreign Subsidiaries", "label": "Number Of Foreign Subsidiaries", "terseLabel": "Number of foreign subsidiaries" } } }, "localname": "NumberOfForeignSubsidiaries", "nsuri": "http://www.shockwavemedical.com/20230331", "presentation": [ "http://www.shockwavemedical.com/role/OrganizationandBasisofPresentationAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "swav_PercentageOfCashContributionReceivableFromExchangeOfEquityWithinOneYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of cash contribution receivable from exchange of equity within one year.", "label": "Percentage Of Cash Contribution Receivable From Exchange Of Equity Within One Year", "terseLabel": "Percentage of cash contribution receivable from exchange of equity within one year" } } }, "localname": "PercentageOfCashContributionReceivableFromExchangeOfEquityWithinOneYear", "nsuri": "http://www.shockwavemedical.com/20230331", "presentation": [ "http://www.shockwavemedical.com/role/EquityMethodInvestmentsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "swav_PercentageOfCashContributionReceivedFromExchangeOfEquityCurrent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of cash contribution received from exchange of equity current.", "label": "Percentage Of Cash Contribution Received From Exchange Of Equity Current", "terseLabel": "Percentage of cash contribution received from exchange of equity upon signing of agreement" } } }, "localname": "PercentageOfCashContributionReceivedFromExchangeOfEquityCurrent", "nsuri": "http://www.shockwavemedical.com/20230331", "presentation": [ "http://www.shockwavemedical.com/role/EquityMethodInvestmentsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "swav_PercentageOfEquityStakeReceived": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of equity stake received.", "label": "Percentage Of Equity Stake Received", "terseLabel": "Percentage of equity stake received" } } }, "localname": "PercentageOfEquityStakeReceived", "nsuri": "http://www.shockwavemedical.com/20230331", "presentation": [ "http://www.shockwavemedical.com/role/EquityMethodInvestmentsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "swav_PeripheralMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Peripheral.", "label": "Peripheral [Member]", "terseLabel": "Peripheral" } } }, "localname": "PeripheralMember", "nsuri": "http://www.shockwavemedical.com/20230331", "presentation": [ "http://www.shockwavemedical.com/role/RevenueScheduleofProductRevenueBasedonProductLineDetails" ], "xbrltype": "domainItemType" }, "swav_SecuredOvernightFinancingRateSOFRMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Secured Overnight Financing Rate (SOFR)", "label": "Secured Overnight Financing Rate (SOFR) [Member]", "terseLabel": "Secured Overnight Financing Rate (SOFR)" } } }, "localname": "SecuredOvernightFinancingRateSOFRMember", "nsuri": "http://www.shockwavemedical.com/20230331", "presentation": [ "http://www.shockwavemedical.com/role/TermNotesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "swav_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options intrinsic value.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Intrinsic Value [Abstract]", "terseLabel": "Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract", "nsuri": "http://www.shockwavemedical.com/20230331", "presentation": [ "http://www.shockwavemedical.com/role/StockBasedCompensationScheduleofOptionActivityDetails" ], "xbrltype": "stringItemType" }, "swav_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options shares available for grant.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Shares Available For Grant Roll Forward", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award Options Shares Available For Grant Roll Forward" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward", "nsuri": "http://www.shockwavemedical.com/20230331", "presentation": [ "http://www.shockwavemedical.com/role/StockBasedCompensationScheduleofOptionActivityDetails" ], "xbrltype": "stringItemType" }, "swav_ShareSubscriptionAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share subscription agreement.", "label": "Share Subscription Agreement [Member]", "terseLabel": "Share Subscription Agreement" } } }, "localname": "ShareSubscriptionAgreementMember", "nsuri": "http://www.shockwavemedical.com/20230331", "presentation": [ "http://www.shockwavemedical.com/role/EquityMethodInvestmentsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r15", "r534" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r225", "r226" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "auth_ref": [ "r52" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "negatedLabel": "Amortization of premium and discount on available-for-sale securities" } } }, "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r20" ], "calculation": { "http://www.shockwavemedical.com/role/BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued liabilities", "totalLabel": "Total accrued liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails", "http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r20" ], "calculation": { "http://www.shockwavemedical.com/role/BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Professional services" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r26", "r27", "r28", "r146", "r478", "r487", "r488" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r25", "r28", "r100", "r422", "r483", "r484", "r549", "r550", "r551", "r558", "r559", "r560" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r7" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r366", "r367", "r368", "r558", "r559", "r560", "r582" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r95", "r96", "r328" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r361" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Total stock-based compensation", "verboseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/StockBasedCompensationAdditionalInformationDetails", "http://www.shockwavemedical.com/role/StockBasedCompensationScheduleofTotalStockBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r35", "r286", "r418", "r554" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization of debt issuance costs" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/EquityMethodInvestmentsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r115", "r128", "r144", "r173", "r211", "r215", "r219", "r235", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r391", "r395", "r408", "r534", "r572", "r573", "r586" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS", "verboseLabel": "Assets:" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets", "http://www.shockwavemedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r140", "r148", "r173", "r235", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r391", "r395", "r408", "r534", "r572", "r573", "r586" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "CURRENT ASSETS:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r102" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "terseLabel": "Total assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r64" ], "calculation": { "http://www.shockwavemedical.com/role/CashEquivalentsandShortTermInvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Unrealized Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CashEquivalentsandShortTermInvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails", "http://www.shockwavemedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r65" ], "calculation": { "http://www.shockwavemedical.com/role/CashEquivalentsandShortTermInvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails": { "order": 3.0, "parentTag": "swav_CashEquivalentsAndShortTermInvestments", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Unrealized Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CashEquivalentsandShortTermInvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r228", "r243" ], "calculation": { "http://www.shockwavemedical.com/role/CashEquivalentsandShortTermInvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "terseLabel": "Short-term investments Amortized Cost Basis", "totalLabel": "Short-term investments, amortized cost basis" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CashEquivalentsandShortTermInvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails", "http://www.shockwavemedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate": { "auth_ref": [ "r562", "r563", "r597" ], "calculation": { "http://www.shockwavemedical.com/role/CashEquivalentsandShortTermInvestmentsSummaryofRemainingContractualMaturitiesforAvailableforsaleSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.", "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value", "totalLabel": "Total" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CashEquivalentsandShortTermInvestmentsSummaryofRemainingContractualMaturitiesforAvailableforsaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "auth_ref": [ "r66", "r229", "r476" ], "calculation": { "http://www.shockwavemedical.com/role/CashEquivalentsandShortTermInvestmentsSummaryofRemainingContractualMaturitiesforAvailableforsaleSecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One", "terseLabel": "One year or less" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CashEquivalentsandShortTermInvestmentsSummaryofRemainingContractualMaturitiesforAvailableforsaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r63", "r227", "r243", "r472" ], "calculation": { "http://www.shockwavemedical.com/role/CashEquivalentsandShortTermInvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale", "terseLabel": "Short-term investments, fair value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CashEquivalentsandShortTermInvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r332", "r333", "r334", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r356", "r357", "r358", "r359", "r360" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/NetIncomeLossPerShareComponentsofBasicandDilutedNetIncomeLossPerShareDetails", "http://www.shockwavemedical.com/role/StockBasedCompensationAdditionalInformationDetails", "http://www.shockwavemedical.com/role/StockBasedCompensationScheduleofRSUActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BaseRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum rate investor will accept.", "label": "Base Rate [Member]", "terseLabel": "Base Rate" } } }, "localname": "BaseRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/TermNotesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r388", "r528", "r529" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r98", "r99", "r388", "r528", "r529" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.", "label": "Business Acquisition, Share Price", "terseLabel": "Business Acquisition, Share Price" } } }, "localname": "BusinessAcquisitionSharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/SubsequentEventsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r56", "r57", "r58" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Property and equipment purchases included in accounts payable and accrued liabilities" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Abstract]", "terseLabel": "Cash and Cash Equivalents [Abstract]" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r53", "r142", "r501" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.shockwavemedical.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets", "http://www.shockwavemedical.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [ "r142" ], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Cash and Cash Equivalents [Line Items]", "terseLabel": "Cash And Cash Equivalents [Line Items]" } } }, "localname": "CashAndCashEquivalentsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CashEquivalentsandShortTermInvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r54" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash, Cash Equivalents and Restricted Cash" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "auth_ref": [ "r547" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.", "label": "Cash, Cash Equivalents, and Short-Term Investments", "terseLabel": "Cash, cash equivalents and short-term investments" } } }, "localname": "CashCashEquivalentsAndShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/OrganizationandBasisofPresentationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock": { "auth_ref": [ "r68" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities.", "label": "Cash, Cash Equivalents, and Short-Term Investments [Text Block]", "terseLabel": "Cash Equivalents and Short-Term Investments" } } }, "localname": "CashCashEquivalentsAndShortTermInvestmentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CashEquivalentsandShortTermInvestments" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r47", "r53", "r59" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash equivalents at end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r47", "r53", "r59" ], "calculation": { "http://www.shockwavemedical.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "totalLabel": "Total cash, cash equivalents, and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r47", "r106" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r544" ], "calculation": { "http://www.shockwavemedical.com/role/CashEquivalentsandShortTermInvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails": { "order": 1.0, "parentTag": "swav_CashEquivalentsAndShortTermInvestmentsFairValueDisclosure", "weight": 1.0 }, "http://www.shockwavemedical.com/role/CashEquivalentsandShortTermInvestmentsSummaryofRemainingContractualMaturitiesforAvailableforsaleSecuritiesDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash Equivalents, at Carrying Value", "terseLabel": "Money market funds" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CashEquivalentsandShortTermInvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails", "http://www.shockwavemedical.com/role/CashEquivalentsandShortTermInvestmentsSummaryofRemainingContractualMaturitiesforAvailableforsaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CoVenturerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other venturer from the perspective of the entity in the corporate joint venture.", "label": "Co-venturer [Member]", "terseLabel": "Joint Venture" } } }, "localname": "CoVenturerMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/EquityMethodInvestmentsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r78" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CashEquivalentsandShortTermInvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails", "http://www.shockwavemedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Common stock reserved for issuance (in shares)" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r558", "r559", "r582" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r6", "r534" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r30", "r154", "r156", "r161", "r473", "r479" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Total comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContingentConsiderationByTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of contingent consideration.", "label": "Contingent Consideration by Type [Axis]", "terseLabel": "Contingent Consideration by Type [Axis]" } } }, "localname": "ContingentConsiderationByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContingentConsiderationTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of contingent payment arrangement.", "label": "Contingent Consideration Type [Domain]", "terseLabel": "Contingent Consideration Type [Domain]" } } }, "localname": "ContingentConsiderationTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "auth_ref": [ "r294", "r295", "r314" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Contract with Customer, Liability, Noncurrent", "terseLabel": "Related party contract liability, noncurrent portion" } } }, "localname": "ContractWithCustomerLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets", "http://www.shockwavemedical.com/role/EquityMethodInvestmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r315" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "verboseLabel": "Revenue recognized" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateBondSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).", "label": "Corporate Bond Securities [Member]", "terseLabel": "Corporate Bond Securities", "verboseLabel": "Corporate bonds" } } }, "localname": "CorporateBondSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CashEquivalentsandShortTermInvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails", "http://www.shockwavemedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r38", "r459" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of product revenue" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfRevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cost of Revenue [Abstract]", "terseLabel": "Cost of revenue:" } } }, "localname": "CostOfRevenueAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of product revenue" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/StockBasedCompensationScheduleofTotalStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r36" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/SubsequentEventsDetails", "http://www.shockwavemedical.com/role/TermNotesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/SubsequentEventsDetails", "http://www.shockwavemedical.com/role/TermNotesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r80", "r172", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r280", "r287", "r288", "r290" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Term Notes" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/TermNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r2", "r3", "r4", "r116", "r117", "r126", "r176", "r264", "r265", "r266", "r267", "r268", "r270", "r276", "r277", "r278", "r279", "r281", "r282", "r283", "r284", "r285", "r286", "r419", "r512", "r513", "r514", "r515", "r516", "r556" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/SubsequentEventsDetails", "http://www.shockwavemedical.com/role/TermNotesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Debt interest rate basis" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/TermNotesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r108", "r111", "r264", "r419", "r513", "r514" ], "calculation": { "http://www.shockwavemedical.com/role/TermNotesScheduleofCurrentandNoncurrentDebtandNetDiscountorPremiumBalancesDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "verboseLabel": "Principal amount of debt" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/TermNotesScheduleofCurrentandNoncurrentDebtandNetDiscountorPremiumBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/TermNotesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r22", "r176", "r264", "r265", "r266", "r267", "r268", "r270", "r276", "r277", "r278", "r279", "r281", "r282", "r283", "r284", "r285", "r286", "r419", "r512", "r513", "r514", "r515", "r516", "r556" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/SubsequentEventsDetails", "http://www.shockwavemedical.com/role/TermNotesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPeriodicPaymentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Instrument, Periodic Payment [Abstract]", "terseLabel": "Debt Instrument, Periodic Payment [Abstract]" } } }, "localname": "DebtInstrumentPeriodicPaymentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r22", "r82", "r83", "r84", "r85", "r107", "r108", "r111", "r125", "r176", "r264", "r265", "r266", "r267", "r268", "r270", "r276", "r277", "r278", "r279", "r281", "r282", "r283", "r284", "r285", "r286", "r289", "r419", "r512", "r513", "r514", "r515", "r516", "r556" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]", "terseLabel": "Debt Instrument [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/TermNotesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet": { "auth_ref": [ "r107", "r108", "r109", "r110", "r111", "r575" ], "calculation": { "http://www.shockwavemedical.com/role/TermNotesScheduleofCurrentandNoncurrentDebtandNetDiscountorPremiumBalancesDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount (premium).", "label": "Debt Instrument, Unamortized Discount (Premium), Net", "negatedLabel": "Debt issuance costs" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/TermNotesScheduleofCurrentandNoncurrentDebtandNetDiscountorPremiumBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": { "auth_ref": [ "r233", "r246" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss", "terseLabel": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CashEquivalentsandShortTermInvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "auth_ref": [ "r564" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale [Table Text Block]", "terseLabel": "Summary of Remaining Contractual Maturities for Available-for-sale Securities" } } }, "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CashEquivalentsandShortTermInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": { "auth_ref": [ "r232", "r244", "r511" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position", "terseLabel": "Debt Securities, Available-for-Sale, Unrealized Loss Position" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CashEquivalentsandShortTermInvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r371", "r372" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred tax assets" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxesAndTaxCredits": { "auth_ref": [ "r52" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.", "label": "Deferred Income Taxes and Tax Credits", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxesAndTaxCredits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r51", "r75" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Abstract]", "terseLabel": "Disaggregation of Revenue [Abstract]" } } }, "localname": "DisaggregationOfRevenueAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation Of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/RevenueScheduleofProductRevenueBasedonLocationDetails", "http://www.shockwavemedical.com/role/RevenueScheduleofProductRevenueBasedonProductLineDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r313", "r518", "r519", "r520", "r521", "r522", "r523", "r524" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation Of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/RevenueScheduleofProductRevenueBasedonLocationDetails", "http://www.shockwavemedical.com/role/RevenueScheduleofProductRevenueBasedonProductLineDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r576" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Schedule of Product Revenue Based on Product Line and Location" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/RevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r331", "r363", "r364", "r365", "r370", "r531" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/StockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown": { "auth_ref": [ "r51", "r74", "r77" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a disposal group. Excludes discontinued operations.", "label": "Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down", "terseLabel": "Loss on write down of fixed assets" } } }, "localname": "DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Net income per share" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r162", "r182", "r183", "r184", "r185", "r186", "r190", "r192", "r197", "r198", "r199", "r203", "r399", "r400", "r474", "r480", "r508" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (USD per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss", "http://www.shockwavemedical.com/role/NetIncomeLossPerShareComponentsofBasicandDilutedNetIncomeLossPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r162", "r182", "r183", "r184", "r185", "r186", "r192", "r197", "r198", "r199", "r203", "r399", "r400", "r474", "r480", "r508" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (USD per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss", "http://www.shockwavemedical.com/role/NetIncomeLossPerShareComponentsofBasicandDilutedNetIncomeLossPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r200", "r201", "r202", "r204" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Income (Loss) Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/NetIncomeLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r409" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "terseLabel": "Effect of exchange rate changes on cash and cash equivalents" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r174", "r374", "r382" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Federal statutory income tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r20" ], "calculation": { "http://www.shockwavemedical.com/role/BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Employee compensation" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": { "auth_ref": [ "r362" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost capitalized for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Amount Capitalized", "terseLabel": "Share-based compensation expenses capitalized amount" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/StockBasedCompensationScheduleofTotalStockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "Employee Stock" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/NetIncomeLossPerShareComponentsofBasicandDilutedNetIncomeLossPerShareDetails", "http://www.shockwavemedical.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]", "terseLabel": "Stock Options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/NetIncomeLossPerShareComponentsofBasicandDilutedNetIncomeLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r81", "r138", "r157", "r158", "r159", "r177", "r178", "r179", "r181", "r187", "r189", "r205", "r237", "r293", "r366", "r367", "r368", "r378", "r379", "r398", "r410", "r411", "r412", "r413", "r414", "r415", "r422", "r483", "r484", "r485" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r70" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity Method Investment, Ownership Percentage", "terseLabel": "Equity percentage" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/EquityMethodInvestmentsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r69", "r212", "r545" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Investments", "terseLabel": "Equity method investment" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets", "http://www.shockwavemedical.com/role/EquityMethodInvestmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Method Investments and Joint Ventures [Abstract]", "terseLabel": "Equity Method Investments and Joint Ventures [Abstract]" } } }, "localname": "EquityMethodInvestmentsAndJointVenturesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": { "auth_ref": [ "r236" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.", "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]", "terseLabel": "Equity Method Investments" } } }, "localname": "EquityMethodInvestmentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/EquityMethodInvestments" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquityMethodInvestmentsPolicy": { "auth_ref": [ "r46", "r71", "r105" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.", "label": "Equity Method Investments [Policy Text Block]", "terseLabel": "Equity Method Investments" } } }, "localname": "EquityMethodInvestmentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ExtinguishmentOfDebtAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount of debt extinguished.", "label": "Extinguishment of Debt, Amount", "terseLabel": "Debt extinguished" } } }, "localname": "ExtinguishmentOfDebtAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/SubsequentEventsDetails", "http://www.shockwavemedical.com/role/TermNotesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r401", "r402", "r406" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r103" ], "lang": { "en-us": { "role": { "documentation": "Class of asset.", "label": "Asset Class [Domain]", "terseLabel": "Asset Class" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r102", "r104" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]", "terseLabel": "Asset Class" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r278", "r319", "r320", "r321", "r322", "r323", "r324", "r402", "r431", "r432", "r433", "r513", "r514", "r525", "r526", "r527" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r401", "r402", "r403", "r404", "r407" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r405" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Financial Instruments and Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/FinancialInstrumentsandFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r278", "r319", "r324", "r402", "r431", "r525", "r526", "r527" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r278", "r319", "r324", "r402", "r432", "r513", "r514", "r525", "r526", "r527" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r278", "r319", "r320", "r321", "r322", "r323", "r324", "r402", "r433", "r513", "r514", "r525", "r526", "r527" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r278", "r319", "r320", "r321", "r322", "r323", "r324", "r431", "r432", "r433", "r513", "r514", "r525", "r526", "r527" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r405", "r407" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FederalFundsEffectiveSwapRateMember": { "auth_ref": [ "r581" ], "lang": { "en-us": { "role": { "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap having its variable-rate leg referenced to Federal Funds effective rate with no additional spread over Federal Funds effective rate on that variable-rate leg.", "label": "Fed Funds Effective Rate Overnight Index Swap Rate [Member]", "terseLabel": "Fed Funds Effective Rate Overnight Index Swap Rate" } } }, "localname": "FederalFundsEffectiveSwapRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/TermNotesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r230", "r231", "r238", "r239", "r240", "r241", "r242", "r245", "r247", "r248", "r289", "r292", "r397", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r511", "r565", "r566", "r567", "r600", "r601", "r602", "r603", "r604", "r605", "r606" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instruments" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CashEquivalentsandShortTermInvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r39" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r34" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/StockBasedCompensationScheduleofTotalStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r37", "r173", "r211", "r214", "r218", "r220", "r235", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r408", "r510", "r572" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r31", "r113", "r122", "r136", "r211", "r214", "r218", "r220", "r475", "r510" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Net income before taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r32", "r51", "r69", "r121", "r134", "r209" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).", "label": "Income (Loss) from Equity Method Investments", "negatedLabel": "Loss from equity method investment", "negatedTerseLabel": "Loss from equity method investment", "terseLabel": "Loss from equity method investment" } } }, "localname": "IncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss", "http://www.shockwavemedical.com/role/EquityMethodInvestmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r249", "r250" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/StockBasedCompensationScheduleofTotalStockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r250" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/StockBasedCompensationScheduleofTotalStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r174", "r375", "r376", "r377", "r380", "r383", "r385", "r386", "r387" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Tax Disclosure" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r175", "r188", "r189", "r210", "r373", "r381", "r384", "r481" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax expense" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss", "http://www.shockwavemedical.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r48", "r55" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income Taxes Paid", "terseLabel": "Income tax paid" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r50" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r50" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "auth_ref": [ "r553" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "terseLabel": "Accrued and other current liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r50" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r553", "r584" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Increase (Decrease) in Operating Lease Liability", "terseLabel": "Lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r50" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase (Decrease) in Other Operating Assets", "negatedLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r50" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r193", "r194", "r195", "r199", "r330" ], "calculation": { "http://www.shockwavemedical.com/role/NetIncomeLossPerShareComponentsofBasicandDilutedNetIncomeLossPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "terseLabel": "Dilutive effect of share-based payment arrangements (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/NetIncomeLossPerShareComponentsofBasicandDilutedNetIncomeLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r109", "r124", "r160", "r208", "r417" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense", "terseLabel": "Interest Expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss", "http://www.shockwavemedical.com/role/TermNotesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r166", "r169", "r170" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest paid" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]", "terseLabel": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r73", "r503" ], "calculation": { "http://www.shockwavemedical.com/role/BalanceSheetComponentsScheduleofInventoryDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/BalanceSheetComponentsScheduleofInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r147", "r502", "r534" ], "calculation": { "http://www.shockwavemedical.com/role/BalanceSheetComponentsScheduleofInventoryDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventory", "totalLabel": "Total inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/BalanceSheetComponentsScheduleofInventoryDetails", "http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r73", "r505" ], "calculation": { "http://www.shockwavemedical.com/role/BalanceSheetComponentsScheduleofInventoryDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory, Raw Materials, Net of Reserves", "terseLabel": "Raw material" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/BalanceSheetComponentsScheduleofInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r73", "r504" ], "calculation": { "http://www.shockwavemedical.com/role/BalanceSheetComponentsScheduleofInventoryDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Work in progress" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/BalanceSheetComponentsScheduleofInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r19", "r173", "r235", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r392", "r395", "r396", "r408", "r509", "r572", "r586", "r587" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "TOTAL LIABILITIES" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r11", "r118", "r132", "r534", "r557", "r568", "r583" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r21", "r141", "r173", "r235", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r392", "r395", "r396", "r408", "r534", "r572", "r586", "r587" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "CURRENT LIABILITIES:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "The effective interest rate at the end of the reporting period.", "label": "Line of Credit Facility, Interest Rate at Period End", "terseLabel": "Line of Credit Facility, Interest Rate at Period End" } } }, "localname": "LineOfCreditFacilityInterestRateAtPeriodEnd", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/TermNotesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r16" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Line of credit facility, maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/TermNotesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Line of Credit" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/SubsequentEventsDetails", "http://www.shockwavemedical.com/role/TermNotesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r4", "r117", "r129", "r277", "r291", "r513", "r514" ], "calculation": { "http://www.shockwavemedical.com/role/TermNotesScheduleofCurrentandNoncurrentDebtandNetDiscountorPremiumBalancesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.shockwavemedical.com/role/TermNotesScheduleofCurrentandNoncurrentDebtandNetDiscountorPremiumBalancesDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "Long-Term Debt", "totalLabel": "Debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/TermNotesScheduleofCurrentandNoncurrentDebtandNetDiscountorPremiumBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r18" ], "calculation": { "http://www.shockwavemedical.com/role/TermNotesScheduleofCurrentandNoncurrentDebtandNetDiscountorPremiumBalancesDetails_1": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-Term Debt, Current Maturities", "negatedLabel": "Less: debt, current portion" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/TermNotesScheduleofCurrentandNoncurrentDebtandNetDiscountorPremiumBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r145" ], "calculation": { "http://www.shockwavemedical.com/role/TermNotesScheduleofCurrentandNoncurrentDebtandNetDiscountorPremiumBalancesDetails_1": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.", "label": "Long-Term Debt, Excluding Current Maturities", "terseLabel": "Debt, noncurrent portion" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/TermNotesScheduleofCurrentandNoncurrentDebtandNetDiscountorPremiumBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermNotesPayable": { "auth_ref": [ "r22" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Notes Payable, Noncurrent", "terseLabel": "Debt, noncurrent portion" } } }, "localname": "LongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/TermNotesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r22", "r79" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-Term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/TermNotesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r578" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CashEquivalentsandShortTermInvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails", "http://www.shockwavemedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r168" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r168" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r47", "r49", "r52" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r33", "r52", "r123", "r135", "r139", "r153", "r155", "r159", "r173", "r180", "r182", "r183", "r184", "r185", "r188", "r189", "r196", "r211", "r214", "r218", "r220", "r235", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r400", "r408", "r510", "r572" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": { "order": 3.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income (loss)", "totalLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss", "http://www.shockwavemedical.com/role/NetIncomeLossPerShareComponentsofBasicandDilutedNetIncomeLossPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]", "terseLabel": "Numerator:" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/NetIncomeLossPerShareComponentsofBasicandDilutedNetIncomeLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "NON-CASH INVESTING AND FINANCING ACTIVITIES:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NotesPayableCurrent": { "auth_ref": [ "r18" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.", "label": "Notes Payable, Current", "terseLabel": "Debt, current portion" } } }, "localname": "NotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r211", "r214", "r218", "r220", "r510" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Income from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r421" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Lease liability, current portion" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r421" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Lease liability, noncurrent portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r420" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r554" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for right-of-use asset from operating lease.", "label": "Operating Lease, Right-of-Use Asset, Amortization Expense", "terseLabel": "Non-cash lease expense" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r0", "r101" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Organization and Basis of Presentation" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/OrganizationandBasisofPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r20" ], "calculation": { "http://www.shockwavemedical.com/role/BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r143" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax": { "auth_ref": [ "r149", "r150" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax", "terseLabel": "Unrealized gain (loss) on available-for-sale securities" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax": { "auth_ref": [ "r149", "r150", "r151" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax and after adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax", "terseLabel": "Unrealized gain on available-for-sale securities, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive income (loss):" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": { "auth_ref": [ "r26", "r29", "r67", "r152" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.", "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax", "negatedTerseLabel": "Adjustment for net gain realized and included in other income", "terseLabel": "Adjustment for net gain realized and included in other income" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CashEquivalentsandShortTermInvestmentsNarrativeDetails", "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss", "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r40" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income (expense), net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]", "terseLabel": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r165" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "negatedLabel": "Payments of taxes withheld on net settled vesting of restricted stock units" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r41", "r62", "r163" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Payments to Acquire Debt Securities, Available-for-Sale", "negatedLabel": "Purchase of available-for-sale securities" } } }, "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r42", "r389" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Payments to Acquire Businesses, Gross" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r43" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedTerseLabel": "Purchase of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "terseLabel": "Performance-Based Restricted Stock Units" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/StockBasedCompensationAdditionalInformationDetails", "http://www.shockwavemedical.com/role/StockBasedCompensationScheduleofRSUActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r5", "r534" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r547" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfDebt": { "auth_ref": [ "r552" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.", "label": "Proceeds from Issuance of Debt", "terseLabel": "Proceeds of supplemental term loan" } } }, "localname": "ProceedsFromIssuanceOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/SubsequentEventsDetails", "http://www.shockwavemedical.com/role/TermNotesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r45" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds from Issuance of Long-Term Debt", "terseLabel": "Proceeds from debt financing, net of issuance costs" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": { "auth_ref": [ "r44", "r93" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.", "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised", "terseLabel": "Proceeds from issuance of common stock under employee stock purchase plan" } } }, "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": { "auth_ref": [ "r62", "r163", "r164" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale", "terseLabel": "Proceeds from maturities of available-for-sale securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r44", "r93" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from stock option exercises" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductAndServiceOtherMember": { "auth_ref": [ "r577" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.", "label": "Product and Service, Other [Member]", "terseLabel": "Other" } } }, "localname": "ProductAndServiceOtherMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/RevenueScheduleofProductRevenueBasedonProductLineDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r139", "r153", "r155", "r167", "r173", "r180", "r188", "r189", "r211", "r214", "r218", "r220", "r235", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r390", "r393", "r394", "r400", "r408", "r475", "r510", "r532", "r533", "r551", "r572" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net income (loss)" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r76", "r133", "r477", "r534" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r325", "r423", "r424" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/EquityMethodInvestmentsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "auth_ref": [ "r112", "r423" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transactions with related party during the financial reporting period.", "label": "Related Party Transaction, Amounts of Transaction", "terseLabel": "Related party transaction. transaction price" } } }, "localname": "RelatedPartyTransactionAmountsOfTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/EquityMethodInvestmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r325", "r423", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r585" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/EquityMethodInvestmentsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r97", "r137", "r594" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/StockBasedCompensationScheduleofTotalStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r544", "r555", "r595", "r598" ], "calculation": { "http://www.shockwavemedical.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [ "r142" ], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.", "label": "Restricted Stock, Shares Issued Net of Shares for Tax Withholdings", "negatedTerseLabel": "Taxes withheld on net settled vesting of restricted stock units (in shares)" } } }, "localname": "RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/NetIncomeLossPerShareComponentsofBasicandDilutedNetIncomeLossPerShareDetails", "http://www.shockwavemedical.com/role/StockBasedCompensationAdditionalInformationDetails", "http://www.shockwavemedical.com/role/StockBasedCompensationScheduleofRSUActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.", "label": "Restricted Stock, Value, Shares Issued Net of Tax Withholdings", "negatedLabel": "Restricted Stock, Value, Shares Issued Net of Tax Withholdings" } } }, "localname": "RestrictedStockValueSharesIssuedNetOfTaxWithholdings", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r8", "r86", "r131", "r486", "r488", "r534" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings (accumulated deficit)" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r138", "r177", "r178", "r179", "r181", "r187", "r189", "r237", "r366", "r367", "r368", "r378", "r379", "r398", "r483", "r485" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r206", "r207", "r213", "r216", "r217", "r221", "r222", "r224", "r312", "r313", "r459" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Product revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss", "http://www.shockwavemedical.com/role/RevenueScheduleofProductRevenueBasedonLocationDetails", "http://www.shockwavemedical.com/role/RevenueScheduleofProductRevenueBasedonProductLineDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r317", "r506" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r316", "r317" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/Revenue" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenue:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/SubsequentEventsDetails", "http://www.shockwavemedical.com/role/TermNotesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accrued Liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/BalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashAndCashEquivalentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.", "label": "Schedule of Cash and Cash Equivalents [Table]", "terseLabel": "Schedule Of Cash And Cash Equivalents [Table]" } } }, "localname": "ScheduleOfCashAndCashEquivalentsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CashEquivalentsandShortTermInvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of cash and cash equivalents.", "label": "Schedule of Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Schedule of Cash and Cash Equivalents" } } }, "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.", "label": "Cash, Cash Equivalents and Investments [Table Text Block]", "terseLabel": "Summary of Cash Equivalents and Short-Term Investments" } } }, "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CashEquivalentsandShortTermInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Debt [Table Text Block]", "terseLabel": "Schedule of Current and Noncurrent Debt and Net Discount or Premium Balances" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/TermNotesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r561" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Components of Basic and Diluted Net Income (Loss) Per Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/NetIncomeLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r91", "r94" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/StockBasedCompensationScheduleofTotalStockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r91" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of Total Stock-Based Compensation" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of Equity Method Investments [Line Items]", "terseLabel": "Schedule Of Equity Method Investments [Line Items]" } } }, "localname": "ScheduleOfEquityMethodInvestmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/EquityMethodInvestmentsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEquityMethodInvestmentsTable": { "auth_ref": [ "r72", "r139", "r173", "r235", "r408" ], "lang": { "en-us": { "role": { "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.", "label": "Schedule of Equity Method Investments [Table]", "terseLabel": "Schedule Of Equity Method Investments [Table]" } } }, "localname": "ScheduleOfEquityMethodInvestmentsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/EquityMethodInvestmentsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r401", "r402" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Financial Assets and Liabilities Measured at Fair Value" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/FinancialInstrumentsandFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r1", "r12", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of Inventory" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/BalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": { "auth_ref": [ "r59", "r114", "r130" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.", "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Restrictions on Cash and Cash Equivalents" } } }, "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r327", "r329", "r332", "r333", "r334", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r356", "r357", "r358", "r359", "r360" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/StockBasedCompensationAdditionalInformationDetails", "http://www.shockwavemedical.com/role/StockBasedCompensationScheduleofRSUActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r87" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Schedule of RSU Activity under 2019 Plan" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r87", "r88", "r89" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of Option Activity under 2009 Plan and 2019 Plan" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Selling and Marketing Expense", "terseLabel": "Sales and marketing" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingAndMarketingExpenseMember": { "auth_ref": [ "r34" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling and marketing expense.", "label": "Selling and Marketing Expense [Member]", "terseLabel": "Sales and marketing" } } }, "localname": "SellingAndMarketingExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/StockBasedCompensationScheduleofTotalStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r50" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r531" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r349" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "RSUs forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/StockBasedCompensationScheduleofRSUActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r349" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "RSUs forfeited (USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/StockBasedCompensationScheduleofRSUActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r347" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "RSUs granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/StockBasedCompensationScheduleofRSUActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r347" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "RSUs granted (USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/StockBasedCompensationScheduleofRSUActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r344", "r345" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Ending balance of period (in shares)", "periodStartLabel": "Beginning balance of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/StockBasedCompensationScheduleofRSUActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Number of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/StockBasedCompensationScheduleofRSUActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r344", "r345" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Ending balance of period (USD per share)", "periodStartLabel": "Beginning balance of period (USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/StockBasedCompensationScheduleofRSUActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted-Average Grant Date Fair Value Per Share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/StockBasedCompensationScheduleofRSUActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r348" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "RSUs vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/StockBasedCompensationScheduleofRSUActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r348" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "RSUs vested (USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/StockBasedCompensationScheduleofRSUActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/StockBasedCompensationAdditionalInformationDetails", "http://www.shockwavemedical.com/role/StockBasedCompensationScheduleofRSUActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r92" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "terseLabel": "Shares available for issuance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Weighted- Average Remaining Term" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/StockBasedCompensationScheduleofOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r338" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Vested and exercisable shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/StockBasedCompensationScheduleofOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r338" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Vested and exercisable shares (USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/StockBasedCompensationScheduleofOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r342" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Options cancelled (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/StockBasedCompensationScheduleofOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r92" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/StockBasedCompensationScheduleofOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r336", "r337" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Balance end of period (in shares)", "periodStartLabel": "Balance beginning of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/StockBasedCompensationScheduleofOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/StockBasedCompensationScheduleofOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r336", "r337" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Ending balance of period (USD per share)", "periodStartLabel": "Beginning balance of period (USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/StockBasedCompensationScheduleofOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted- Average Exercise Price Per Share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/StockBasedCompensationScheduleofOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r352" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Vested\u00a0and\u00a0expected\u00a0to\u00a0vest,\u00a0 March 31, 2023" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/StockBasedCompensationScheduleofOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r352" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Vested and expected to vest shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/StockBasedCompensationScheduleofOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r352" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Vested and expected to vest shares (USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/StockBasedCompensationScheduleofOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r332", "r333", "r334", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r356", "r357", "r358", "r359", "r360" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/NetIncomeLossPerShareComponentsofBasicandDilutedNetIncomeLossPerShareDetails", "http://www.shockwavemedical.com/role/StockBasedCompensationAdditionalInformationDetails", "http://www.shockwavemedical.com/role/StockBasedCompensationScheduleofRSUActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r341" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Options exercised (USD per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/StockBasedCompensationScheduleofOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r342" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Options cancelled (USD per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/StockBasedCompensationScheduleofOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r335", "r354", "r355", "r356", "r357", "r360", "r369", "r370" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-Based Payment Arrangement [Policy Text Block]", "terseLabel": "Share-based Payment Arrangement" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r579" ], "lang": { "en-us": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Vesting percentage" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r92" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Vested and exercisable, March 31, 2023" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/StockBasedCompensationScheduleofOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r92" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Vested and exercisable, March 31, 2023" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/StockBasedCompensationScheduleofOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r90" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Balance (USD per share)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/StockBasedCompensationScheduleofOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r352" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Vested\u00a0and\u00a0expected\u00a0to\u00a0vest,\u00a0 March 31, 2023" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/StockBasedCompensationScheduleofOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase price of common stock expressed as a percentage of its fair value.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent", "terseLabel": "Purchase shares of common stock, price per share, percentage of fair market value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance, shares (in shares)", "periodStartLabel": "Beginning balance, shares (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-Term Debt, Type [Axis]", "terseLabel": "Short-term Debt, Type" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/SubsequentEventsDetails", "http://www.shockwavemedical.com/role/TermNotesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.", "label": "Short-Term Debt, Type [Domain]", "terseLabel": "Short-term Debt, Type" } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/SubsequentEventsDetails", "http://www.shockwavemedical.com/role/TermNotesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r119", "r120", "r127", "r546" ], "calculation": { "http://www.shockwavemedical.com/role/CashEquivalentsandShortTermInvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails": { "order": 2.0, "parentTag": "swav_CashEquivalentsAndShortTermInvestmentsFairValueDisclosure", "weight": 1.0 }, "http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short-Term Investments", "terseLabel": "Short-term investments" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CashEquivalentsandShortTermInvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails", "http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r60", "r171" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r24", "r81", "r138", "r157", "r158", "r159", "r177", "r178", "r179", "r181", "r187", "r189", "r205", "r237", "r293", "r366", "r367", "r368", "r378", "r379", "r398", "r410", "r411", "r412", "r413", "r414", "r415", "r422", "r483", "r484", "r485" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r177", "r178", "r179", "r205", "r459" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r5", "r6", "r81", "r86" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Issuance of common stock under employee stock purchase plan (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r5", "r6", "r81", "r86" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "verboseLabel": "Ordinary shares issued (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/EquityMethodInvestmentsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r5", "r6", "r81", "r86" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Issuance of common stock in connection with vesting of restricted stock (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r5", "r6", "r81", "r86", "r341" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "terseLabel": "Exercise of stock options (in shares)", "verboseLabel": "Options exercised (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://www.shockwavemedical.com/role/StockBasedCompensationScheduleofOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r5", "r6", "r81", "r86" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Issuance of common stock under employee stock purchase plan" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r24", "r81", "r86" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r6", "r9", "r10", "r61", "r534", "r557", "r568", "r583" ], "calculation": { "http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "TOTAL STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets", "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "STOCKHOLDERS\u2019 EQUITY:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r416", "r426" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/SubsequentEventsDetails", "http://www.shockwavemedical.com/role/TermNotesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r416", "r426" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r416", "r426" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/SubsequentEventsDetails", "http://www.shockwavemedical.com/role/TermNotesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r416", "r426" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/SubsequentEventsDetails", "http://www.shockwavemedical.com/role/TermNotesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r425", "r427" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r548" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "terseLabel": "Balance Sheet Components" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/BalanceSheetComponents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TaxesPayableCurrent": { "auth_ref": [ "r18" ], "calculation": { "http://www.shockwavemedical.com/role/BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Taxes Payable, Current", "terseLabel": "Excise, sales, income and other taxes" } } }, "localname": "TaxesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r230", "r231", "r289", "r292", "r397", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r565", "r566", "r567", "r600", "r601", "r602", "r603", "r604", "r605", "r606" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CashEquivalentsandShortTermInvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r580" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/EquityMethodInvestmentsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfCostGoodOrServiceExtensibleList": { "auth_ref": [ "r577" ], "lang": { "en-us": { "role": { "documentation": "Indicates type of cost from product sold and service rendered.", "label": "Cost, Product and Service [Extensible Enumeration]", "terseLabel": "Type of Cost, Good Or Service [Extensible List]" } } }, "localname": "TypeOfCostGoodOrServiceExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_TypeOfRevenueExtensibleList": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources.", "label": "Revenue, Product and Service [Extensible Enumeration]", "terseLabel": "Type of Revenue [Extensible List]" } } }, "localname": "TypeOfRevenueExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r507", "r525", "r596" ], "lang": { "en-us": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "US Government Agencies Debt Securities [Member]", "terseLabel": "US Government Agencies Debt Securities" } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CashEquivalentsandShortTermInvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails", "http://www.shockwavemedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r507", "r525", "r527", "r596" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "US Treasury Securities [Member]", "terseLabel": "U.S. Treasury securities" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CashEquivalentsandShortTermInvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails", "http://www.shockwavemedical.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/TermNotesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/TermNotesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r191", "r199" ], "calculation": { "http://www.shockwavemedical.com/role/NetIncomeLossPerShareComponentsofBasicandDilutedNetIncomeLossPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "totalLabel": "Diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss", "http://www.shockwavemedical.com/role/NetIncomeLossPerShareComponentsofBasicandDilutedNetIncomeLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Denominator:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss", "http://www.shockwavemedical.com/role/NetIncomeLossPerShareComponentsofBasicandDilutedNetIncomeLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r190", "r199" ], "calculation": { "http://www.shockwavemedical.com/role/NetIncomeLossPerShareComponentsofBasicandDilutedNetIncomeLossPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shockwavemedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss", "http://www.shockwavemedical.com/role/NetIncomeLossPerShareComponentsofBasicandDilutedNetIncomeLossPerShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28567-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(f))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(10))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "17A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL34724391-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "323", "URI": "https://asc.fasb.org/topic&trid=2196965", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e689-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(12))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "21D", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=SL94080555-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(a)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r538": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r539": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r541": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r542": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r543": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(10))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r548": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "https://asc.fasb.org/topic&trid=2122208", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r564": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=124256753&loc=SL5864739-113975", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r601": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r602": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r603": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r604": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r605": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r606": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(b)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2443-110228", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 66 0001642545-23-000031-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001642545-23-000031-xbrl.zip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Ì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end